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Obesity is a worldwide problem and is a factor in the pathogenesis of the metabolic syndrome 
and kidney disease through the development of obesity-related hypertension and neuro-
hormonal mechanisms that include the action of leptin.  
 
As there appear to be no focussed studies that have looked at the association of the LEP gene 
with kidney disease phenotypes or cardiovascular disease markers like hypertension, the 
metabolic syndrome and obesity, and especially so in native black Africans, this study sought 
to establish an association between the obesity gene (LEP) and kidney disease phenotypes 
(independent of diabetes and hypertension) in a homogenous black African population. This 
study was of cross – sectional design and was carried out in the hypertension clinic of a 
native black South African population.  
 
The study was also designed to identify the prevalence of genotypes of the LEP gene in black 
South Africans, the relationship between the LEP gene, obesity, hypertension, the Metabolic 
Syndrome, markers of kidney disease and serum leptin concentration, the effect of the 
metabolic syndrome o  kidney disease phenotypes in this population and to identify 
candidate genes for the metabolic syndrome through a bioinformatics approach.   
 
We not only confirmed results from other population in which kidney disease has been shown 
to be associated with the metabolic syndrome but also found significant inverse correlation 
between leptin and body mass index with glomerular filtration rate, making a strong case for 













We also report, for the first time, an association between the A19G genotypes of the LEP 
gene with kidney disease in non-diabetic hypertensives and normotensive subjects. 
Individuals with the AA genotype of this polymorphism had significantly higher albumin-to-
creatinine ratio compared to subjects with the AG or GG genotypes. We also identified two 
haplotypes of the leptin gene with effects on kidney disease markers; one of the haplotypes 
(GCAT) appeared to have a protective effect on markers of kidney disease while the second 
haplotype (GAAC) was observed to have an effect that increased urine ACR, possibly 
making it a risk haplotype for renal disease.    
 
Although an association between the LEP gene and microalbuminuria was seen in this 
population, we found no association between the LEP gene and obesity and the metabolic 
syndrome, considered as important driving factors for kidney disease. Therefore, we used a 
bioinformatics approach to select 19 top-scoring candidate genes for the metabolic syndrome. 
The candidates selected are found to most commonly represent pathways involving 
metabolism of lipids and lipoproteins, as well as transmembrane signalling and subsequent 






















ACR     Albumin-to-creatinine ratio 
ATPIII     Adult treatment panel (III) 
BMI     Body mass index 
CKD     Chronic Kidney disease 
CVD     Cardiovascular disease 
DAVID  Database for Annotation, Visualization and Integrated 
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1.1 NON-COMMUNICABLE DISEASES (NCDs) 
 
There is an increasing tendency in today‘s world for the integration of ideas, people 
(culturally and politically), commerce, financial capital and technology - this is called 
globalisation and may have both beneficial and harmful effects on the health of populations 
(Woodward et al 2001). The effect of globalisation on health has for the most part been 
directed towards control of communicable diseases, provision of affordable medicines, and 
changes required in international trade to improve access to healthcare. By contrast, the 
growing burden of non-communicable diseases (NCDs) (such as kidney disease, heart 
disease, obesity, diabetes and stroke) has been neglected, especially in the developing 
countries of the world (Beaglehole and Yach 2003). 
 
Non-communicable diseases are the largest cause of death in the world, led by cardiovascular 
disease (CVD) (17 million deaths
 
in 2002, mainly from ischaemic heart disease and stroke) 
followed by cancer (7 million deaths), chronic lung diseases
 
(4 million), and diabetes mellitus 
(almost 1 million) (WHO 2003). Moreover, the World Health Organisation (WHO) have 
declared that ―obesity has reached epidemic proportions globally‖ and that ―more than 1 
billion adults are overweight and at least 300 million of them clinically obese‖ with obesity 















In several developing countries there has been a rapid increase of chronic disease risk
 
and 
mortality profiles (WHO 2002). For instance, in China, death rates from circulatory disease 
increased
 
between 200% and 300% in those aged 35 through 44 years between
 
1986 and 
1999, and by more than 100% in those aged 45 through
 
54 years (Yach et al 2004).  
 
Although communicable diseases such as malaria, tuberculosis, HIV/AIDS are very common 
in developing countries, they are, in some cases, gradually becoming displaced by chronic 
NCDs. Thus, many developing countries are starting to experience a polarized and protracted 
double burden of disease (Popkin 2004; Frenk et al 1989). For example, India, with the 
highest number of
 
diabetics in the world is projected to have an annual death from coronary 
heart disease of about 2 million by the year 2010 (Basnayar et al 2004). In addition, India still 
needs to be seriously concerned about the 2.5 million
 
children who die from infectious 
diseases every year. In South Africa, infectious diseases such as HIV/AIDS and tuberculosis
 
account for 28% of years of lives lost while chronic diseases
 
account for 25%
   
(Steyn et al., 
2003). 
 
Global projections of mortality and burden of disease from 2002 to 2030 have shown a 
dramatic shift in distribution of deaths from younger to older ages and from communicable, 
maternal, perinatal and nutritional causes to NCD causes. The proportion of deaths due to 
non-communicable causes is projected to increase from 59% in 2002 to 69% in 2030 with 














In all countries, the increased burden of chronic NCDs has led to growing economic costs 
with increasing proof of this increased burden emerging for CVD,
 
diabetes, and obesity 
(Thompson et al 2001). Many developed nations have focused
 
considerable efforts on 
addressing the burden of chronic diseases.
 
However, the rising burden of chronic NCDs on 
developing
 
countries has received very little attention
 
(Beaglehole and Yach 2003). 
 
1.2 NON-COMMUNICABLE DISEASES IN AFRICA 
In 1990 the Global Burden of Disease (GBD) study suggested that NCDs diseases accounted 
for only 14% of the total burden in sub-Saharan Africa (SSA) but the estimates also 
suggested that in absolute terms the probability of death from NCDs is higher in SSA than in 
developed nations (Unwin et al 2001). Due to the lack of reliable data from SSA, these 
estimates were heavily based on assumptions and extrapolations. 
 
Tanzania, one of Africa‘s poorest countries has provided real data that can be used in support 
of these assumptions. Studies from this country (at least up until the year 2000) have shown 
that the probabilities of dying from a non-communicable cause are indeed higher than that 
from a communicable cause (Setel et al 2000, Kitange 1996). In addition, these studies show 
that among adults in Tanzania, the age-specific death rates from non-communicable diseases 
are substantially higher in all age groups when compared with developed countries.  
 
The projections for SSA from the GBD study suggest that by the year 2020, the proportion of 
NCD will increase to somewhere between 26% and 34% and among adults aged 15 59 
years to between 37% and 42% respectively (Unwin et al 2001). Despite these frightening 
figures, some have argued against an increased prioritization of NCDs in developing 












reason that in SSA, patients with NCDs only make a significant additional demand on an 
already depleted health care resources unable to cater for present problems of infectious 
diseases; hence that available scarce resources should be used to cater for patients with 
communicable diseases (Gwatkin et al 1999).  
 
1.3 NCD: SOCIO-DEMOGRAPHIC FACTORS. 
There are various factors that influence the global pattern of non-communicable diseases. 
Ethnicity is one such factor and encompasses both
 
genetic and cultural differences
 
(Anand et 
al 1999), and because individuals of different ethnic backgrounds tend to
 
live in distinct 
regions and societies, variations in disease
 
rates by ethnicity are also intertwined with 
geographic differences and may explain the variable impact of diseases in different 
populations.
 
For instance, a specific ethnic group within a location may adopt a
 
certain 
lifestyle, whereas the same ethnic group if in another
 
location may adopt substantially 
different lifestyles.  
 
Secondly, factors which promote selective survival of an individual in a population in 
response to the common environmental challenges experienced by that population also 
contribute to the variation of NCDs and especially CVDs. An example is the ―thrifty gene 
hypothesis‖ that postulates that certain genes in humans have evolved to maximize metabolic 
efficiency, lipid storage and food searching behaviour, and that in times of abundance these 
genes predispose their carriers to diseases caused by excess nutritional intake, such as obesity 
(Hales et al 1992). This hypothesis has been used to explain the common occurrence of 
















Thirdly, the state of intrauterine, infant, and
 
early childhood nutrition may later bring about 
population differences in CVDs (Barker 1994).  For example, adverse foetal development due 
to poor maternal nutrition may confer a selective
 
survival advantage to the foetus by 
programming it for
 
reduced insulin sensitivity. However, as the child is exposed
 
to excess 
nutrition in later years, such
 





Fourthly, differences in the epidemiologic transition of a country and exposure to specific 
associated environmental factors related to CVD risk may explain
 
discrepancies in the risk of 
incident CVD within populations. This may provide
 
the basis for differences in individual 
susceptibility to a particular disease in a
 
common and relatively homogenous environment. 
The Ni-Hon-San
 
study of Japanese migrants (Kagan et al 1974) provides a good example of 
how differences in demographic profiles, environmental
 
factors, early childhood 
programming influences as well as differences
 
in gene frequency or expression can contribute 
to variations
 
in CVD between different populations. This study revealed how blood 
cholesterol levels
 
and coronary heart disease rates rose from relatively low levels among 
those in
 
Japan, to intermediate levels in Japanese migrants in Honolulu, and to high levels
 
in 
those in San Francisco. 
 
 
Finally, the rate of migration to western environments (often arising from urbanisation and 
related to epidemiologic transition) has been increasing globally, from 36.6% of the world 
population
 
living in urban areas in 1970, to 44.8% in 1994. This proportion
 
is projected to 
increase to 61.1% by 2025
 












factors related to the emergence of NCDs in South Africa Bourne et al (2002) described 
shifts in dietary intake, which from a health perspective was of a less prudent pattern, taking 
place with increasing momentum in urbanised black South Africans. This review also 
brought to light the report of the South African Demographic and Health Survey (SADHS) in 
which the increasing prevalence of hypertension, diabetes and especially obesity among black 
South Africans was described and related to dietary transition and urbanisation (Steyn et al 
2003). 
 
Therefore, the disparity in CVD rates observed in different parts of
 
the world also mirror 
environmental changes usually arising from increasing urbanization with an associated 
dietary transition and a range of other influences occurring from early
 
childhood to 
adulthood. Subsequent chapters will now attempt to trace the development of CVDs, factors 
which propel the increasing global incidence and prevalence of CVDs and particularly how 



























About 1 billion people in the world are overweight or obese, compared to 850 million who 
are underweight (WHO 2000). In the US, the National Health and Nutrition Examination 
Surveys (NHANES) show that the prevalence of obesity has risen across all age and ethnic 
groups substantially between 1976 and 1994, going from 14.5% to 22.5% (Flegal et al 1998).  
 
Also, data from the adult health section of the 1998 SADHS had shown that the malnutrition 
pattern seen in adult South African population is one of predominantly over-nutrition rather 
than under-nutrition with a concomitant high prevalence of obesity, especially among black 
South Africans (Puoane et al 2002). 
 
Obesity and overweight are the propellers of the global increase in type 2 diabetes, and both 
conditions have, during the past decade, joined underweight, malnutrition, and infectious 
diseases as the major health problems developing countries need to contend with (Haslam et 
al 2005). Approximately 60% of all cases of diabetes can be directly attributed to weight gain 
(James et al 2003). The rising incidence of concomitant obesity and type 2 diabetes, which 
was once considered a disease of adulthood, is increasingly being diagnosed in paediatric 
populations (ADA 2000). 
 
The aim of this chapter is the consideration of the risks and complications associated with 
obesity. These metabolic disorders are discussed in the light of their relationship with CVDs. 












2.2 DEFINITION OF OBESITY 
The world health organisation defines obesity based on the risks of increased mortality and 
morbidity (WHO 1997). A body mass index (BMI) below 18.5 kg/m
2
 is defined as 
underweight; a BMI between 18.5 and 24.9 is normal weight. Pre-obese or overweight 
individuals are those with a BMI between 25 and 29.9 kg/m
2
 and are at increased risk of 
morbidity and mortality from obesity complications. Obesity is conventionally defined as 
BMI ≥ 30 kg/m
2
. (Table 2.1)  
 
Sub-classification of obesity into class I, II, and III correspond to mild (BMI between 30 and 
34.9 kg/m
2
), moderate (BMI between 35 and 39.9 kg/m
2
) and severe or morbid obesity (BMI 
≥ 40 kg/m
2
) respectively. Severely obese individuals are at higher risk of disease irrespective 
of the presence of other risk factors. Although the BMI is generally used to define obesity, 
other parameters such as waist circumference (WC) and waist-to-hip ratio (WHR) are also 























Table 2.1: Definition and Classification of Obesity with associated Disease Risk.  
 Disease risk relative to normal 





Men ≤ 102 cm 
Women ≤ 88cm 
Men ≥ 102 cm 
Women ≥ 88cm 
Underweight < 18.5  - - 
Normal 18.5-24.9  - - 
Overweight 25-29.9  Increased High  
Obesity 30-34.9 I High Very high 
 35-39.9 II Very high Very high 
Extreme obesity ≥ 40 III Extremely high Extremely high 
 
 
Table 2.2: Ethnic specific Waist circumferences as recommended by the International 
Diabetes Federation. 
 
Ethnic group Waist circumference. 
Europeans Men: ≥ 94 cm 
Women: ≥ 80cm 
South Asians Men: ≥ 90 cm 
Women: ≥ 80cm 
Chinese Men: ≥ 90 cm 
Women: ≥ 80 cm 
Japanese Men: ≥ 85 cm 
Women: ≥ 90 cm 
South and Central Americans Use South Asian recommendations until 
more specific data are available 
Sub-Saharan Africans Use European recommendations until 
more specific data are available 
Middle East (Arab) populations Use European recommendations until 














2.3 MEASUREMENT OF OBESITY 
The most commonly used measurement for determining obesity is the BMI, which is 








) x 703. The BMI 
provides a measurable estimate of body fat and is related to the risk of complications 
associated with obesity (Kushner et al 2003).  
 
Anthropometry provides both absolute circumferential and skin fold measurements and 
derived estimates of body composition. Anthropometric measurements are made using simple 
devices such as the tape measure for circumferences and skinfold callipers for skinfolds 
(Table 2.3). Other methods, often used in research, include underwater weighing (hydro-
densitometry) (Siri 1961), total body water estimation (Schoeller et al 1980), dual energy X-
ray absorptiometry (DEXA) (Mazess et al 1984), bioimpedance analysis (Segal et al 1991) 
and imaging methods such as computed tomography (CT) and magnetic resonance imaging 
(MRI) (Lewis et al 1986). The later two methods can reliably differentiate between 






















Table 2.3: Anatomic location of skinfold and circumference measurement sites. (Blackburn 
et al, 1994) 
 
Skinfold Anatomic site 
Bicep A vertical fold taken anteriorly halfway between the acromian and 
olecranon process  
Tricep Avertical fold taken posteriorly to the bicep skinfold 
Subscapular A diagonal fold taken just below the inferior angle of the scapula 
Suprailiac A diagonal fold taken just above the iliac crest at the midaxillary line 
Chest A diagonal fold taken halfway between the armpit and the nipple for men 
and one-third the distance for women 
Thigh A vertical fold taken anteriorly halfway between the hip and the knee 
Circumference Anatomic site 
Upper arm Measured halfway between the acromian and olecranon processes 
Chest Measured at the nipple line in men; at the largest circumference above the 
breasts in women 
Abdomen The smallest circumference in the abdominal area 
Waist Measured at the level of the iliac crest 
Hips The largest circumference below the umbilicus 
Buttocks The largest circumference in the gluteal area  
Thigh Measured just below the gluteal fold 





















2.4 OBESITY RISK FACTORS 
Except in the rare monogenic forms, obesity tends to occur as a result of the interactions of 
several risk factors. These factors, working together with small contributions from each part 
eventually lead to the common obese phenotype.  
 
2.4.1. GENETIC 
The commonly observed coexistence of several obese members within a family suggests the 
involvement of genetic factors in obesity and the risk of excessive weight gain in children of 
some families with obese parents is increased two- to three-fold for moderate obesity and up 
to eight times for severe obesity (Bouchard 2001). This genetic influence affects African-
American adolescents more so than white adolescents (Allison et al 1994).  The genetics of 
obesity is to be further explored in chapter 6. 
 
2.4.2. DIET 
Diet plays possibly the biggest role in obesity. Generally, the three ways that relate diet to 
obesity are: (i) the amount of calories an individual consumes, (ii) changes of the dietary 
pattern of the general population and (iii) marketing strategies by food industries.  
Firstly, cross-sectional studies have shown that obese subjects in general consume more 
calories than do normal-weight subjects (Astrup et al 1994). In a study of a rural South 
African population, comparison was carried out of nutrient intake between 1969 and 1989 
(Walker et al 1992). Energy intake was reported to have risen from 7.2 to 7.8 MJ with a 
consequent increase of mean BMI by 5.4% in that population.  
Secondly, dietary transitions also contribute significantly to obesity and have been reported 












such countries. In China for instance, changes in patterns of diet over the past few decades 
can be used to estimate the rising trend of obesity.  Average daily energy intake per capita 
was 2060 Kcal in 1959 and had risen to 2485 Kcal in 1982. Also, while total energy 
consumption remained relatively stable between 1982 and 1992, the diet composition 
continued to change, with a larger proportion of energy provided by fat (18% of energy in 
1982 compared with 22% in 1992) and lower consumption of carbohydrates (80% of energy 
in 1982 compared with 72% in 1992) (Zhou 1998). Concurrently, within a decade (1989 to 
1997), the prevalence of obesity in urban Chinese children had risen from 1.5% to 12.6% 
(Luo et al 2002).  
 
Thirdly, marketing of food has also greatly impacted on the changes observed in dietary 
patterns in different populations. Global marketing and the systematic moulding of taste by 
giant corporations has become a central feature of the globalization of the food industry 
(Barnett et al 1994). Big brand names like Coca Cola and Pepsi were recognized by 65% and 
42% of the Chinese population within a comparatively short time of their introduction into 
that country (Lang 2001). The huge sums of money spent on direct advertising and 
promotions cost the food industry in the US about US$ 30 billion each year and all of this is 
to get people to consume more calories (Jacobsen et al 2000).  
 
2.4.3. PHYSICAL ACTIVITY 
A low level of activity generally contributes to ill health. Today‘s environment is designed to 
promote physical inactivity; for example, television, cars, elevators, internet shopping and 
delivery are increasingly prevalent. Western populations today are almost sedentary 
compared with their very active ancestors. In Southern Africa, although high levels of 












rural and urban areas, levels have now decreased, particularly in the latter areas probably due 
to an increased tendency to sedentary activities (Walker 1998). 
 
Studies have shown that exercise facilitates weight reduction, improves insulin sensitivity, 
and decreases blood pressure. (Sowers et al., 2004) Exercise and insulin resistance exhibit an 
inverse relationship. Increased physical activity can cause a decrease in blood pressure and 
improve insulin sensitivity through several mechanisms like decreasing sympathetic nerve 
activity and improving vasodilatation as a result of an increase in the release of endothelium-
derived nitric oxide (Whaley et al 1999). 
 
2.4.4. SOCIOECONOMIC STATUS  
Obesity has always been associated with the better circumstanced.  It is now, however, 
becoming much more common among the poor (Kopleman 1999). In a review of some 
studies published before 1989 it was concluded that socio-economic status (SES) showed a 
consistent positive relationship to obesit  in developing countries (Sobal et al 1989). Another 
review on studies conducted between 1989 and 2003 from developing countries portrayed a 
different picture.  This review concluded that firstly, obesity in the developing world can no 
longer be considered solely a disease of groups with higher SES. Secondly, it showed that the 
burden of obesity in each developing country tends to shift towards the groups with lower 
SES as the country's gross national product increases. Finally, it showed that the shift of 
obesity towards women with low SES occurs at an earlier stage of economic development 
















In African culture, obesity in women is regarded with far less disfavour than in the case of 
white women (Walker 1998). Accordingly, there is only limited incentive in obese African 
women to reduce their weight, except among urban dwellers that are better educated and in 
higher socio-economic circumstances. Also, in most of Africa, especially southern Africa, 
HIV/AIDS is readily associated with a lean body mass. Overweight or obese men and women 
in most communities therefore prefer to maintain their body masses and avoid stigmatisation 
associated with the disease.  
 
2.5 COMPLICATIONS OF OBESITY 
Some studies had indicated that increasing body weight is associated with higher mortality; a 
relationship that remained controversial until the results of a large prospective study 
involving over a million men and women in North America was published, strengthening the 
association of obesity with mortality (Calle et al 1999). The study revealed death rates from 
all causes (cardiovascular, cancer or other diseases) increased throughout the range of 
moderate and severe overweight for both men and women in all age groups. Although there 
are numerous complications associated with obesity, only those related to cardiovascular 
complications are discussed in this section. Any attempts to discuss all the complications 
associated with obesity are considered as beyond the scope of this work. 
 
2.5.1. HYPERTENSION 
The relationship between obesity and hypertension is widely recognized as studies have 
shown that weight gain increases blood pressure while weight loss has been shown to be 
effective at lowering blood pressure (Hall et al 2002; Hall et al 2001; Jones et al 1994). 












75% of the risk for hypertension can be directly attributed to excess weight (Jones et al 
1994).  
The two mechanisms (haemodynamic changes and impaired pressure natriuresis) have been 
proposed for how hypertension results from the obesity state. This has been summarised in 
figure 2.1 
 
2.5.1.1 Haemodynamic changes  
Obesity is associated with increased regional blood flow to the extra fat tissue and increased 
cardiac output (Hall et al 2002; Rocchini 1990). The blood pressure increase in obesity is 
related to the marked increase in cardiac output related to volume expansion from increased 
retention of sodium (discussed below) and from an increased sympathetic activity. Blood 
flow to non- adipose tissue (kidney, skeletal muscle etc) also increases with weight gain.  
 
2.5.1.2 Impaired renal-pressure natriuresis 
In obesity, hypertension is associated with a reduced capacity of the kidneys to lose sodium 
(impaired pressure natriuresis) (Rocchini 1990). This is initially due to an increased renal 
reabsorption of sodium because the glomerular filtration rate (GFR) and renal plasma flow 
are increased. Increased sodium reabsorption will thus result in volume expansion and 
elevated blood pressure (Hall 1997).  
 
With prolonged obesity, increases in arterial pressure, renal vasodilation and glomerular 
hyperfiltration, neurohumoral activation, and metabolic changes may cause glomerular injury 
and further impairment of renal-pressure natriuresis, resulting in more severe hypertension 












There are 3 mechanisms that have been clearly shown to mediate this increased reabsorption 
of sodium in the kidneys: (a) increased renal sympathetic activity, (b) activation of the renin-
angiotensin aldosterone system and (c) altered intrarenal physical activities. 
 
2.5.1.2.1 Increased Renal Sympathetic Activity 
Several studies have shown that excess weight gain is associated with increased sympathetic 
activity, especially in the kidney (Landsberg et al 1989; Esler 2000). In experimental dogs for 
instance, it has been shown that increased sympathetic activity appears to raise blood pressure 
mainly through the renal sympathetic nerves (Kassab et al 1995).  
 
Although the mechanism for the increased sympathetic activity in obesity is not clear, 
hyperleptinaemia has been proposed as one way through which obesity may increase 
sympathetic activity (Hall et al 2001). Both acute and chronic infusions of leptin have been 
demonstrated to cause sympathetic activation and to chronically sustain elevated blood 
pressure (Haynes et al 1997; Shek et al 1998). How increased leptin does this is also not 
clearly understood but it is suggested that important interactions with other neurochemicals in 
the hypothalamus may be the mechanism for leptin induced sympathetic overdrive. (Details 
on leptin, its biology, signalling pathways and relationship to CVDs, especially kidney 
diseases will be discussed in chapter 5).  
 
2.5.1.2.2 Activation of the Renin-Angiotensin-Aldosterone System (RAAS)  
Obese subjects have increased plasma renin activity (PRA), plasma angiotensinogen, 
angiotensin-converting enzyme (ACE) activity, and plasma angiotensin-2 (ANG II) levels 
despite marked sodium retention and an expanded extracellular fluid volume. A significant 












causing hypertension in obesity has been supported by the reports that treatment of obese 
dogs with an ANG II antagonist or ACE inhibitor blunts sodium retention and volume 
expansion, as well as increased arterial pressure (Hall et al 1997; Robles et al 1993).  
 
ACE inhibitors are also effective in reducing blood pressure in obese humans, particularly in 
young patients (Reisen et al 1997). In addition to raising blood pressure, activation of the 
RAAS may also contribute to glomerular injury and nephron loss associated with obesity 
because increased ANG II formation constricts the efferent arterioles and exacerbates the rise 
in glomerular hydrostatic pressure caused by systemic arterial hypertension (Hall et al 1999). 
 
2.5.1.2.3 Altered Intra-Renal Physical Forces.  
The intra-abdominal pressure of obese subjects is increased, reaching levels as high as 35 to 
40 mmHg in some subjects with central obesity (Sugerman et al 1997). The kidney is 
retroperitoneally positioned and almost completely covered by adipose tissue that also 
penetrates into the medullary sinuses causing compression and increased intrarenal pressures 
(Hall et al 2002). It has been suggested that these increased intrarenal and intra-abdominal 
pressures may impair pressure natriuresis in the kidneys and contribute to obesity-associated 


























Figure 2.1: Summary of mechanisms and hormonal systems involved in obesity related 
hypertension (Adapted from Rahmouni et al 2005). 
 
 
FFA; Free fatty acids, NO; Nitric oxide, RAAS, Renin angiotensin aldosterone system. 
 
2.5.2. DIABETES 
The link between obesity prevalence and rates of diabetes in different populations was 
reported by West (1978) who demonstrated that the prevalence of type 2 diabetes rises as the 
population becomes more obese. Data from NHANES has shown that for each kilogram 
increase in weight of the population the risk of diabetes increased by 4.5% (Ford et al 1997) 
and more recent data have even shown that in the US there is a 9% increase of risk of 
diabetes with each kilogram body weight gain (Mokdad et al 2000).  
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The mechanism of the occurrence of diabetes mellitus arising from obesity is summarised in 
figure 2.2. The adipose tissue, however, is increasingly being considered not only as an 
energy storage tissue but as an endocrine organ that communicates with the brain and 
peripheral tissues, secreting several hormones that regulate appetite and metabolism 
(Kershaw et al 2004). This endocrine function appears to be modulated by a number of 
factors relating to the adipose tissue.  
 
The first is the location of the adipose tissue; that is whether the adipose tissue is visceral or 
subcutaneous. It has been reported that of the approximately 1,660 genes that are expressed in 
fat tissue, 17.9% of these genes showed at least a twofold increase in their expression in 
visceral fat compared to subcutaneous fat. Many of these genes are involved in glucose 
homeostasis and insulin action or in lipid metabolism (Atzmon et al 2002).  
 
Secondly, the relative size of the average adipocyte in the tissue may determine if it could 
have an endocrine function. Large subcutaneous abdominal adipocyte size has been 
associated with insulin resistance, and was shown to predict the occurrence type 2 diabetes in 
Pima Indians (Weyer et al 2001).  
 
The third factor relates to the metabolism of glucose and corticosteroids in adipocytes. 
Downregulation of the glucose transporter, (GLUT 4) that mediates insulin-stimulated 
glucose uptake in adipocytes and muscle has been shown to cause insulin resistance in mice 
and therefore increases the risk of developing diabetes (Abel et al 2001). The activity of 11β 
hydroxysteroid dehydrogenase type 1 (11β HSD-1) plays a pivotal role in determining 
intracellular glucocorticoid concentrations and has been suggested to serve as a tissue-












overexpressing the 11β HSD-1 exhibited pronounced insulin-resistant diabetes, 
hyperlipidemia, and hyperleptinaemia (Masuzaki et al 2001). 
 
 








Fourthly, the increased levels of free fatty acids (FFAs) found in obese individuals also 
contribute to the defects in glucose use and storage. Increased body fat leads to increased 
lipolysis with elevated FFA mobilization and as a result to increased FFA oxidation in muscle 
and liver. Glucose use begins to decline as FFA is used as the alternative fuel and hepatic 
glucose production increases in response to the higher FFA oxidation. These actions result in 

























Lastly, the adipose tissue also secretes a large number of proteins (cytokines) in addition to 
leptin that modulate glucose metabolism and insulin action (Kershaw et al 2004). Studies of 
mouse genetic models have established the causal role of some of these cytokines in insulin 
resistance and diabetes. Studies of humans generally suggest that circulating levels of these 
proteins are elevated in individuals with type 2 diabetes (Gabay et al 1999).  
 
 






























These proteins are known to play a role in innate immunity, for instance, tumour necrosis 
factor-alpha (TNF-α) and interleukin-6 (IL-6) are produced by macrophages as well as by 
adipocytes and both act directly on inflammatory cells and also contribute indirectly to 
inflammation by acting on the liver to produce acute phase proteins (Gabay et al 1999). They 
induce suppressor of cytokine signaling-3 (SOCS-3), an intracellular signalling molecule that 
impairs the signalling of both leptin and insulin and SOCS-3 levels which are elevated in 
obesity and may represent a final common pathway of obesity-associated resistance to the 
actions of both leptin and insulin (Shi et al 2004). 
 
2.5.3. INSULIN RESISTANCE AND HYPERINSULINEMIA 
Reduction to insulin sensitivity can occur through an inherited defect, or as a consequence of 
obesity. The impact of obesity on insulin resistance independent of genetic factors is 
illustrated from a study of identical twins that were discordant for weight (Ronnemaa et al 
1997). Within both male and female twin pairs, the obese member had higher fasting insulin 
levels and showed lower insulin sensitivity in the 75-g oral glucose tolerance test than the 
non-obese member and these differences were particularly evident among members with high 
abdominal fat distribution.  
 
Once hyperinsulinemia and insulin resistance is acquired, it starts a cascade of metabolic 
changes that can lead to diabetes, dyslipidemia, hypertension, hypercoagulability, and 
eventually CVD. The relationship between insulin sensitivity and BMI is illustrated using the 
minimal model technique of Bergman (Bergman et al 1979). Khan and his colleagues (1993) 
applied this model to a group of non-diabetic subjects with widely varying BMI and found 













In both the fasting and postprandial states, obese subjects require insulin levels that are 
several times higher than non-obese subjects to maintain normal glucose tolerance. At the 
cellular level, insulin normally binds to its receptor on the surface of target cells, thereby 
causing tyrosine auto-phosphorylation and consequent intracellular signalling. These events 
culminate in cellular responses, such as the translocation of glucose transporters to the cell 
surface to allow glucose uptake for use or glycogen storage. In obesity, however, insulin 
signalling is defective. Insulin stimulated protein kinase activity of the insulin receptor, which 
mediates tyrosine auto-phosphorylation, is reduced in obese subjects relative to non-obese 
ones, and it is further reduced in obese type 2 diabetes patients (Caro et al 1989).  
 
2.5.4. CARDIOVASCULAR DISEASES 
It has been stated that ―no risk factor has as strong an impact on the cardiovascular risk 
profile as obesity‖ (Kannel 1997). Abdominal adiposity is particularly associated with CVD 
risk and obesity is a risk factor for unfavourable lipid profile: decreased high-density 
lipoprotein (HDL) cholesterol level, increased low-density lipoprotein (LDL) cholesterol and 
increased triglyceride levels all of which are related to CVD (Van den Hoogen et al 2000; 
Rexrode et al 1998).  
 
American women from the Nurses‘ Health Study with BMI above 30 kg/m
2
, had a threefold 
risk of developing nonfatal myocardial infarction compared with women with a BMI below 
21 kg/m
2
 (Manson et al 1990). Framingham data, based on 26 years of follow-up of 
approximately 5200 men and women aged 28–62, also showed that high relative weights 
were predictive of myocardial infarction, sudden death, congestive heart failure, and 
atherothrombotic strokes (Hubert et al 1983). It was estimated from the Framingham Study 












fewer strokes or episodes of heart failure (Hubert et al 1983). Independent of other risk 
profiles like hypertension and lipid levels, obesity has also been shown to be directly related 



































THE METABOLIC SYNDROME 
 
3.1 INTRODUCTION: HISTORY OF THE METABOLIC SYNDROME.  
The first mention in literature on what is currently described as the metabolic syndrome (MS) 
was reported in the early 20
th
 century by some European physicians who wrote about the 
relationship between metabolic disorders, blood pressure and diabetes (Hitzenberger and 
Richter- Quitter, 1921; Hitzenberger 1921; Kylin 1921; Maranon. 1922). Table 3.1 displays 
the names of authors and the year in which they reported on findings related to the MS.   
 
Reaven, after several years of research on resistance to insulin-mediated glucose uptake, 
reported in 1988 that this disorder was present in the majority of subjects with type 2 diabetes 
mellitus or impaired glucose tolerance (IGT), but it was also present in 25% of the 
individuals with normal glucose tolerance. He thus formed the hypothesis that insulin 
resistance is the common aetiological factor for a group of disorders, consisting of IGT, 
hyperinsulinaemia, high levels of very low-density lipoprotein (VLDL)-triglycerides, low 
levels of high-density lipoprotein (HDL) cholesterol and hypertension. He then named this 
group of disorders ―syndrome X‖ in an attempt to stress its unknown aspects and pointed out 
that individuals with the syndrome are at increased risk of atherosclerosis (Reaven 1988).  
Reaven‘s description of syndrome X was the spark that has since ‗lit the fire‘ on the research 

















Table 3.1: Previous mentions of the metabolic syndrome in literature 





Metabolic trisyndrome Camus, 1966 
Pleurimetabolic syndrome Avogaro and Crepaldi, 1967 
Syndrome of affluence Mehnert and Kuhlmann, 1968 
Metabolic syndrome Hanefeld and Leorhardt, 1981 
Syndrome X Reaven, 1988 
Deadly quartet Kaplan, 1989 
Insulin resistance syndrome DeFronzo and Ferrannini, 1991; Haffner, 1992 
 
 
3.2 DEFINITION OF THE METABOLIC SYNDROME 
There have been different definitions of the MS and the lack of a uniform definition from 
different expert groups essentially stems from different concepts about its origin and its 
importance in clinical practice. Opinions have varied as to whether it should be defined to 
indicate insulin resistance, defined for CVD risk stratification, or should simply reflect a 
collection of statistically related factors. Therefore, different expert groups have attempted to 
produce diagnostic criteria to define the MS being that its critical importance lies in 
identifying individuals at high risk of both type 2 diabetes and CVD.  
 
The World Health Organisation (WHO) in 1998 first proposed a definition for the MS 
(Alberti and Zimmet 1998). The WHO criteria (Table 3.2) had insulin resistance or its 
surrogates (impaired glucose tolerance or diabetes) as essential components, together with at 












obesity (as measured by WHR or BMI), and microalbuminuria. The European Group for the 
Study of Insulin Resistance (EGIR) then produced another definition which was essentially a 
modification of the then existing WHO criteria by excluding people with diabetes mellitus 
(Balkau and Charles 1999). The EGIR criteria required hyperinsulinaemia to be present, used 
WC instead of BMI or WHR as measure of adiposity and had different cutoffs for other 
variables (Table 3.2).  
 
In 2001, the National Cholesterol Education Program (NCEP) Adult Treatment Panel III 
(ATP III) proposed a definition to facilitate clinical diagnosis and primarily aimed at defining 
CVD risk (NCEP 2001). The ATP III definition shifted from the previous two definitions by 
deemphasizing hyperinsulinaemia and insulin resistance, and required 3 of any 5 of: central 
obesity (measured as WC), raised blood pressure, raised triglycerides, low HDL-cholesterol, 
and fasting hyperglycaemia to be present in order to make a diagnosis of the MS (Table 3.2). 
 
Due to these differences in definition, the confusion created from lack of specificity of the 
previous definitions, the inability to compare between studies carried out into the MS using 
these different definitions, and the view of the international diabetes federation (IDF) on the 
MS as the major driver of the worldwide epidemic of type 2 diabetes and CVDs, a new 
worldwide definition was then proposed in 2005 (IDF 2005). This new definition 
recommended the use of the diagnostic glucose level of the American Diabetic Association 
(ADA) for impaired fasting glucose (5.6mmol/L) to be used rather than the measurement of 
insulin resistance which was thought to be unrealistic. Waist circumference which had 
previously been linked to CVDs was the preferred measure of obesity with ethnic specific 












recommended reference to the individual‘s ethnic group, and not country of residence. The 
cutoffs for other variables of the MS were the same as those in the ATP III definition.  
 
Finally, the IDF recommended some criteria to be used for research into the MS, including: 
measurement of insulin resistance, oral glucose-tolerance test, tests for endothelial 
dysfunction, imaging of visceral adiposity and liver fat, measurement of adipocytokines and 
inflammatory markers (adiponectin, leptin, IL-6, TNF-α), urinary albumin, and 
prothrombotic factors (plasminogen activator inhibitor type 1, fibrinogen) (IDF 2005). Since 
these recommendations were made, no groups have proposed any other definition for the MS 
rather the search now is for mechanisms causing it and leading to associated CVDs. 
 
3.3 PREVALENCE OF THE METABOLIC SYNDROME 
There are few national surveys reporting the prevalence of the MS, however available data 
suggest a wide variation from one population to another depending on the criteria used 
(Lakka et al 2002; Ford et al 2004; Gu et al 2005; Illanne-Parikka et al 2004). In the United 
States, data from the third NHANES of 1999-2000 using the ATP III criteria reported a 
prevalence of 27% (Ford et al., 2004) while the Kuopio study in Finland, carried out in non-
diabetic middle aged men, free of CVD reported a prevalence of 8.8% by the ATP III criteria 
and 14.2% by the WHO criteria (Lakka et al 2002).  
 
Reported prevalence tends to be dependent on the group studied within a given population 
(diabetics, specific gender, ethnicity/race, age groups). For instance, in a population based 
study of diabetic subjects in Italy, a prevalence of 75.6% was reported (Bruno et al 2004), 
while from the same country, when the study was carried out in subjects with diabetic 


































IGT, IFG, T2DM, or 
Reduced Insulin 
sensitivity  plus 2 of : 
 
Plasma insulin > 75th 
percentile 
plus any 2 of: 
None 
 








Men: WHR > 0.90; 
Women: WHR > 0.85 
and/or BMI > 30kg/m2  
 
Men: WC ≥ 94cm  
Women: WC ≥ 80cm 
 
Men: WC ≥ 102cm 












TG ≥ 1.7mmol/L 
  
 
                And / or 
TG ≥ 1.7mmol/L 
 
 
And / or 
TG ≥ 1.7mmo/L 
 
TG ≥ 1.7 mmol/L 
 




Men: < 0.9 mmol/L 
Women: < 1.0 mmol/L 
HDL: 
 
Men: < 1.0 mmol/L 




Women: 1.3 mmol/L 
HDL: 
 
Men: 1.0 mmol/L 
Women: 1.3 mmol/L 















≥ 130/85 mmHg 
 
≥ 130mmHg systolic or 
≥85 mmHg diastolic or 






IGT, IFG, or T2DM 
 
IGT, or IFG 
(Diabetes excluded) 
 
> 6.1 mmol/L (includes 
diabetes) 
 


































Gender differences in prevalence have been reported from several studies carried out in 
different populations (Illane-Parikka et al 2004; Oh et al 2004; Ford et al 2004). However, 
prevalence usually increases with age in men and women irrespective of race or ethnicity. 
The InterASIA study of 15,540 adults in China (Gu et al 2005) reported higher prevalence in 
women than in men in every age group, rising from 8.4% in men aged 35 to 44 years to 
28.6% in women aged 65 to 74 years.  
 
Significant variation in MS prevalence has also been reported among the different ethnic 
groups in the United States (Park et al 2003(a); Ford et al 2002). The age-adjusted prevalence 
of the MS from the NHANES III was 31.9% among Mexican Americans, 23.8% among non-
Hispanic whites, and 21.6% among African Americans (Ford et al 2002). Data from the 
Third NHANES (NHANES III, 1988-1994) indicated that Mexican American men and 
women have the highest prevalence of the MS in the United States (Ford et al 2002). The 
age-adjusted prevalence of the MS was 31.9% among Mexican Americans, 23.8% among 
non-Hispanic whites, and 21.6% among African Americans (Ford et al 2002). 
 
There have been far fewer studies reporting prevalence of the MS from Africa compared to 
studies from Europe, North America and South East Asia. However, available reports have 
also had differences in reported prevalence, depending on which definition is used and the 
specific population studied. Two studies from Nigeria using type 2 diabetics reported 
prevalence of 25.2% (Alebiosu and Odunsan 2004) and 59.1% (Isezuo and Ezunu 2005)  
even though the WHO criteria was used in defining the condition. The discrepant prevalence 
rates obtained from the two studies from Nigeria could be related to differences in ethnicity 












3.4 PATHOGENESIS OF THE METABOLIC SYNDROME   
The aetiology of the MS is still not clear yet and likely to be complex in nature. Poor 
nutrition, physical inactivity, and subsequent increases in body weight have often been 
blamed as causes of the MS. What precisely causes the MS and how it comes about will 
remain important research questions until definitive answers are found. At present, 
mechanisms leading to the MS revolve around 2 major theories: insulin resistance and 
obesity.  
 
3.4.1 METABOLIC SYNDROME: THE INSULIN RESISTANCE MECHANISM. 
Metabolic syndrome and insulin resistance are often used interchangeably and there is a 
strong case for insulin resistance being the primary cause of MS. Although there is lack of 
clinical evidence to show that reduction in insulin resistance in people with the MS will 
prevent CVD, insulin resistance is still thought to be at the core of the MS.  
 
Evidence for the central role of insulin resistance in the development of the MS is supported 
by the Bruneck Study in Italy which examined the prevalence of insulin resistance among 
4800 subjects aged 40–79 using the homeostasis model assessment (HOMA) method. In this 
study, the degree of insulin resistance correlated with the number of metabolic abnormalities, 
and when several abnormalities were clustered together, insulin resistance was almost always 
present (Nesto 2003).  
 
The findings from the Bruneck study, however, do not explain the link between insulin 
resistance and most components of the MS. Mechanisms that have been proposed to connect 












effects of mild to moderate hyperglycaemia, (2) tissue and cellular effects of compensatory 
hyperinsulinemia and (3) unbalanced pathways of insulin action as described further below. 
 
Mild to moderate, sub-diabetic, post-prandial hyperglycaemia, may lead to a variety of 
effects usually associated with diabetes such as accelerated atherosclerosis via advanced 
glycosylated end products or via enhanced collagen formation (discussed further in the next 
chapter in relation to diabetic kidney disease). However, evidence for such an association is 
very weak (UKPDS. 1998). Hence a more important mechanism for this effect may be the 
accompanying compensatory hyperinsulinaemia and the unbalanced pathways of insulin 
actions that results. 
 
Insulin is normally secreted from the beta cells in response to post-prandial hyperglycaemia; 
the secreted insulin stimulates muscle uptake of the ingested glucose and suppresses 
gluconeogenesis in the liver. However, in insulin resistance, the hepatic and myocyte actions 
of insulin become compromised and the resultant hyperglycaemia turns into a continuous 
stimulus for insulin secretion. 
 
Insulin binds to and activates its receptor through the phosphorylation of tyrosine phosphate 
residues thus initiating the intracellular signalling cascade (Figure 3.1). The two major 
pathways for insulin signalling are the phosphatidylinositol 3-kinase (PI-3K) and the 
mitogen-activated protein kinase (MAPK) pathways (Le Roith and Zick 2001). 
 
The PI-3K pathway is initiated by tyrosine phosphorylation of a member of the insulin 
receptor substrate family (IRS-1/2/3/4), which associates with the p85 regulatory subunit of 












phosphatidylinositol 3, 4, 5-phosphate (PIP3) to be produced, resulting in the activation of 
protein kinase B (Akt) and other downstream effector molecules that mediate the metabolic 
response to insulin, which includes translocation of GLUT4 to the membrane (Cusi et al 
2000).  
 
The MAPK pathway begins with phosphorylation of Src homology 2 domain-containing 
(SHC) or insulin receptor substrate, which binds Grb2 and activates Ras via mammalian Son 
of Sevenless (mSOS). Ras then binds and disinhibits Raf, which activates another kinase, 
MEK1. MEK1 activates extracellular signal-regulated kinases ERK1 and ERK2. Activated 
ERKs, which are a type of MAPK, mediate the mitogenic and proinflammatory responses of 
insulin signalling (Cusi et al 2000).  
 
In MS and type 2 diabetes mellitus, the pathways leading to activation of PI-3K are blocked, 
possibly through serine phosphorylation of the insulin receptor and/or IRS proteins, whereas 
the MAPK pathway remains open and may even be hypersensitive (Cusi et al 2000). Thus, 
antagonists of the appropriate serine kinase might reverse insulin resistance and restore the 
balance of MAPK and PI-3K signalling pathways. This has been demonstrated by Potenza et 
al who administered Rosiglitazone to spontaneous hypertensive rat (SHR) models of the MS.  
After three weeks of treatment, blood pressure, insulin levels, and ET-1 levels were lower, 
and adiponectin levels and insulin sensitivity were increased, with increased vasodilator 
response to insulin, consistent with rebalancing between PI 3-kinase and MAPK branches of 





















Activation of the PI-3K signalling pathway also results in increases of cellular levels of nitric 
oxide, which is a potent inhibitor of vascular smooth muscle cell growth. Thus, an 
impairment in the PI-3K pathway could contribute to vascular endothelial dysfunction. 
Conversely, smooth muscle cell growth and proliferation are stimulated by activation of the 
ERK-MAPK pathway, which maintains normal sensitivity to insulin even in insulin-resistant 
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The overall effect of this unbalanced insulin pathway which creates a condition favourable to 
vascular endothelial dysfunction, smooth muscle cell growth and proliferation may well be to 
enhance atherogenesis and features of the MS (Cusi et al 2000; Hsueh and Law 1999). 
3.4.2 THE METABOLIC SYNDROME: THE FAT (OBESITY) MECHANISM.  
The purpose of adipose tissue throughout the body is energy storage. Calories are stored as 
triglycerides and released as fatty acids when energy is needed. It is safest for the body to 
store triglyceride in small peripheral adipocytes and if the capacity of these adipocytes to 
store triglyceride is exceeded, triglyceride accumulates in liver cells, skeletal muscle cells and 
visceral fat cells. This abnormal triglyceride deposition may lead to the development of 
hepatic and muscular resistance to insulin action. Excess triglyceride in myocytes and in 
abnormally large peripheral adipocytes appears to cause insulin resistance in these cells 
(Kelley and Mandarino 2000).  
 
The lipotoxic effect of elevated FFA is thought to be the major mechanism through which 
obesity brings about features of the MS. However, this can occur through any or a 
combination of these processes: oxidative stress, proinflammatory signalling or through the 
actions of ceramide. Firstly, studies using magnetic resonance spectroscopy in humans have 
shown that increased fatty acid levels directly inhibit glucose transport by causing 
mitochondrial dysfunction (Lowell and Shulman 2005; Savage et al 2005) and stimulating 
certain protein kinases like PKC-theta, that then promote insulin resistance (Lowell and 
Shulman 2005).  
 
Secondly, increased reactive oxygen species in response to fatty acids activates nuclear factor 
kappa B (NF-кB), which further stimulates the production of other proinflammatory 












signalling intermediates namely, IкB kinase beta (IKKβ) and Jun kinase 1 (JNK) which play 
a central role in cross-talk between inflammatory signalling and insulin signalling, leading to 
insulin resistance by phosphorylating IRS-1/2 on serine residues (Hirosumi et al 2002; Gao et 
al 2004). In other words, the process of inflammation triggered off by excess fat may be the 
cause of organ damage that results in the MS phenotypes. 
 
Finally, ceramide, a product derived from long-chain saturated fatty acids inhibits insulin-
stimulated activation of Akt and translocation of GLUT4 (Chavez et al 2003). Ceramide 
content in skeletal muscle of obese humans is increased, (Adams et al 2004) and 
overexpression of acid ceramidase protects against FFA-induced insulin resistance in vitro 
(Chavez et al 2005). 
 
3.4.3 THE METABOLIC SYNDROME: OTHER MECHANISMS 
The MS has been likened to Cushing syndrome which results from excess circulating 
glucocorticoids and manifests with h pertension, obesity, diabetes, and dyslipidaemia 
amongst other things. Peripheral fat is known to be shifted to central (visceral) depots by 
excess cortisol, hence the link between glucocorticoid excess and the MS. Activity and 
expression of 11- beta hydroxysteroid dehydrogenase type 1 (11-β HSD1), the enzyme 
responsible for the conversion of inactive cortisone to its active form cortisol, has been 
reported in adipose tissue of centrally obese women (Katz et al 1999; Engeli et al 2004). The 
expression levels of 11-β HSD1 were directly proportional to WC and insulin resistance 
(Engeli et al., 2004). Some studies have reported the relevance of locally formed 
glucocorticoids in white adipose tissue to the MS. Masuzaki and colleagues (Masuzaki et al 
2001; Masuzaki et al 2004) described the occurrence of metabolic abnormalities and 












and his colleagues (2004) found that high-fat feeding failed to produce the MS in 11-β HSD1 
deficient mice (Seckl et al 2004). 
 
The hypothesis of foetal programming (thrifty phenotype) has come out of extensive 
epidemiological evidence, that is, that events occurring during foetal life permanently alter 
the structure and function of developing organs in the foetus with consequent predisposition 
to various metabolic diseases in adulthood (Barker 1994). Intrauterine growth retardation 
(IUGR) arising from foetal undernutrition can lead to permanently reduced nephron number 
(Brenner and Chertow 1994; Vehaskari et al 2001), permanently reduced pancreatic insulin-
secreting β-cells (Holemans et al 2003), and permanently reduced skeletal muscle fibre 
number (Dwyer et al 1995) and mitochondrial mass (Park et al 2003b).  
 
In the face of abundant nutrients, the ―thrifty phenotype‖ (a smaller body size, a lowered 
metabolic rate and a reduced level of behavioural activity; adaptations to an environment that 
is chronically short of food) generates body size excess relative to organ capacity, deposits 
excess abdominal fat and promotes abdominal obesity, and the reduced pancreatic insulin 
secretory capacity may hasten transition from hyperinsulinemia to overt diabetes. Lower 
muscle mass—which persists in adults who experienced IUGR (Yajnik 2003)—could 
promote obesity via low basal metabolic rate and biologically based inactivity. The reduced 
skeletal muscle oxidative capacity and smaller mitochondria described in offspring with 
IUGR (Park et al 2003) could increase susceptibility to insulin resistance by favouring 
accumulation of myocyte FFA.  
 
The ―Birth-to-Ten Cohort‖ was a prospective study that investigated the relationship between 












(Yach et al 1991). In this study, systolic blood pressure and blood glucose inversely 
correlated with birth weight at age 5years and 7 years respectively independent of current 
weight, maternal age, gestational age and socioeconomic status. Another study in Cape Town 
South Africa in a cohort of full-term offspring of primiparous women of mixed ancestry 
revealed significantly higher blood pressure and prevalence of impaired glucose tolerance in 
those with low birth weights compared to those with normal weights (Levitt et al 2000). 
 
This chapter has reviewed the MS from the perspective of its different definitions and rising 
prevalence, and has attempted to explore its origins with a view to linking it to obesity. The 
clinical manifestations and complications of the MS are obviously beyond the scope of this 
work. The role of adipocyte hormones in inflammation will be discussed in chapter 5. The 
next chapter will discuss kidney disease as a model of CVD arising from obesity and the MS; 
reasons why hypertension alone cannot be blamed for kidney disease in black Africans will 
























CHRONIC KIDNEY DISEASE 
4.1 INTRODUCTION 
Chronic kidney disease (CKD) is defined by the presence of sustained abnormalities of renal 
function and results from different causes of renal injury. CKD can lead to progressive loss of 
renal function, and may terminate in end-stage renal disease (ESRD) after a variable period 
of time following the initiating injury (NKF 2002). The public health impact of ESRD has led 
to increased interest in clinical and public health interventions that can delay or prevent the 
occurrence of ESRD in individual patients and in high-risk populations with CKD.  
 
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-
KDOQI) Clinical Practice Guidelines for Chronic Kidney Disease recommend that CKD be 
adopted to define the presence of kidney injury and impaired kidney function (NKF 2002). 
The National Kidney Foundation criteria includes the presence for 3 or more months of 
impaired renal function across a continuum of renal injury from isolated anatomic, 
radiographic, biomarker, and urinary abnormalities to decreased glomerular filtration rate 
(GFR), irrespective of the primary cause of the renal injury (NKF 2002). Classification of 
CKD requires the establishment of presence or absence of renal injury, estimate of GFR, and 
determination that kidney disease has persisted for 3 or more months. Equations that convert 
the serum creatinine into an estimated GFR or creatinine clearance are available and are used 
















An estimated GFR above 60 mL/min/1.73 m
2
, in the absence of other anatomic, radiographic, 
or urinary abnormalities, is not classified as CKD. The NKF classification defines five stages 
of CKD by increasing degree of impaired kidney function (Table 4.1), and as kidney damage 
progresses the remaining nephrons compensate for the reduction in nephron mass by 
increasing the single nephron filtration rate with this hyperfiltration promoting further injury 
(Brenner and Mackenzie 1997). At each stage, therefore, patients can benefit from measures 
that delay or prevent the progressive loss of renal function such as modification of 
medications with renal clearance, avoidance of nephrotoxins, and reduction of cardiovascular 
risk factors (St Peter et al 2003). Patients with CKD need to be monitored for progression to 
kidney failure, and patients who advance to CKD stage 3 require increased monitoring and 
control of hypertension, anaemia, renal bone disease, and nutrition.  
 
Recognition and early referral of patients who advance to stage 4 and 5 CKD is important if 
the transition to ESRD treatment is to be successful. It is thought that for patients in these 
early stages of CKD, early recognition and administration of appropriate treatment may delay 
the onset of ESRD. For example, delayed referral for ESRD treatment has been associated 
with less than optimal vascular access placement, failure to manage renal bone disease and 
nutrition, poor anaemia control, impaired quality of life, and increased risk of severe 
hypertension, uremic symptoms, pulmonary oedema, and emergent dialysis (Arora et al 

















Table 4.1: NKF-KDOQI Classification of Kidney disease by varying levels of GFR. (NKF 
2002). 
 











Kidney damage* with normal or mild decrease in 
GFR 
 




Moderate decrease in GFR 
 




Severe decrease in GFR 
 




Kidney failure / ESRD 
 
<  15 
 
CKD is defined as either kidney damage or GFR<60 ml/min/1.73m
2
 for ≥3 months. 
* Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood 
or urine tests or imaging studies. 
GFR – Glomerular filtration rate. 
 
 
4.2 EPIDEMIOLOGY OF CHRONIC KIDNEY DISEASE: 
4.2.1. CKD AS A PUBLIC HEALTH PROBLEM 
Chronic kidney disease is a worldwide public health problem. According to the World Health 
Report 2002 and Global Burden of Disease (GBD) project, diseases of the kidney and urinary 
tract contribute to the global burden of diseases, with approximately 850,000 deaths every 





 cause of death and disability respectively.  
 
Patients with ESRD consume a disproportionate share of health care resources. The total cost 
of the ESRD program in the US was $22.8 billion in 2001, an 11.5 percent increase from 
2000 (USRDS 2003). The projected number of ESRD patients by the year 2010 has been 












USD (USRDS 2000). Although such data are not available in Africa, available estimates 
from Cape Town South Africa show that the annual cost of dialysis treatment per patient is 
$25, 000 and only about 100 patients are allowed into the National renal replacement 
programme at a given time due to cost (From Dr MD Pascoe, head of the Nephrology Unit 
University of Cape Town).   
 
Despite the magnitude of the resources committed to the treatment of ESRD and the 
substantial improvements in the quality of dialysis therapy, these patients continue to 
experience significant mortality and morbidity, and a reduced quality of life. In 2000 alone, 
72,342 ESRD patients died and the survival probabilities for dialysis patients at 1, 2, 5 and 10 
years were 80, 67, 40, and 19 percent, respectively (USRDS 2003). Moreover, 50 percent of 
dialysis patients have three or more comorbid conditions, the mean number of hospital days 
per year is approximately 14 per patient, and self-reported quality of life is far lower in 
dialysis patients than in the general population (McClellan et al 1991; DeOreo 1997). 
 
4.2.2. PREVALENCE OF CKD AND ESRD  
An estimate of the global burden of ESRD was provided in a survey which included 122 
countries. It reported that the approximate number of patients on renal replacement therapy 
(RRT) is over 1.4 million and that more than 80% of these patients live in Europe, North 
America, and Japan (Moeller et al 2002). Reported prevalence rates of patients on RRT are 
generally used to assess the prevalence of ESRD. 
 
There is a wide variation in prevalence rate, expressed as number of patients per million 
population (ppmp), among countries and several factors may be responsible for these 












income, and governmental infrastructure, as these can influence both the availability and 
quality of dialysis and transplantation services. The prevalence rate of RRT is 644 ppmp in 
the 15 countries of the European Union (Berthoux et al 1999), compared with a prevalence 
rate of 166 patients per million population in Central and Eastern European countries 
(Rutkowski 2002).  
 
Secondly, the reported prevalence rates in poorer countries like those of Africa and Asia 
being far less than those of developed economies is generally related to poor infrastructure.  
In West Africa for instance, the prevalence of ESRD ranges from 1.6 ppmp in Ghana to 20 
ppmp in Mauritania (Fogazzi et al 2003) and in the countries of North Africa that have better 
established renal replacement programs, it ranges from 30 ppmp in Libya to 186.5 ppmp in 
Egypt (Naicker 2003). Data from the South African Dialysis and Transplant Registry 
(SADTR) of 1994 revealed that 3399 patients (99 ppmp) were alive and on treatment for 
ESRD (SADTR 1994). 
 
Thirdly, the maintainance and updating of renal registries is not standardised. Renal registries 
offer an important source of information on several aspects of CKD and are very useful in 
gaining insight on the burden of kidney diseases and allowing comparisons of incidence and 
prevalence of ESRD, mortality and morbidity, patient demographics and treatment modalities 
among countries (Stengel et al 2003a). Also, renal registries often record data of patients who 
are at the last stage of kidney disease with very little known about the prevalence of earlier 
stages of CKD and it has been acknowledged that the majority of individuals at early stage of 
CKD have gone undiagnosed and under-treated. However, several countries do not have 
registries and the content of national registries is often uneven, for example, some registries 














Fourthly, there are striking racial and ethnic differences in the incidence and prevalence rates 
of CKD and ESRD. In 1999, the incidence rates for ESRD in the United States were 237 
ppmp in Caucasians, 953 ppmp in African Americans, 386 ppmp in Asian Americans and 
native Hawaiians and other Pacific Islanders, and 652 ppmp in American Indians and Alaska 
Natives. Furthermore, 10 percent of all new ESRD patients were Hispanic (USRDS 2001). 
There is also significant variability in the causes of ESRD among the various racial and 
ethnic groups. As an example, whereas diabetic nephropathy is the most common cause of 
ESRD in all racial/ethnic groups, hypertensive nephropathy is the cause of ESRD in 33 
percent of African Americans, compared to less than 25 percent in all other racial/ethnic 
groups. The age and gender adjusted ratio (African American to Caucasian) of hypertensive 
ESRD is 6 to 1. African Americans, and to a lesser extent other racial and ethnic minorities, 
also have a disproportionately higher incidence rate of ESRD due to diabetes and 
glomerulonephritis compared to Caucasians,  and these minority groups in the US tend to 
reach ESRD at a younger age than Caucasians (mean age 57 and 58 years, compared to 63 
years) (USRDS 2001). 
 
4.2.3. POPULATIONS AT HIGH RISK OF CKD AND PROGRESSION TO ESRD  
A number of populations are considered to be at high risk of developing ESRD and include 
these four groups: (1) patients with diabetes mellitus, (2) patients with hypertension, (3) 
patients with CVD, and (4) family members of incident ESRD patients. There are however, 
several other risk factors (including those that are components of the MS) associated with 















4.2.3.1 Diabetes mellitus. 
Diabetes mellitus is the most common cause of ESRD reported by the USRDS for the United 
States population and it accounted for nearly 45% of all new cases of ESRD starting renal 
replacement therapy between 1996 and 2000 (USRDS 2002). High blood glucose level is the 
common factor in the initiation and progression of renal injury among diabetic patients. Renal 
cells are stimulated by hyperglycaemia to produce humoral mediators, cytokines, and growth 
factors that are responsible for the structural alterations such as increased deposition of 
extracellular matrix (ECM) and the functional alterations such as increased permeability of 
glomerular basement membrane or shear stress (Schena and Gesualdo 2005).  
 
Hyperglycaemia additionally induces an abnormal activation of protein kinase C (PKC), 
which is involved in the development of diabetic nephropathy. Upregulation of PKC has been 
observed in the kidneys of rats with diabetic nephropathy (Koya et al 1997) and associated 
with transforming growth factor-β1 (TGF-β1), fibronectin, and collagen type IV 
upregulation.  
 
Glucose Transporter-1 (GLUT-1), a surface receptor of resident renal cells, modulates the 
influx of glucose into renal cells. Mesangial cells have been shown to overexpress GLUT-1 
mRNA when exposed to high glucose concentrations leading to overproduction of GLUT-1 
protein and increased glucose transport into the cells (Heilig et al 1997).  
 
Chronic hyperglycaemia can also result in glycosylation of serum and tissue proteins leading 












glucose combines with free amino acids on serum or tissue proteins, initially forming 
reversible early glycosylation products and later irreversible advanced glycosylation end 
products (AGEs) via an ―Amadori‖ rearrangement (figure 4.1) (Vlassara 1996). Circulating 
and cellular AGE concentrations are increased in diabetic patients, particularly in those with 
renal insufficiency, since AGEs are normally excreted in the urine. This results in tissue 
accumulation of AGEs, in part by crosslinking with collagen, which can contribute to the 
renal and microvascular complications (Makita et al 1991). There is increasing evidence 
supporting a contribution of AGEs to the pathogenesis of diabetic kidney disease. Yang et al 
(1994) have shown that the administration of AGE-modified albumin to normal rats for four 
weeks led to glomerular hypertrophy and increased ECM production in association with 
activation of collagen, laminin, and transforming growth factor-β genes (Yang et al 1994). 
 
Figure 4.1: Formation of advanced glycosylation end products in the presence of persistent 




4.2.3.2 Hypertension  
Hypertension is ranked as the second most common cause of ESRD in the United States, 
accounting for 23% of incident ESRD patients between 1996 and 2000 (USRDS 2002). The 
higher USA incidence of hypertension-associated ESRD may relate to its higher incidence in 












disproportionate increase in the incidence of hypertensive ESRD in all age groups (USRDS 
1999). In South Africa, hypertension accounted for 45.6% of all ESRD, second only to 
glomerulonephritis (52.1%) from the 1994 SADTR data (SADTR 1994).  
 
Approximately 70% to 80% of individuals with CKD have hypertension, and its prevalence 
increases as glomerular filtration rate declines (Coresh et al 2001). Even mild-to-moderate 
hypertension is an important risk factor for progression of CKD toward irreversible renal 
failure (Coresh et al 2001). Typically, significant hypertension initially affects the renal 
vasculature, resulting in hyaline thickening of small arteries and arterioles. Eventually, the 
vascular lesions progress to vessel wall necrosis (fibrinoid necrosis, necrotizing arteriolitis 
and hyperplastic arteriolosclerosis), which may extend to the glomerulus as well (necrotizing 
glomerulitis) (Kumar et al 2003).  
 
Mule and colleagues (2005) have analysed the influence of MS on target organ damage 
(cardiac, renal and retinal) in a group of non diabetic patients with essential hypertension. 
They found that the presence of the MS may amplify hypertension-related cardiac and renal 
changes, over and above the potential contribution of each single component of this 
syndrome (Mule et al 2005). Cuspidi et al, (2004) in a study of hypertensive subjects, 
reported equal values of ambulatory blood pressures in patients with and without the MS but 
found increased cardiac and extra-cardiac involvement including microalbuminuria in 
patients with the MS (Cuspidi et al 2004). 
 
In the MS, hypertension is often related to obesity and is accompanied by impaired pressure 
natriuresis, renal vasodilation and glomerular hyperfiltration, neurohumoral activation, and 












pressure natriuresis, resulting in more severe hypertension and a gradual loss of kidney 
function
 
(Hall et al 2002; Hall 1997). 
 
4.2.3.3 Dyslipidemia 
Lipid abnormalities are independent risk factors for the incidence and progression of CKD. 
Hunsicker et al (1997) described a systematic analysis to determine baseline factors that 
predict the decline in GFR, or which change the efficacy of the diet or blood pressure 
interventions in subjects that had participated in the Modification of Diet in Renal Disease 
(MDRD) Study. They found six factors including low serum HDL cholesterol to 
independently predict a faster decline in GFR (Hunsicker et al 1997).  
 
Lipotoxicity, mediated via long chain non-esterified fatty acids (NEFA), has been linked to 
many of the manifestations of the MS. High-circulating NEFA from abdominal fat mass 
drives the cellular uptake of more fatty acid, which inhibits the secretion of adiponectin and 
reduces the mitochondrial uptake and oxidation of FA. The excess intracellular FA is shunted 
toward the production of reactive intermediates, such as ceramide, diacylglycerol, and fatty 
acyl- CoA (Figure 4.2). These reactive compounds are cytotoxic and capable of inducing cell 
apoptosis and organ damage (Bagby 2004; Kamijo et al 2002).  
 
In the kidney, filtered NEFA can aggravate the chronic tubule damage and inflammatory 
phenotype that develop during proteinuric states. Lipid loading of both glomerular and 
tubular cells is a common response to renal injury that contributes to the progression of 















There is growing evidence that obesity may be a risk factor for progressive renal injury 
(Stengel et al 2003b; Fox et al 2004). The risk of either incident ESRD or kidney disease–
related death among NHANES III participants was independently associated with a BMI 
greater than or equal to 35 kg/m
2
 (Stengel et al., 2003b). Obese participants in the 
Framingham study who were initially free of kidney disease at baseline were more likely to 
have a decrease in estimated GFR (Fox et al 2004).  
 
Figure 4.2: Cellular mechanisms of Lipotoxicity (Adapted from Weinberg 2006). 
 
 
Obesity-associated renal dysfunction including proteinuria, nephrotic syndrome, and CKD 
are frequently seen in clinical practice (USRDS 2003). In a review of over 6800 renal 
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biopsies carried out in a study on obesity related glomerulopathy (ORG – defined as focal 
segmental glomerulosclerosis (FSGS) and glomerulomegaly or glomerulomegaly occurring 
alone), Kambham et al (2001) reported a progressive, 10-fold increase in biopsy frequency of 
ORG from 0.2% in 1986 to 1990 to 2.0% in 1996 to 2000 (Kambham et al 2001). 
 
The first cases of obesity related FSGS in the paediatric population were reported in 2001 
(Adelman et al 2001). Seven African- American adolescents with severe obesity were 
followed up over a 12 year period and had renal biopsies for the diagnosis of unexplained 
heavy proteinuria. Calculated creatinine clearance was normal in six patients and decreased 
in one. Observed histologic features included glomerular hypertrophy, FSGS, increased 
mesangial matrix and cellularity, relative preservation of foot process morphology, and 
absence of evidence of inflammatory or immune-mediated pathogenesis.  
 
Compared with lean subjects, obese subjectss have reduced renal vascular resistance and 
increased renal blood flow, elevated GFR, and abnormal pressure natriuresis that shifts 
toward a higher blood pressure, often referred to as impaired pressure natriuresis (Reisin et al 
1995; Reisin 2001). The increased activity of the sympathetic nervous system (SNS) and the 
renin-angiotensin-aldosterone system (RAAS), the blunted activity of the natriuretic peptides, 
accompanied with hyperleptinemia, and hyperinsulinemia, all contribute to renal sodium 
retention and a hyper-hemodynamic state in cases of obesity (Reisin 2001). Physical 
compression of the kidneys by adipose tissue is also thought to contribute to this complex 
interaction that ultimately gives rise to glomerular hyperfiltration, glomerular cell 
proliferation, matrix accumulation, and, finally, glomerulosclerosis and the loss of nephrons 













Although the exact mechanisms that link obesity and renal damage have not yet been 
elucidated completely, it has been speculated that some of the many inflammatory cytokines 
that are secreted by adipose tissue may be involved in promoting renal impairment (Wisse 
2004). Leptin is one of the many cytokines produced by fat cells and serum leptin levels and 
overall fat mass (Considine et al 1996) are positively correlated. Massively obese patients 
with hyperleptinaemia tend to develop FSGS (Kasiske and Crosson 1986). In the glomerular 
endothelial cells, leptin increases TGF-β1 synthesis and upregulates TGF-β type II receptor 
expression without influencing TGF-β1 synthesis in mesangial cells. TGF-β produced by 
endothelial cells may reach neighbouring mesangial cells and induce an amplified response 
because of upregulated TGF-β type II receptors (Figure 4.3). Leptin also stimulates the 
synthesis of type I collagen in mesangial cells and type IV collagen in glomerular endothelial 
cells. Activation of the TGF-β system by leptin eventually contributes to extracellular matrix 





































Figure 4.3: Transforming Growth Factor- beta (TGF-β) pathways between glomerular 




4.2.3.5 Cardiovascular Disease  
Patients with CVD and CKD are at increased risk of developing ESRD. Autopsy studies have 
found a correlation between extent of atherosclerosis and degree of glomerular scarring 
(Kasiske 1987; Smith et al 1989). In one such study, it was observed that the prevalence of 
glomerulosclerosis was substantially greater among individuals with moderate to severe 
atherosclerosis (15%) compared with individuals with mild disease (8%). Further, 
comparison of the mean glomerular area of nonsclerotic glomeruli suggested that there were 
compensatory increases in glomerular size in individuals with moderate to severe 
atherosclerotic disease and glomerular area was independently associated with increasing 






























4.2.3.6 Family members of patients with end-stage renal disease 
ESRD aggregates within families (Ferguson et al 1988; Freedman et al 1997). An association 
between family history of ESRD and an increased risk of ESRD was first reported by 
Ferguson and his colleagues (Ferguson et al 1988) who noted that a family history of a first- 
or second-degree relative with CKD was reported by 26% of prevalent ESRD patients and 
11% of community controls. A study in North Americans has reported that a family history of 
ESRD among first- or second-degree relatives is reported by 20% of incident ESRD patients 
in a single year (Freedman et al 1997). In that study there was substantial racial disparity in 
the frequency of a positive family history of ESRD among race-sex groups, with 14.1% of 
white men, 14.6% of white women, 22.9% of black men, and 23.9% of black women 
reporting a first- or second-degree relative with ESRD. A positive family history was 
reported more frequently among individuals with ESRD attributed to diabetes mellitus 
(22.2%) and hypertension (18.9%) compared with those without either diagnosis (13%). 
Patients reporting a positive family history were more likely to be black, to be younger, and 
to be better educated.  
 
4.2.3.7 Urine protein excretion 
The presence and degree of proteinuria are strong risk factors for progressive kidney disease 
in both diabetic and non-diabetic kidney disease (Peterson et al 1995; ACE Inhibitors in 
Diabetic Nephropathy Trialist Group 2001). A meta-analysis of patient-level data from 11 
randomized, controlled trials found that the risk of doubling of baseline serum creatinine 
level or onset of kidney failure was independently associated with both blood pressure 
reduction and urine protein excretion less than 2 g/d and was associated with the lowest risk 












follow-up, determined by the difference between baseline and final levels of proteinuria, was 
found to increase the risk of progressive kidney disease by nearly sixfold for each 1 g/d 
higher protein excretion (ACE Inhibitors in Diabetic Nephropathy Trialist Group 2001). 
 
4.2.3.8 Dietary protein consumption 
It is now well established that restricting the amount of protein consumed in the diet delays 
the progression of CKD to ESRD. Wrone et al (2003) examined the association between 
dietary protein intake as assessed from 24-hour dietary recall and the prevalence of 
albuminuria among NHANES III participants and they reported that persons with both 
hypertension and diabetes and in the highest quintile of dietary protein consumption had over 




Smoking is a well recognized risk factor for CVD, malignancy, and pulmonary disease. It is 
also a pleiotropic risk factor for genitourinary disease, including cancer, proteinuria, and 
CKD (Chuahirun et al 2004). A number of  observational studies have reported that smoking 
cessation is associated with reduced risk of progressive renal injury, suggesting that smoking 
should be considered a risk factor for progressive renal insufficiency and cessation may be 
renoprotective and beneficial to general and cardiovascular health (Chuahirun et al 2004). 
 
4.2.3.10 Race and Poverty 
Blacks have a disproportionate risk of ESRD. In contrast to ESRD, an unequivocally 
disproportionate risk of CKD among blacks compared with whites has not been demonstrated 












incident ESRD are not clear. It has been suggested that higher ESRD incidence rates among 
blacks could reflect a faster progression of CKD, and racial differences in the progression of 
CKD to ESRD have been reported in a study using NHANES III data (Hsu et al 2003). 
Among black and white NHANES III participants with a GFR between 15 and 59 
mL/min/1.73 m
2
 it was estimated that, despite comparable prevalence of CKD, the 
subsequent risk of ESRD for blacks during follow-up was fivefold.  
 
There is growing evidence that racial disparities in the risk of progressive CKD may reflect 
socioeconomic, environmental, and behavioural factors. Black participants in the NHANES 
II survey had an 8.9-fold increase in risk of treated ESRD (Tarver-Carr et al 2002). After 
adjusting for age and gender 43.8% of the excess risk among blacks was explained by 
lifestyle and clinical risk factors that were potentially modifiable.  
 
Whittle et al (1991) have reported the role of poverty and access to health care in racial 
differences in ESRD risk. An eightfold disparity in risk of ESRD among blacks compared 
with whites was noted before accounting for such factors like community specific 
characteristics where the individual resided before initiation of renal replacement therapy. 
However, after controlling for these factors and measures of socioeconomic and health care 
status there was a 5.5-fold reduction in risk.  
 
There may also be racial differences in the response to protective benefits of antihypertensive 
therapy. Walker et al (1992) evaluated the rate of loss of renal function among white and 
black participants in the Multiple Risk Factor Intervention Trial (MRFIT). During follow up 
the mean rate of change in renal function as measured by serum creatinine for black subjects 












pressure control was similar for both blacks and whites. Factors associated with increased 
rate of change in serum creatinine included age and degree of blood pressure control. When 
the MRFIT participants were stratified by race, better blood pressure control was associated 
with slower loss of renal function in whites, but not in blacks.  
 
4.3 WHY IS THERE A PREPONDERANCE OF HYPERTENSION RELATED ESRD 
IN BLACK AFRICANS? 
 
Data from the USRDS has shown that hypertension is the most common cause of ESRD in 
America. Some have questioned the labelling of ―ESRD secondary to hypertension‖ in 
dialysis registries as this is very often racially biased (Perneger et al 1995) and unsupported 
by valid histological proof (Luft 2000) or documentation to show that hypertension was 
present before the existence of evidence of renal disease (Schlessinger et al 1994).  
 
In a study of 43 subjects referred for kidney transplant with a diagnosis of ESRD secondary 
to hypertension it was found that few of the patients had undergone kidney biopsy and that 
none of those who had undergone biopsy had the classic features of benign nephrosclerosis. 
Fewer than 5% of patients had hypertension documented at any time with normal renal 
function (Schlessinger et al 1994). In other words, it was not possible to determine whether 
renal disease or hypertension presented first. Interestingly, 86% of the patients in this study 
were black (versus 50% in the overall transplant referral population at that centre).  
 
The possibility of over-diagnosis of ―hypertensive nephrosclerosis‖ among African-
Americans was explored in another study (Perneger et al 1995). The researchers sent written 
case histories of ESRD patients to practicing nephrologists and asked for ―the primary 












assigned as ―black‖ or ―white‖. The authors found that ―black‖ patients were almost twice as 
likely to be given a diagnosis of hypertensive ESRD as ―white‖ patients with identical case 
histories (Perneger et al 1995).  
 
In a review, Seedat (1999) had noted that over a 10 year period, the incidence of stroke and 
myocardial infarction, 2 major complications arising from hypertension had reduced by about 
25% in black Africans following effective treatment of hypertension but that this trend was 
not seen in ESRD. Factors suggested explaining this racial disparity of excess hypertension 
related ESRD included: misdiagnosis, socioeconomic status, higher prevalence and greater 
severity of diabetes and hypertension in black Africans and an increased inherited 
susceptibility of black Africans to kidney diseases (Seedat 1999; Krop et al 1999; Brancati et 
al 1992; Freedman et al 1991).  
 
Although it is not fully known why people of African decent suffer more hypertension related 
kidney disease, an interesting mechanism to explain this racial difference in severity of 
hypertensive nephrosclerosis may be due to increased production of fibrogenic growth factors 





















THE ADIPOSE TISSUE AS AN ENDOCRINE ORGAN 
 
5.1 INTRODUCTION:  
The adipose tissue, previously only considered an organ for storage of energy is increasingly 
being seen as an endocrine tissue. There are two forms of adipose tissue: white adipose tissue 
(WAT) which stores energy in the form of triglycerides and secretes a vast amount of 
hormones or so-called adipocytokines that act in an autocrine, paracrine, or endocrine fashion 
to control various metabolic functions (Table 5.1) and brown adipose tissue (BAT) which 
serves primarily to dissipate energy.  
 
Although it was initially suggested that insulin resistance and hyperinsulinemia are primarily 
responsible for the development of all components of the MS and for the atherosclerotic or 
pro-atherogenic effects of obesity (Reaven 1988), studies have shown that adipose tissue 
hormones are also involved in this process (Hotamisligil et al 1993).  
 
Epidemiological studies have demonstrated that inflammation is an important link between 
CKD and CVD. Evidence suggests a fundamental role for innate and adaptive immunity in 
all stages of atherosclerosis and the pathogenesis of CVD as well as progression of CKD 
(Ross 1999). Patients with CKD have higher circulating levels of cytokines and abnormal 
cytokine metabolism, leading to elevated levels of acute phase proteins.  
 
In CKD, once a certain number of the nephron mass is lost, ‗nonspecific‘ glomerular and 
tubulointerstitial scarring begins and progresses, and this is seen in all forms of CKD. The 












hypertension, hyperfiltration in the remnant glomeruli, systemic hypertension, poor glycemic 
control (in diabetics), mesangial, endothelial, and epithelial injury from protein and 
macromolecular trafficking, and hyperphosphatemia. Inflammatory and profibrotic cytokines 
have also been shown to facilitate the progression of glomerular injury leading to CKD as 
they may modulate glomerular responses to infectious, dietary and environmental antigens 
(Ketteler et al 1995). In the kidney, cytokines induce (a) resident cells to proliferate, 
(Nakamura et al 1992) (b) aberrant matrix metabolism, (Coleman et al 1992) (c) 
procoagulant activity of endothelium, (Bevilacqua et al 1986) (d) reactive oxygen/nitrogen 
species, (Sharma et al 2005) and expression of (e) adhesion receptors, (Park et al 1998) 
bioactive lipids, (Zager and Johnson 2001) and metalloproteinase (Atkins 1995). These 
molecules may be the effectors through which the renin–angiotensin system and 
hemodynamic factors mediate their actions (Ketteler et al 1995). 
 
Although the relationships between several of these vasoactive substances, growth factors 
and cytokines with CVD or CKD have been previously studied and reported, this section will 
focus on leptin being the hormone of interest to this thesis and having the ability to cause 
CVDs through the inflammatory process. The biology, receptors, pathways and evidence for 























Improves insulin sensitivity, improves fatty acid transport and utilisation 
Adipsin 
 
Required for the synthesis of ASP, possible link between activation of complement pathway 
and adipose tissue metabolism 
Agouti 
 




Regulator of blood pressure and electrolyte homeostasis 
aP 2 
 
Involved in intracellular trafficking and targeting of fatty acids 
ASP 
 
Activates diacylglycerol acyltransferase, inhibits hormone sensitive lipase, stimulates GLUT-4 
translocation to the cell surface 
IGF-1 
 
Stimulates cell proliferation and mediates many of the effects of growth hormone 
IL-6 
 
Increases hepatic glucose production and triglyceride synthesis. 
Leptin 
 
Feedback effect on hypothalamic energy regulation; maturation of reproductive function 
MIF 
 
Involved in proinflammatory processes and immunoregulation 
PAI-1 
 
Potent inhibitor of the fibrinolytic system 
PGI2  and PGF2 α 
 
Implicated in inflammation and blood clotting, ovulation and menstruation. 
Resistin 
 
Appears to impair insulin sensitivity 
TGF-ß 
 
Regulates growth and differentiation of numerous cell types  
TNF-α 
 
Mediator of the acute phase response, inhibits lipogenesis, stimulates lipolysis and impairs 
insulin-induced glucose uptake, thus leading to insulin rsistance and weight loss 
 
aP2 – Adipocyte protein 2, ASP – Acylation stimulating protein, IGF-1 – Insulin-like growth factor 1, IL-6 – 
Interleukin -6, MIF – Macrophage migration inhibition factor, PAI-1 Plasminogen activator inhibitor-1, PGI – 
Prostacyclin, PGF2α – Prostaglandin F-2 alpha, TGF-β – Transforming growth factor beta, TNF-α – Tumour 

















5.2 THE BIOLOGY OF LEPTIN 
Leptin was identified in 1994 by Zhang et al (1994) through positional cloning of the ob gene 
which determines the development of obesity in ob/ob mice. Leptin is the product of ob gene 
coding for a 167 amino acid protein with a 21 amino acid signal peptide (Zhang et al 1994). 
Its crystal structure indicates that leptin is a member of the cytokine family and has four 
helical segments (Madej et al 1995). In adult animals, leptin mRNA is primarily detected in 
WAT and BAT (Masuzaki et al 1996), however, it is also synthesized and secreted in a 
number of extra adipose tissues that include the gastric mucosa (Bado et al 1998), mammary 
epithelial cells (Smith- Kirwin et al 1998), myocytes (Wang et al 1998), the placenta (Senaris 
et al 1997), and the testes, ovary and hair follicles (Hoggard et al 1997). 
Leptin circulates in the plasma as a free form or bound to leptin-binding proteins. The great 
majority of leptin circulates in the bound form in lean individuals and in the free form in 
obese subjects (Sinha et al 1996).  
 
Leptin levels rapidly decrease during fasting and remain low until four to six hours after 
eating when they begin to rise again (Schoeller et al 1997). Plasma leptin levels show a 
diurnal pattern with a nocturnal peak shortly after midnight and a midmorning trough 
between 10 am and 12 noon (Sinha et al 1996b). Insulin also plays a role in the regulation of 
leptin secretion: prolonged insulin infusions markedly increase serum leptin levels (Boden et 
al 1997). 
 
Leptin slowly declines during aging and this reduction is higher in women than in men 
(Isidori et al 2000). Leptin provides the brain with the information about the fat stores of the 
body and thus acts as a part of the feedback mechanism that can function as a lipostat. It has 












leptin, which is secreted into the circulation (Klein et al 1996). When leptin reaches the brain 
it decreases appetite and enhances the metabolic rate. In human subjects, a high correlation 
between the body fat content and plasma leptin concentrations has been found and data 
indicate that loss of body fat decreases leptin levels, which induces a state of positive energy 
balance and other adaptive changes (Ahima et al 1996). 
 
Although the main role of leptin is as an adipostat, recent studies have shown that leptin has a 
broad range of effects in different tissues (Margetic et al 2002). Leptin affects these different 
functions either by direct action in peripheral tissues or through its action in the CNS (Figure 
5.1). 
 
5.3 LEPTIN RECEPTOR AND MECHANISMS OF SIGNALLING  
5.3.1 LEPTIN RECEPTORS 
Leptin receptors are the product of the diabetes (db) gene, which is alternatively spliced to 
produce at least six isoforms; obRa–obRf (Figure 5.2). Each of obRa–obRd and obRf are 
identical in their extracellular and transmembrane domain. The obRe has no transmembrane 
or intracellular component and exits as a soluble receptor isoform, does not play a direct role 
in leptin signalling but is likely to be important in determining the amount of leptin in the 
circulation (Huang et al 2001). The other isoforms possess a transmembrane domain, which 
is comprised of 23 amino acids and the extracellular domain of the leptin receptor consists of 



















Figure 5.1: Role of Leptin in the regulation of body weight and other functions (Adapted 




The obRb has a long intracellular domain whereas obRa, obRc, obRd and obRf all possess 
short intracellular domains (Figure 5.2). The intracellular domain of obRb is approximately 
306 amino acids and in the short forms is 32–40 amino acids (Tartaglia et al 1995). The 
intracellular domain of all these isoforms contains an identical 29 amino acid sequence 
containing a ‗Box 1‘ Janus-family tyrosine kinase (JAK) binding domain in the 
juxtamembrane region while obRb also contains a ‗Box 2‘ motif and signal transducers and 
activators of transcription (STAT) binding sites. Human obRb contains five tyrosines, and 
each may be associated with the activation of distinct downstream signalling pathways 
(Banks et al 2000). Although obRb is traditionally viewed as the ‗signalling isoform‘, there is 
 








































clear evidence that short receptor isoforms are capable of signalling and indeed show 
divergent signalling capacities (Bjorbaek et al 1998 b). 
 
Expression of obRb is highest in hypothalamus (Fei et al 1997), yet, it is also found in many 
peripheral tissues at lower levels (Morton et al 1998). The obRa is expressed fairly 
ubiquitously and represents the major isoform of many peripheral tissues (Fei et al 1997). 
Other short receptor isoforms tend to be expressed at low levels. However, examination of 
obR isoform expression in various tissues by RT–PCR has often been inconsistent. 
 
5.3.2 LEPTIN SIGNALLING PATHWAYS 
The signalling pathways regulated by leptin include: The Janus kinase / signal transducer and 
activator of transcription (JAK/STAT) pathway, Src-like homology 2 (SH2) domain 
containing protein tyrosine phosphatase (SHP-2) pathway, mitogen-activated protein kinases 
(MAPK) pathway, suppressors of cytokine signalling (SOCS) pathway, Phosphatidylinositol 
(PI) 3-kinase and insulin receptor substrate (IRS) proteins pathway. Others are the protein 
kinases (PKB, also called Akt and PKC), cyclic AMP PDE, Nitric oxide (NO) and the Rho 




















Figure 5.2: Isoforms of the leptin receptor derived from differential splicing (Adapted from 
Wolf et al 2002).  
 
 
These receptors share an identical extracellular amino-terminal end, which binds leptin, but differ at their 
carboxy-terminal ends. Five of these isoforms contain transmembrane domains. The long form of the receptor 
(Ob-Rb), principally found in the hypothalamus, is classically associated with signal transduction. The short 
form (Ob-Ra), expressed in peripheral tissues, is much more abundant.  
Ob-Re, which lacks both transmembrane and intracellular domains, is a circulating leptin receptor of unknown 



































Figure 5.3: Summary of the numerous pathways in which leptin has been shown to be 





The JAK/ STAT pathway was the first signalling mechanism associated with the leptin 
receptor (Vaisse et al 1996). Activation of this signalling pathway in the hypothalamus is 
initiated upon the conformational changes in the leptin receptor triggered by leptin binding. 
Intracellular JAK proteins (JAK2 and possibly JAK1) are associated with the binding motifs 
located in the proximal region of the leptin receptor and are subsequently activated by 
transphosphorylation. Activated JAK proteins, in turn, phosphorylate tyrosine residues of the 
receptor, providing docking sites for STAT proteins, which become tyrosine-phosphorylated 













Phosphorylated STAT molecules dimerize and translocate to the nucleus to modulate the 
transcription of target genes. In vitro studies have shown that leptin receptors signal through 
different STAT molecules, in vivo studies have demonstrated that, in the hypothalamus, this 
occurs specifically through activation of STAT3 (Bates et al 2003).  
 
The STAT3 signalling by leptin receptors mediates the critical effects of leptin on food intake 
and body mass control. Also, leptin‘s effects on the suppressors of the cytokine signalling 
family (SOCS) represent a negative-feedback mechanism proposed to underlie the 
development of leptin resistance in relation to the hyperleptinaemia seen in the majority of 
obesity cases (Banks et al 2000).  SOCS proteins negatively regulate the JAK/STAT 
pathway, either by directly blocking JAKs or through inhibition of further STAT 
phosphorylation (Bjorbaek et al 1998 a). 
 
Several other intracellular signalling mechanisms have been associated with the leptin 
receptor. For instance, by engaging JAK2, the leptin receptor is able to stimulate insulin 
receptor substrate (IRS)-2, which, in turn, activates phosphoinositol- 3 kinase (PI3-K) 
through an association to its regulatory subunit (Niswender et al 2001) (Figure 5.4). Most 
insulin-dependent actions involve PI3K activation, making this a relevant point of cross-talk 
between the insulin and leptin signalling pathways (Fruhbeck and Salvador 2000a). PI3K 




























Leptin shares with other cytokines, growth factors and stressors the ability to activate the 
stress-activated protein kinase, JNK (c-Jun N-terminal kinase). Through this mechanism, 
leptin reportedly enhances TNFα production via p38 and JNK MAPK (Shen et al 2005). In 
vascular smooth muscle cells, leptin induces hypertrophy via p38 MAPK (Shin et al 2005), 
indicating the potential relevant role of this hormone in cardiovascular physiology and an 
impact on vascular remodelling (Fruhbeck and Salvador 2000b).  
 
Although a definitive picture of leptin signal transduction, including upstream activators and 
downstream targets of the p38 and JNK MAPK pathways, is yet to be completely understood, 
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the regulation of NF-κB appears also to be a likely downstream target of leptin, since this 
essential transcription factor is known to play a pivotal role in the transcriptional regulation 
of pro-inflammatory cytokines such as TNFα and IL-1β. 
 
5.4 LEPTIN AND THE CARDIOVASCULAR SYSTEM 
5.4.1 LEPTIN, VASCULAR FUNCTION AND BLOOD PRESSURE 
Like other metabolic hormones such as insulin, leptin possesses potent vascular effects and 
participates in the regulation of sympathetic tone and arterial blood pressure (Haynes et al 
1997). The regulatory effects on vascular tone and blood pressure have been experimentally 
demonstrated. Intracerebroventricular administration of leptin was found to elicit an increase 
in arterial blood pressure (Matsumura et al 2000), consistent with its ability to activate the 
sympathetic nervous system. Also, chronic intravenous infusion of leptin has significantly 
enhanced arterial blood pressure associated with an elevated circulating plasma leptin level 
(Shirasaka et al 2003).  
 
Leptin also has direct peripheral vascular actions through some vasoactive mediators such as 
NO and endothelin-1 (ET-1) as it has been shown directly to induce relaxation of the blood 
vessels through NO-dependent as well as NO-independent mechanisms (Kimura et al 2000). 
Leptin has been shown to stimulate endothelial NO synthesis, upregulate ET-1 production 
and promote accumulation of reactive oxygen species (ROS) in human umbilical vein 
endothelial cells (Lembo et al 2000; Quehenberger et al 2002).  
As evidence suggests an association between sympathetic activity and plasma leptin levels, 
factors like hyperinsulinaemia have also been suggested to be responsible for the enhanced 














5.4.2 LEPTIN, HEART RATE AND CARDIAC FUNCTION 
Acute leptin infusions have been shown to fail to significantly alter the heart rate whereas 
chronic infusions have elicited a significant increase in heart rate along with an increase in 
sympathetic nervous activity (Shek et al 1998). Also, a positive correlation between 
hyperleptinaemia and tachycardia has been confirmed in mildly obese or mildly hypertensive 
human subjects (Narkiewicz et al 1999). While this increase in heart rate may enhance 
cardiac output and provide short-term benefits, sustained tachycardia may cause cardiac 
hypertrophy and lead to heart failure. Patients with advanced congestive heart failure have 
also exhibited elevated plasma levels of leptin and its soluble receptor, indicating that leptin 
may participate in the catabolic state leading to the development of cardiac cachexia (Schulze 
et al 2003). 
 
5.4.3 LEPTIN AND ATHEROSCLEROSIS 
Hyperleptinaemia is believed to be associated with lower arterial distensibility, a circulatory 
function relevant to the atherosclerotic process (Singhal et al 2002). Leptin promotes 
angiogenesis and potentiates the pro-thrombotic aggregation of platelets through a novel 
leptin receptor-dependent mechanism (Konstantinides et al 2001). The mechanisms of leptin 
induced atherosclerosis include: endothelial dysfunction through large amounts of NO 
generated from inducible nitric oxide synthase (Naseem 2005), abnormal lipid metabolism in 
the vessel wall (Maingrette and Renier 2003), induction of a proinflammatory state (La Cava 
et al 2004), increased reactive oxygen species thereby causing oxidative stress in the vessel 
wall (Bouloumie et al 1999), increased proliferation and migration of vascular smooth 
muscle cells (Li et al 2005) and increased platelet aggregation and abnormal haemostasis 













Designed to examine the effectiveness of pravastatin in primary prevention of ischemic heart 
disease in men with moderate hypercholesterolemia, the West of Scotland Coronary 
Prevention Study (WOSCOPS) is one among many clinical studies that has shown 
convincing evidence of the proatherogenic role of leptin in humans. This study demonstrated 
that elevated plasma leptin predicted acute cardiovascular events (combined acute myocardial 
infarction, need for revascularization and mortality) during a 5-year follow-up period 
(Wallace et al 2001). 
 
5.5 LEPTIN AND RENAL DISEASE  
Accumulating data suggest that leptin may exert direct and indirect effects on the kidney that 
may contribute to deterioration in renal function (Stenvinkel et al 1999). In this section, the 
importance of leptin as a progression factor in renal disease (from the review of available 
reports on this subject) will be explored.   
 
5.5.1 RENAL CLEARANCE OF LEPTIN 
Leptin is principally cleared by the kidney (Nordfors et al 1998) consequently, plasma leptin 
concentrations are increased in patients with end-stage renal disease or those undergoing 
hemodialysis (Sharma et al 1997). A number of studies have investigated a relationship 
between leptin concentration and obesity in chronic renal failure (Stenvinkel et al 1999). 
Animal studies have shown that renal elimination of leptin occurs by the uptake of leptin into 













5.5.2 LEPTIN'S ACTIONS IN THE KIDNEY  
The renal effects of leptin are summarised in the figure 5.5. Leptin mediates sympathetic 
nerve activation and infusions of leptin into rats have been shown to increase renal 
sympathetic nervous activity (Haynes et al 1997). In the transgenic skinny mouse, which 
overexpresses leptin, systolic blood pressure and urinary catecholamine excretion are 
elevated (Aizawa-Abe et al 2000). Two proopiomelanocortin products, α-melanocyte-
stimulating hormone (α-MSH) and β-endorphin, have been suggested as the possible 
mediators of these effects of leptin on sympathetic activity and mean arterial pressure 
(Dunbar and Lu 1999).  
 
Figure 5.5. Summary of the effects of leptin that may contribute to pathological changes in 
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Transforming growth factor-beta (TGF-β) is a recognised mediator of fibrogenesis in various 
renal diseases and leptin has been shown to stimulate the proliferation of cultured glomerular 
endothelial cells and to induce mRNA expression and protein secretion of transforming 
growth factor-β1 (TGF-β1) in these cells (Wolf et al 1999).  
 
Short-term infusion of leptin (72 hours) induced glomerular TGF-β1 expression and also 
increased the total number of proliferating cells detected by proliferating cell nuclear antigen 
staining. However, long-term infusion of leptin (3 weeks) enhanced glomerular expression of 
type IV collagen. However, in mesangial cells, leptin failed to stimulate TGF-β1 synthesis, 
but dose-dependently increased mRNA levels in TGF-β type II receptors in db/db-derived 
mesangial cells as well as cellular glucose uptake, augmented type 1 collagen mRNA and 
protein production (Han et al 2001). This suggests that the leptin system may cross-talk 
between glomerular endothelial and mesangial cells. (See figure 4.3) Activation of this 
paracrine TGF-β system by leptin eventually contributes to extracellular matrix deposition, 
glomerulosclerosis, and proteinuria (Ballermann 1999).  
 
5.5.3 LEPTIN AND THE KIDNEY IN SYSTEMIC DISEASES  
An increased incidence of glomerulosclerosis has been described in patients with massive 
obesity (Kasiske and Crosson 1986). Because obese individuals show a marked increase in 
serum leptin concentrations, the hormone may contribute to the development of 
glomerulosclerosis seen in this population. This effect may be exaggerated by the loss of 
functioning nephrons. Praga et al (2000) reported that obese patients are at high risk for 













It has also been suggested that the pathophysiological effects of leptin may be more relevant 
in patients with type 2 diabetes who have high serum leptin concentrations (Widjaja et al 
1997). A fibrogenic role for leptin in diabetic nephropathy remains to be established; 
however, clinical clues are suggestive: massively obese patients with high serum leptin levels 
tend to develop focal glomerulosclerosis whereas patients with type 2 diabetes and 
hyperinsulinemia, who tend to be obese, exhibit high serum leptin levels (Widjaja et al 1997).  
Leptin levels are increased in patients with type 2 diabetes with microalbuminuria or 
macroalbuminuria (Fruehwald-Schultes et al 1999) and urine leptin concentrations in Pima 
Indians have positively correlated with urinary albumin-creatinine ratios and inversely 
correlated with glomerular filtration rates (Wilson et al 1998). Increased serum leptin levels 
also correlated with increased urine albumin excretion in women with type 1 diabetes 
(Rudberg and Persson 1998).  
These observations raise the possibility that leptin may cooperate with other mediators to 
promote increased ECM production in some forms of renal disease, such as diabetic 























GENETICS: OBESITY, KIDNEY DISEASE AND THE METABOLIC SYNDROME 
 
6.1 INTRODUCTION 
The ability to pass on specific traits to offspring has allowed humans to adapt through genetic 
selection to changing situations (Fauci et al 2001). Hence, an individual‘s genotype is able to 
influence both cell development and functions throughout life and the phenotype results from 
the interaction of the genotype and environmental influences. However, the process of 
associating a gene with a phenotype is made difficult by the low density of functionally 
coded DNA and by multiple interactions among genes and lifestyle factors (Shuldiner and 
Munir 2003). 
As CVDs generally result from interactions of multiple lifestyle factors, it is assumed that to 
find specific genes that account primarily for specific CVD will be a very difficult task. 
However, a number of studies either using the candidate gene approach or the genome wide 
scan have reported genes related to obesity, the MS and kidney diseases. This chapter gives 
an overview of such genes which have been reported in the literature to be associated with 
these conditions. In the context of this thesis I will use the term polymorphism (and single 
nucleotide polymorphism (SNP)) as referring to an inheritable change in a single nucleotide 
of a specific sequence of genomic DNA among individuals that occurs in more than 1% of 
the population. Generally, a SNP can occur through inversion, deletion, repetition, insertion 
















6.2 THE GENETICS OF OBESITY  
Obesity involves environmental and genetic factors. The environmental factors which 
influence obesity have been discussed in chapter 2. The role of genetic factors in obesity 
mostly comes from the commonly observed coexistence of several obese members within a 
family. In some families with obese parents, it has been observed that the risk of excessive 
weight gain in children of such families is increased two- to three-fold for moderate obesity 
and up to eight times for severe obesity (Bouchard 2001). Also, twin and adoption studies 
substantiate a role for genetics in obesity. Allison et al. (1996) have reported estimates of 
heritability (h
2
) of obesity to be 0.65, 0.75 and 0.85 in 17 Finnish, 10 Japanese and 26 
American twin pairs respectively. Figure 6.1 shows some genes involved in weight 
homeostasis categorised by their mechanism of obesity. 
 
6.2.1 MONOGENIC FORMS OF OBESITY 
The mutations in genes that encode proteins with likely roles in appetite regulation are 
responsible for Mendelian disorders in which obesity is the most obvious phenotype.  
Rare monogenic recessive forms of human obesity such as those caused by mutations in the 
genes that encode leptin (LEP) (Montague et al 1997), leptin receptor (LEPR) (Clement et al 
1998), and proopiomelanocortin (POMC) (Krude et al 1998) all of which result in a 
phenotype of excessive energy intake relative to energy expenditure have been reported. The 
regulatory role of molecules like the melanocortin 4 receptor (MC4R) and the agouti related 
peptide (AGRP) in monogenic forms of obesity have also been established through genetic 
















FIGURE 6.1: Some genes involved in body weight homeostasis categorised by processes. 
 
 
NPY – Neuropeptide Y, LEP – Leptin, POMC – Pro-opiomelanocortin, MCR4 – Melanocortin receptor type 4, 
UCP – Uncoupling protein, ADRβ – Adrenergic receptor beta, FABP – Fatty acid binding protein, PPAR – 




6.2.2 SYNDROMIC OBESITY 
Syndromic obesity refers to Mendelian disorders in which patients are clinically obese and 
additionally have characteristics such as mental retardation, dysmorphic features, and organ-
specific developmental abnormalities (Farooqi and O‘Rahilly. 2005). These syndromes arise 
from discrete genetic defects or chromosomal abnormalities, and can be either autosomal or 
X-linked disorders. Although these syndromes have been well characterised clinically, 
analysis of their genetic components have shown that multiple genes within a biological 
pathway may produce similar phenotypes (Chung and Leibel. 2005). The most common 
disorders known are Prader-Willi syndrome, Bardet-Biedl syndrome, and Alstrom syndrome, 





































6.2.3 POLYGENIC OBESITY 
Polygenic obesity refers to the common variant of obesity. This form of obesity has a 
substantial contribution from environmental / lifestyle factors as well as genetic factors 
involving several genes, each contributing a small part to the overall obesity phenotype. 
Studying the genetic basis of common obesity usually involves the analysis of variations in 
genomic DNA situated within or near candidate genes. The aim of genetic studies, whether 
they are carried out in family members or unrelated subjects and depending on the statistical 
methods employed (linkage family studies, association studies in unrelated obese subjects), is 
to establish whether an association exists between a particular variant or ‗allele‘ of a gene and 
obesity phenotype which is often defined as BMI, WHR or WC (Hebebrand et al 2003). Two 
different approaches to elucidating the genetic basis of disease are described below. 
 
6.2.3.1 The genome regions linked to obesity 
This method employs the systematic examination of all the chromosomes in the families of 
obese subjects using highly polymorphic markers to detect increased allelic sharing in obese 
sibpairs. This task is performed without preconceptions about the functions of the genes and 
aims to identify known or uncharacterised genes predisposing to obesity. This method has 
been applied to different patient cohorts worldwide and has brought to light several 
chromosomal locations linked to obesity including those on chromosomes 2, 3, 5, 6, 7, 10, 
11, 17 and 20 (Loos and Bouchard 2003). 
 
6.2.3.2 Candidate genes 
This approach entails the identification of good candidate genes for the disease according to 
the properties of those genes. The candidate gene approach in the genetic analysis of obese 












role of such candidate genes in the pathogenesis of common obesity. The reasons for this 
includes the difficulty of replicating most association and linkage results performed in 
different populations, usually through the lack of statistical power to detect modest effect, 
lack of control over type-1 error rate (a false positive error - the proportion of negative 
instances that were erroneously reported as being positive), complex population stratification 
and over-interpretation of marginal data. Other reasons include non-genetic factors like 
environmental or cultural factors that differ between populations and are known to strongly 
influence the development of obesity.  
 
The choice of a candidate gene in obesity research is usually based on several arguments 
including the physiological role of its encoded protein in the mechanism of obesity, its 
chromosomal location in a region linked to obesity in human or animal models, the 
phenotypic consequences of its genetic manipulation in rodent models and eventually the in 
vitro functional characteristics of gene mutations or variations studied. The obesity gene map 
published each year extensively summarizes all the genes and variants screened (Perusse et al 





























Table 6.1: Examples of genes frequently associated with obesity phenotypes in humans 
 
Genes (HGNC Code) Locus Human Obesity Locus 
 Food intake:    
LEP 7q31 Yes  
LEPR 1p31 Yes  
AGRP 16q22 Yes  
Energy metabolism:   
UCP 1 4q28-31 No  
UCP 2 11q13 Yes  
UCP 3 11q13 Yes  
ADRβ3 9p12 Yes  
GNB3 12p13.3 Yes  
Adipose tissue metabolism:   
ACDC 3q27 Yes  
PPARG 3p25 No 
TNF-α 6p21.3 Yes  
ADRβ2 5q31-32 Yes  
IL-6 7p21 No  
LIPE 19q13.2 Yes  
GR 5q31 Yes  
Lipid and glucose metabolism:   
INS 11p15.5 Yes  
LDLR 19p13 Yes  
 
HGNC - Hugo Gene Nomenclature Committee  
LEP – Leptin, LEPR – Leptin receptor, AGRP – Agouti related peptide, UCP –Uncoupling protein, ADRβ – 
Adrenergic receptor beta, GNB3 – G-protein beta 3, ACDC – Adiponectin, PPARG – Peroxisome proliferator 
activator receptor gamma, TNF-α – Tumour necrosis factor alpha, IL-6, Interleukin 6, LIPE – Lipase, hormone 




















6.3 THE OBESITY GENE (LEP) 
6.3.1 DESCRIPTION  
The leptin gene (LEP) is the human homolog of the obesity gene (ob) in the mouse 'obese' 
phenotype. The ob gene of the mouse was isolated in 1994 by positional cloning by Zhang et 
al and the group also cloned and sequenced its human homolog (Zhang et al 1994). The gene 
encodes a 4.5-kb adipose tissue mRNA with a highly conserved 167-amino acid open reading 
frame. The predicted amino acid sequence is 84% identical between human and mouse and 
has features of a secreted protein.  In 1991, Friedman et al suggested that the human ob 
homolog maps to 7q31 (Friedman et al 1991). In the perspective of this thesis, LEP will be 
used as referring to the obesity gene.  
 
In 1995, Green et al mapped the human LEP gene on a YAC contig (a contig is a set of 
overlapping DNA segments derived from a single genetic source) from 7q31.3 that contained 
sequence tagged sites corresponding to microsatellite-type genetic markers. Because of their 
close physical proximity to the human LEP gene, these genetic markers represented valuable 
tools for analyzing families with evidence of hereditary obesity and for investigating the 
possible association between LEP mutations and human obesity.  
 
6.3.2 GENE STRUCTURE  
The LEP gene spans approximately 20,000 bases and contains 3 exons separated by 2 introns 
(Isse et al 1995). The gene's 3 exons cover approximately 15 kb of genomic DNA. The entire 
coding region is contained in exons 2 and 3 separated by a 2-kb intron. The first small 30-bp 
untranslated exon is located more than 10.5 kb upstream of the initiator ATG codon (Miller et 
al 1996). The first intron, approximately 10.6 kb, is in the 5-prime untranslated region, 29 bp 
upstream of the ATG start codon. The second intron of 2.3 kb is located at glutamine +49. By 












to 57 bp upstream of the ATG start codon (Isse et al 1995). The gene structure and common 
polymorphisms of the LEP gene are shown in figure 6.2 
 
6.3.4 GENE FUNCTION  
(The functions of the gene via its protein leptin have been discussed in the previous chapter). 
6.3.5 LINKAGE TO OBESITY-RELATED TRAITS 
Duggirala et al (1996) tested for linkage between various obesity-related traits plus associated 
metabolic traits in 15 markers on human chromosome 7 by using sibship data obtained from 
32 Mexican American pedigrees. They found evidence for linkage between markers in the 
LEP gene region and obesity phenotype measured as extremity skin folds (LOD = 3.1) (LOD 
is the total relative probability, expressed on a logarithmic scale, that a linkage relationship 
exists among selected loci and is an acronym for "logarithmic odds"). A putative 
susceptibility locus linked to the marker D7S514 explained 56% of the total phenotypic 
variation in extremity skin folds. Weaker evidence for linkage to several other obesity-related 
traits (e.g., WC, BMI, fat mass by bioimpedance, etc.) was observed for a genetic location 
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6.3.6 MOLECULAR GENETIC STUDIES RELATED TO THE LEP GENE 
The LEP gene expression in abdominal subcutaneous adipocytes from lean and obese humans 
has been studied by Considine et al (1995) and they detected no difference in the sequence of 
an RT-PCR product of the coding region from 5 lean and 5 obese subjects. Later, Hager et al 
(1998) screened patients with morbid obesity for mutations in the leptin gene and for 
association with a polymorphism in the 5-prime untranslated region of the gene. Although no 
polymorphisms were detected in the coding region of the gene, a single A-to-G transition was 
found in nucleotide 26 of the untranslated first exon. In metabolic studies, they showed that 
patients homozygous for the G allele of the exon 1 variant had significantly lower fasting 
leptin levels compared to subjects being either heterozygous (AG) or homozygous for the A 
allele despite a similar BMI (p = 0.01).  
 
Eight genetic variants were later identified (C2549A, T2437G, C1887T, C1823T, G1387A, 
C633T, C188A, G19A) in the 5-prime region of the LEP gene and one of the mutations 
(2548G-A), wrongly designated 2549C-A at that time, was found to be associated with a 
difference in BMI reduction following a low calorie diet in overweight women (Mammes et 
al 1998). The genotype and allele frequencies of this SNP were significantly different 
between groups, with the G allele being more frequent in the overweight subjects (p < 0.01). 
In men, carriers of this allele had lower leptin concentrations adjusted for fat mass. The 
results indicated that variations at the leptin locus are associated with common obesity 
phenotypes, and not only with extreme obesity or the rare Mendelian obesity syndromes 














Karvonen and his group (1998), studying the LEP gene for variants by screening both its 
putative promoter and its coding region in 200 obese Finnish subjects found a  144G-A 
transition in codon 48 and a 328G-A transition in codon 110 in 2 obese subjects, both of 
whom had very low serum leptin levels. A rare silent polymorphism (538C-T) was also 
reported 33 bp downstream of the translation stop codon (TGA), and a common 
polymorphism (19A-G) was identified in the untranslated exon 1. This polymorphism was 
not associated with obesity and the allele frequencies were similar between 64 normal-weight 
and 141 obese Finns. The authors concluded that there is no common LEP gene variation 
associated with obesity in that population. Lucatoni et al (2000) also found no significant 
correlations between the A19G polymorphism and serum leptin levels and other metabolic 
parameters they considered (Lucatoni et al 2000).  
 
The genetic association of the leptin gene polymorphism with obesity, insulin resistance, and 
hypertension was examined by Shintani et al (2002). They found no significant difference in 
BMI with the different genotypes in both hypertensives and controls. However, they reported 
a higher frequency of class I genotype in the hypertensives and concluded that the leptin gene 
polymorphism was associated with hypertension independent of obesity.  
 
There was only one study where polymorphism of the LEP gene was reported to be 
associated with specific cardiovascular markers. The impact of this gene on blood pressure, 
BMI and subclinical atherosclerosis was assessed and it was found that the rare T allele at the 
C538T polymorphism substantially influenced pulse pressure and carotid intima-medial 
thickness, but did not appear to exert this effect through actions on plasma leptin level or 
BMI. This suggested that an autocrine or paracrine effect in vascular tissue may be an 












6.4 GENETICS OF KIDNEY DISEASE 
6.4.1 EVIDENCE FOR A GENETIC COMPONENT OF CKD/ESRD 
ESRD is widely held to be a complex genetic trait with significant genetic heterogeneity, and 
gene–gene and gene–environment interactions. This hypothesis is supported by extensive 
evidence that ESRD in the black population has a strong genetic component (Freedman 
2002). Black Americans with close relatives having ESRD are at markedly increased risk for 
developing future ESRD (Freedman et al 1993). Evidence suggests that renal disease in the 
general population has a genetic component. Studies that have shown such evidence take the 
form of evaluating familial aggregation of CKD and or ESRD. The first description of 
familial aggregation in renal disease was carried out in Caucasian type 1 diabetic (T1DM) 
families in which individuals who had undergone kidney transplantation were compared to 
families who contained diabetes-affected individuals without substantial renal disease 
(Seaquist et al 1989). In this study, significant renal disease was reported in the diabetic 
siblings of probands receiving renal transplants compared to diabetic siblings of probands 
without nephropathy. Familial clustering of renal disease has been described in patients with 
type 2 diabetes (T2DM) from different populations (Bowden 2003). 
 
6.4.2 CKD AS A COMPLEX GENETIC TRAIT 
Multiple lines of evidence indicate that susceptibility to the development and progression of 
kidney disease is genetically determined (Bowden 2003). Three main sources of evidence for 
a genetic contribution to kidney disease risk were identified as: (1) diabetic and non-diabetic 
ESRD clustering in families; (2) after controlling for socioeconomic status in geographically 
dispersed populations, incidence of kidney disease in ethnic minorities in the US and 
aboriginal peoples in Australia is increased compared to patients of European descent; and 












nephropathy and urinary albumin excretion in diabetic Pima Indians and Caucasians, 
respectively (Bowden 2003). 
 
Genetic pathways regulating susceptibility to common forms of CKD are difficult to explain. 
Since CKD is a heterogeneous entity, no one pathophysiologic mechanism leads to kidney 
disease, but rather multiple processes that may include immunologic, metabolic, 
hemodynamic, ischemic, toxic, or anatomic, work together to cause kidney injury. Often at 
diagnosis, 60% to 70% of nephrons have already been destroyed, further confounding the 
identification of initiating CKD mechanisms. Hence, from a genetic perspective, common 
causes of CKD represent complex traits. There is no simple or known link between the 
clinical manifestations of the disease phenotypes and genetic mutations and with no obvious 
Mendelian inheritance patterns, mutations causing monogenic kidney diseases do not 
appropriately model the genetic mechanisms of more common kidney diseases such as 
diabetic nephropathy.  
 
Genetic mutations responsible for Mendelian syndromes result in loss of protein function and 
early onset clinical phenotypes. In contrast, genes that regulate common CKD are better 
described as ―liability alleles‖, whose genetic variations have modest impact on protein 
function. Unlike most mutations for Mendelian kidney diseases, liability alleles only result in 
affection when a biological threshold is exceeded. In other words, CKD ―liability alleles‖ 
each have a small individual effect but can sum together to result in disease. Further 
complicating genetic analyses, CKD risk is modified by environmental factors, especially 
diabetes (i.e. glucose control) and hypertension (i.e. blood pressure control), gene-gene 













6.4.3 THE SEARCH FOR RENAL DISEASE GENES 
With the wide acceptance that inheritance contributes to renal disease susceptibility, 
investigators have applied two main methods, using different study designs to identify ESRD 
genes. 
 
6.4.3.1 Candidate genes 
Using this method, specific genes are selected for analysis based on a function that could be 
closely related renal disease or through direct evidence that the gene product (protein) is 
associated with renal pathology. Often, these studies are done as case-control studies in 
which the allele frequencies in renal disease patients are compared with allele frequencies in 
patients without renal disease. Table 6.2 summarises some candidate genes that have shown 
association with renal disease, the populations they were studied in and the mechanism of 
renal disease. 
 
6.4.3.2 Genome wide screen 
This approach is more difficult than the candidate gene approach but has the advantage of 
being able to locate new (novel) genes. This approach gives a comprehensive map of 
inheritance of all parts of the human genome in families expressing a specific trait like 
ESRD. Since the Phoenix group first reported their finding in T2DM Pima Indians of kidney 
disease linkage to chromosome 7 (Imperatore et al 1998), a number of other genome wide 
















Table 6.2: Candidate genes reported to be associated with kidney disease. 
GENE (HGNC CODE) REFERENCE POPULATION MECHANISM 
Renin-Angiotensin 
System (RAS) 
   
Effect on tissue 
haemodynamics and 
glomerular cell function 
- ACE Yoshida et al 1996 DM1, DM2 Nephropathy 
- AGT Rogus et al 1998 DM1 Nephropathy 
Growth factors and 
cytokines 
   
Mesangial cell 
proliferation, ECM 
production and role in 
renal hypertrophy 
- IL-1 Loughrey et al 1998  
- IL1-RN Shu et al 2000 DM1, DM2 Nephropathy 
- TNF-α Shu et al 2000  
- TGF-β Reeves and Andreoli. 
2000 
 
Kallikrein-kinin system    
 
Inflammatory process 
- KLKB1 Yu et al 1998 Non-DM renal disease 
- KLK1 Promoter Yu et al 1998 Non-DM renal disease 
- BDKRB1 Zychma et al 1999 ESRD 
Vasoactive mediators    
Regulation of vascular 
tone and  
Homocysteine 
metabolism 
- EDN Freedman et al 2000  
- NOS Yokoyama et al 1998 Non-DM renal disease 
- MTHFR Kimura et al 2000  
 
HGNC - Hugo Gene Nomenclature Committee 
DM1 – Type 1 diabetes, DM2 – Type 2 diabetes, ECM – Extracellualr matrix 
ACE – Angiotensin converting enzyme, AGT – Angiotensinogen, IL-1 – Interleukin 1, IL1-RN – Interleukin 
1receptor antagonist, TNF-α – Tumour necrosis factor alpha, TGF-β – Transforming growth factor beta, 
KLKB1 – Kallikrein B, KLK Promoter – Kallikrein promoter, BDKRB1 – Bradykinin receptor B, EDN – 














Freedman et al (2003) performed a genome-wide scan to assess for loci contributing to urine 
albumin-to-creatinine ratio (ACR) in participants enrolled in the Hypertension Genetic 
Epidemiology Network (HyperGEN study) (Freedman et al 2003). Linkage was tested 
between 387 markers spanning the genome at an average interval of 9.32 cM. The genome-
wide scan revealed a maximum LOD score of 2.73 on chromosome 19 and a LOD score of 
2.0 on chromosome 12. Their findings demonstrate the marked heritability of urine ACR in 
families enriched for the presence of members with essential hypertension and suggest that a 
gene(s) associated with urinary ACR may be present on human chromosomes 19 and 12. 
Other genome wide studies are summarised in table 6.3.  
 
There has been little consistency among these studies, probably reflecting differences in 
phenotypes and population groups studied. A region that has shown some consistency across 
several studies is the 7p region linked to GFR in type 2 diabetes studies (Placha et al 2005). 
A genome-wide panel of 372 autosomal short tandem repeat markers was typed by Chen et al 
(Chen et al. 2007) in 691 West Africans with type 2 diabetes by using a multipoint variance 
components linkage on 3 phenotypes of renal disease. Linkage to creatinine clearance was 
observed on chromosomes 16 (LOD score = 3.56, p=0.0001), 17 (LOD score = 2.08, p = 
0.0018), and 7 (LOD score = 1.84, p=0.0022). This is highly supportive of the leptin gene on 



























































































Freedman et al 2005 
 
All cause ESRD, 
African American 
 




Chen et al 2007 
 
T2DM, West Africans 
 

























6.5 GENETICS OF THE METABOLIC SYNDROME 
Family studies have clearly indicated a heritable component to MS; however several 
association studies have yielded a large number of MS-associated loci without subsequent 
identification of aetiological genes. To date, existing approaches have in general failed to 
identify genes underlying complex diseases or traits such as MS, as they often present with a 
wide range of phenotypes and generally involve multiple aetiological mechanisms and 
contributing genes. The contribution of each of several causative genes is likely to be small 
and only the joint effect of several susceptibility genes, often in concert with environmental 
factors, would lead to the complex disease state (Glazier et al 2002).  
 
Some studies have suggested that the components of the MS may share genetic determinants. 
For instance, results from a Swedish study showed that all five principal components of the 
MS were influenced by a single latent genetic factor (Hong et al 1997). These studies indicate 
the presence of an underlying pleiotropic factor among the components of the MS. 
 
6.5.1 CANDIDATE GENES FOR THE METABOLIC SYNDROME 
The ―thrifty gene hypothesis‖ proposes that efficient storage of energy could have been 
associated with survival advantage (Neel 1962) hence; efficient storage of energy must 
include storage of fat and weight gain. Obesity genes could therefore predispose to T2DM 
and therefore the MS. A number of candidate genes have been shown from both human and 
animal studies to be related to insulin resistance. Most of these genes are related to adipose 















6.5.1.1 Agouti, Pro-Opiomelanocortin (POMC), And Melanocortin Receptors (MCR) 
The α-melanocyte-stimulating hormone (α-MSH) normally binds to the melanocortin 1 
receptor (MCR1) in the skin to control pigmentation and to MCR4 in the hypothalamus to 
suppress appetite (Fan et al 1997). Also, the agouti protein normally antagonizes the effect of 
α-MSH on MCR1. However, when the mutated protein is ectopically expressed in the 
hypothalamus it antagonizes the effect of α-MSH on MCR4, resulting in uncontrolled 
appetite. In humans the counterpart of the agouti protein is the agouti-related peptide (AGTR; 
Ollman et al 1997). Mutations in the MCR4 gene have, in some families, been associated 
with morbid obesity (Vaisse et al 1998). The ligand for the melanocortin receptor α-MSH is, 
together with β-MSH, γ-MSH and ACTH, processed from pro-opiomelanocortin (POMC) by 
different peptidases.  
 
There are several pieces of evidence to support a role of POMC in the pathogenesis of 
obesity. Neuropeptide Y (NPY), which normally stimulates appetite, downregulates the 
expression of POMC mRNA in the brain, whereas leptin, which suppresses appetite, up-
regulates POMC expression. Linkage to the POMC region on chromosome 2p21 has been 
reported for leptin levels and resting metabolic rate (Comuzzie et al 1997). In one family, 
mutations in the POMC gene segregated with progressing obesity and ACTH deficiency 
(Krude et al 1998).  
 
6.5.1.2 Beta-2 and Beta-3 Adrenergic Receptors (ADRβ2 and ADRβ3) 
The β-3 adrenergic receptor (ADRβ3) is expressed in brown adipose tissue of rodents, is 
considered responsible for thermogenesis and has been shown to increase lipolysis in visceral 












mutation have shown more abdominal obesity, higher insulin concentrations; more insulin 
resistance and higher blood pressure than individuals homozygous for the wild type (Widen 
et al. 1995) and In vitro studies have shown that the mutation may be associated with 
impairment in catecholamine-stimulated lipolysis (Hoffstedt et al 1999). A variant at codon 
27 of the ADRβ2 gene has been associated with obesity and hypertension and a 
polymorphism of the ADRβ2 gene is in linkage disequilibrium with the codon 27 variant and 
is associated with obesity and type 2 diabetes in the Japanese (Large et al 1997; Yamada et al 
1999). 
 
6.5.1.3 Glycogen synthase 
Impaired stimulation of glycogen synthesis by insulin is a hallmark of type 2 diabetes and 
IGT. The key enzyme of this pathway, glycogen synthase, could therefore be an important 
candidate for a genetic defect causing insulin resistance. The human glycogen synthase gene 
is assigned to chromosome 19q21 (Orho et al 1995) and a polymorphism of this gene has 
been associated with type 2 diabetes and insulin resistance, particularly impaired insulin-
stimulated glycogen synthesis in skeletal muscle (Majer et al 1996).  
 
6.5.1.4 Glycoprotein PC-1 
The membrane glycoprotein PC-1 was isolated from a patient with extreme insulin resistance 
and found to inhibit insulin receptor tyrosine kinase activity (Maddux et al 1995). A variant 
in exon 4 of the PC-1 gene has been associated with insulin resistance and features of the MS 















6.5.1.5 Insulin receptor substrate -1 (IRS-1) 
Two amino-acid polymorphisms were described in the IRS-1 gene (Almind et al 1993). 
These amino-acid substitutions, which were located close to the tyrosine phosphorylation 
site, were slightly more frequent in type 2 diabetic patients than in control subjects. In obese 
non-diabetic Danish subjects, the presence of the 972 polymorphism was associated with 
insulin resistance (Clausen et al 1995). The 972 variant of the IRS-1 gene seems to be 
predominantly increased in type 2 diabetic patients with the MS.  
 
6.5.1.6 Leptin and the leptin receptor 
A mutation in the LEP gene results in the complete absence of the protein in the ob/ob mouse 
and treatment of ob/ob mouse with leptin leads to marked weight loss (Pelleymounter et al 
1995). However, in obese humans, an elevated rather than decreased level of leptin is seen 
and the leptin levels show a strong positive correlation with total fat mass. Two morbidly 
obese children from consanguine parents had very low circulating leptin levels due to a 
frameshift mutation involving a deletion of a single guanine nucleotide in codon 133 of the 
leptin gene (Montague et al 1997).  
 
The leptin receptor belongs to the cytokine receptor family. The db mutation is due to an 
abnormally spliced leptin receptor with the mutant protein lacking the cytoplasmic region. It 
is suggested that the defect involves impaired leptin signalling in the hypothalamus (Lee et al 
1996). Although the leptin signalling pathway has not yet been described in detail, it has been 
suggested that the leptin signal leads to inhibition of neuropeptide Y, which stimulates food 















The breakdown of triglycerides is regulated by several lipases. A polymorphism in the 
hormone-sensitive lipase (HSL) gene was associated with type 2 diabetes which is seen in the 
MS (Klannemark et al 1998). Importantly, this variant was in a transmission disequilibrium 
test more often transmitted from heterozygous parents to abdominally obese offspring. A 
variant in exon 6 of the endothelial lipoprotein lipase (LPL) gene has been associated with 
high triglycerides, low HDL cholesterol and increased risk of CVD (Knudsen et al 1997).  
 
6.5.1.8 Peroxisome proliferator-activated receptor Gamma (PPARγ) 
There are three forms of PPAR receptors (α, β, γ) which induce transcription of a number of 
target genes in adipose tissue. The human PPARγ gene maps to chromosome 3p24, a region 
implemented in several genome-wide scans for type 2 diabetes. A rare Pro-115-Gln mutation 
in the PPARγ gene that leads to inhibition of phosphorylation, resulting in increased 
adipocyte differentiation was described in four morbidly obese subjects (Ristow et al 1998). 
Another more common Pro-12-Ala variant has been associated with a high BMI (Ek et al 
1999). 
 
6.5.1.9 Tumour Necrosis Factor-Alpha (TNF-α) 
TNF-α is a cytokine which is overexpressed in adipose and muscle tissue of obese animals 
and humans (Hotamisigil et al 1995). A positive correlation has also been demonstrated 
between the level of TNF-α mRNA in fat tissue and the level of hyperinsulinaemia, 
suggesting a role for this cytokine in the pathogenesis of insulin resistance (Hotamisligil et al 
1993). Two polymorphisms (at positions 308 and 238) have been identified in the TNF-α 












discrepant results have been obtained regarding a possible association with human obesity 
and insulin resistance (Walston et al 1999).  
 
6.5.1.10 Uncoupling proteins (ucp) 
The uncoupling proteins are proton-channel proteins on the inner mitochondrial membrane, 
and convert the electrochemical potential of the mitochondria into heat instead of ATP. They 
are responsible for thermogenesis in brown adipose tissue of rodents.  While ucp1 is 
expressed almost exclusively in brown adipose tissue, ucp2 is expressed in most tissues 
including white adipose tissue. The ucp3 gene is strongly expressed in skeletal muscle and so 
has been an attractive candidate gene for the MS. A polymorphism in the promoter region of 
the ucp1 gene on chromosome 4 has been associated with weight gain, especialy if the patient 
has the Trp64Arg mutation in the ADRβ3 gene (Clement et al 1996). 
 
6.5.2 Genome-wide scan 
Several genome-wide scans have been carried out with either obesity, type 2 diabetes or 
insulin resistance (measured as HOMA) as phenotype. Alternatively, BMI, leptin 
concentration or metabolic rate have been used as quantitative traits. In obese Mexican 
Americans, linkage was observed between fat mass or leptin concentrations and a region on 
chromosome 2 (Comuzzie et al 1997). POMC is the most interesting candidate gene in this 
chromosomal region. In the Quebec family study, linkage was found between percentage 
body fat and a region on the long arm of chromosome 20. This region is syngenic to a region 
on mouse chromosome 2, to which linkage was first observed (Lembertas et al 1997). More 
recently, linkage between basal metabolic rate and a region on chromosome 11 was reported 













6.6 THE PRESENT STUDY 
From the preceding chapters it is clear that obesity is a worldwide problem and is a factor in 
the pathogenesis of the MS and kidney disease. Certainly the development of obesity-related 
hypertension and other neuro-hormonal mechanisms that include the action of leptin and 
other inflammatory mediators, undoubtedly play important roles in this pathogenesis.  
 
Although several studies have investigated the association or relationship of the LEP gene 
with some obesity phenotypes (commonly BMI) and to the serum concentrations of leptin, 
only one study has studied this gene and its association with a specific disease viz. the 
cardiovascular disease atherosclerosis, which was defined by the thickness of the carotid wall 
(carotid intima medial thickness (CIMT)). However, there appear to be no focussed studies 
that have looked at the association of the LEP gene with kidney disease phenotypes despite 
the evidence (see chapter 5) that the gene product may be involved in the pathogenesis of 
kidney disease.  
 
Moreover, there are no reports in literature of the study of this gene in the black African 
population. Several reports of study on this gene have been in Caucasians and in a few cases 
in African Americans. Considering the fact that black Africans have a disproportionately 
higher prevalence of kidney disease than people of other races (see Chapter 4), and because 
obesity is becoming very common in Africa, especially in urbanised Africans we designed a 
study to analyse the effects of obesity associated with the MS on kidney disease. The study 
was also designed to define the relationship between the LEP gene and kidney disease in the 
















Due to the afore mentioned relationship between leptin and kidney disease (chapter 5), the 
aim of this thesis is in establishing whether an association exists between the LEP gene and 
kidney disease phenotypes (independent of diabetes and hypertension) in this homogenous 
black African population. 
 
OBJECTIVES: 
The objectives of this thesis therefore include:  
1. To assess the effect of the MS on kidney disease phenotypes in this population 
2. Identifying the prevalence of genotypes of the LEP in black South Africans. 
3. To identify the relationship between the LEP gene, obesity, hypertension, the MS, markers 
of kidney disease and serum leptin concentration in black Africans.  
4. To identify candidate genes for the MS through a bioinformatics approach.  
 
The next three chapters form the bulk of my experimental work and address these objectives 
as follows:  
1. An investigation and analysis of the phenotypes of the MS, obesity, and kidney disease 
and their correlations in a black (South) African population (chapter 7). 
2. An analysis of the LEP gene resulting in establishing the genotype–phenotype 
associations between different SNPs and MS, obesity, and kidney disease phenotypes 
(chapter 8). 
3. A computational – bioinformatics assessment through ―mining‖ various databases in the 

























The MS is strongly associated with the risk for diabetes, CVD including coronary artery 
disease and stroke and with the risk for all-cause mortality. The relationship between insulin 
resistance and kidney disease has been amply reported, however, there are not many studies 
that have reported on the relationship between the MS and kidney disease. Hoehner and 
colleagues (2002) in a cross-sectional survey of 934 non-diabetic Native Americans found 
that the insulin resistance syndrome was associated with microalbuminuria and that persons 
with 3 or more traits for the insulin resistance syndrome had 2.3-fold higher odds of 
microalbuminuria than persons with no traits (Hoehner et al 2002). 
 
Chen et al (2004) were the first to report on the relationship between the MS and kidney 
disease in a large sample of Americans (Chen et al 2004). Using data of the NHANES III, 
they identified a strong, positive, and significant relationship between the MS and risk for 
CKD and microalbuminuria. Although the study of Chen et al (2004) did not reveal the 
fraction of their cohort that had diabetes, (diabetes alone being a potent risk for CKD and 
microalbuminuria), they were however able to show a significant relationship between the 
MS and CKD after excluding all diabetics (Chen et al 2004). 
 
The public health impact of CKD / ESRD has been examined. ESRD requiring RRT comes at 
great cost to the patient and the society and reports have shown that blacks suffer more from 
hypertension related-ESRD, although the reasons for this are still unclear. The Medical 












(including nephritis and nephroses) are the second cause of death (16.6%), second only to 
HIV/AIDS which accounted for 30% of total deaths. The number of years of life lost from 
NCDs amounted to 21% (Bradshaw et al 2003). 
 
The MS presents an opportunity for looking at other factors (aside form hypertension alone) 
that may potentially steer the higher prevalence of kidney disease in people of the black race. 
A recent Pubmed search on the relationship between the MS and kidney disease in any native 
black African population has yielded no reports or studies in this field.  
We thus set about to investigate the relationship between phenotypes of the MS and kidney 






The study was approved by the research ethics committee of the University of Cape Town in 
2005 (REC REF: 043/2005).  
 
7.2.2. SAMPLE SIZE ESTIMATION 
A pilot study was carried out in the hypertension clinic of the Groote Schuur Hospital (GSH) 
with the approval of Prof Brian Rayner, head of the clinic. This was done to enable us have 
an estimate of the number of subjects that will be required for the full study. Data was 
collected from the case notes of about 40 black Xhosa subjects attending this clinic. The data 
included age, gender, blood pressures, height and weight and laboratory variables including 
plasma creatinine, glucose (fasting), lipids and urine ACR. Using this data, it was estimated 
that 269 subjects will be needed to provide the study with sufficient power (80%) to obtain 












7.2.3. STUDY LOCATION AND POPULATION 
South Africa with its rich array of ethnic backgrounds is made up of about 79% Black 
Africans, 9.6% Whites, 8.9% Coloureds and 2.5% Indians/Asians. The black population of 
South Africa is also quite diverse. The Xhosas (relevant to this study) are the second largest 
of the black population (17.6%) after the Zulus who make up 23.8% of the blacks of South 
Africa (Byrnes 1996). 
 
The homeland of the Xhosas is the Eastern Cape (formerly Transkei and Ciskei) and due to 
its proximity to the Western Cape, the majority of black South Africans in the townships of 
the Western Cape are Xhosas who had migrated to this city in search of a job or had been 
born here (Byrnes 1996). 
 
In the Western Cape, several informal settlements or townships had been set up to cater for 
the needs of those coming in search of a job. Gugulethu is one of such townships and is one 
of the oldest black townships in Cape Town and South Africa.  
 
Established in 1958 as Nyanga West as a result of the migrant labour system of the former 
South African government, Gugulethu grew as the number of migrant workers from the 
Transkei increased and Langa (a nearby black township) became too small to accommodate 
them all. Many of the people in this township still have their families in the Eastern Cape 
(Transkei area), a reflection of the past in which hostel dwellers were not allowed to bring 













Gugulethu has a community health centre which operates a daily medical out patients‘ clinic, 
a 24 hour trauma unit, a HIV/AIDS treatment centre and a twice weekly hypertension and 
diabetes clinic with frequent referrals to the GSH.  
 
This study was conducted at the Gugulethu hypertension clinic between May 2005 and July 
2006 and was of a cross-sectional design. Consecutive patients attending this clinic were 
informed of the nature of this study and those willing to participate were screened for 
diabetes by blood glucose testing after a 12 hour fast and after signing the consent forms of 
the study (see appendix (A3) for consent forms).  
 
Through this process, 273 hypertensive subjects were screened with 84 of them requiring the 
oral glucose tolerance test (OGTT) to exclude diabetes. Eight of the subjects were excluded 
on account of incident diabetes mellitus after the OGTT; 12 others declined to continue the 
study for various reasons. Overall, 253 hypertensive subjects were recruited for the study. 
The OGTT involved the oral administration of 75g of glucose in 300ml of water to subjects 
with impaired fasting glucose defined as fasting glucose ≥ 5.6 mmol/L. Blood glucose was 
drawn again from such subjects at time 60 minutes and 120 minutes. Subjects with 2 hour 
blood glucose ≥ 11.1mmol/L were classified as diabetics and excluded from the study. Such 
subjects were then referred to the diabetes clinic for further assessment and treatment.  
 
As the overall aim of this thesis is to test whether an association exists between the LEP gene 
and kidney disease phenotypes (independent of diabetes and hypertension), non-diabetic and 
normotensive first degree relatives of the hypertensives were also invited to take part in the 
study and were therefore included in the analysis of the relationship between MS phenotypes 












study after screening for diabetes and hypertension. Eventually, 336 subjects were recruited 
in total, comprising 253 non-diabetic probands (hypertensives) and 83 (non-diabetic) first 
degree normotensive relatives. However, only 334 subjects were used in the analysis as 
results could not be obtained for 2 of the subjects who were also unavailable for a repeat of 
the tests. 
 
A questionnaire was administered to all participants (see appendix A4) in order to obtain 
information on age (date of birth), sex, ethnicity, smoking, alcohol and physical activity, 
duration of hypertension, history of CVD and family history of hypertension. Height, weight, 
waist and hip circumference were measured and recorded (as described in the next section 
below).  
  
Subjects were not screened for HIV, despite the high prevalence of HIV amongst black South 
Africans and the obvious complication of HIV-associated nephropathy (HIVAN) that could 
result from it. This was because it would be considered unethical screening for HIV for the 
purpose of this study, especially as the theme is not HIV/AIDS related. However, as subjects 
with HIVAN often present with symptoms of uraemia, heavy proteinuria, severe oedema, and 
other symptoms of immunodeficiency, such subjects were essentially excluded as subjects 
with infections or chronic diseases requiring treatment were routinely excluded. Furthermore, 
subjects on highly active anti-retroviral therapy (HAART) were specifically excluded from 
the study to ensure that all cases of lipodystrophy arising from the use of HAART were 













Pregnant women were also excluded from participating as pregnancy is associated with an 
altered haemodynamic state with increased fluid retention, renal blood flow and GFR and 
could be a potential confounding factor.  
Patients with known secondary causes of hypertension (commonly hyperaldosteronism or 
presence of a mutation in the epithelial sodium channel [R563Q] first described by Prof Brian 
Rayner in the Cape population) (Rayner et al. 2003) were also excluded from the study as 
were all those with malignant hypertension.  
 
Finally, although any black population would have been targeted for this study, the choice of 
the Xhosas was to ensure a homogenous population sharing similar alleles inherited from a 
common ancestor, i.e. a population that was identical-by-decent (IBD) rather than one in 
which the disease gene is expected to occur by chance (Lander and Schork, 1994). Ethnicity 
was determined by the individual‘s home language, which is the language of his/her parents 
and not just any other acquired language and we confirmed this in the questionnaire. Hence, 
all black subjects of other nationalities or black South Africans who were not Xhosa were 
excluded from the study. 
 
7.2.4. CLINICAL ASSESSMENT OF SUBJECTS: 
7.2.4.1 Waist and Hip Circumferences: 
To measure WC, a measuring tape was placed snugly in a horizontal plane around the 
abdomen at the level of the iliac crest. The measuring tape was parallel to the floor and the 
measurement was taken at the end of a normal expiration to the nearest 0.1cm. Hip 
circumference was measured at the level of the greater trochanters. This position is generally 
taken as the widest circumference below the WC. It was also measured using the tape 












circumferences. All measurements were done by the same person, using the same tape 
measure throughout the period of the study. 
 
7.2.4.2 Body Mass Index 
The BMI was calculated as weight (kg) divided by height squared (m
2
) 
7.2.4.3 Blood Pressure 
This was taken using a validated Accouson mercury sphygmomanometer. Patients were made 
to sit comfortably for a period of no less than five minutes. Blood pressure was then taken in 
both arms and the arm with the greater reading was used for assessment. Two blood pressure 
measurements were taken from this arm two minutes apart and the average of the two 
readings was taken as the blood pressure reading. Mean arterial blood pressure (MAP) was 
calculated from these readings using the equation: 
 
MAP = DBP + Pulse pressure / 3 (mmHg) 
Pulse pressure was calculated from SBP – DBP (mmHg) (Ganong 1981) 
 
7.2.5. LABORATORY ASSESSMENT: 
Blood was drawn by a trained research nurse and sent to the National Health Laboratory 
Service (NHLS) who handled all the biochemical and hormonal analysis. Spot urine was also 
taken for measuring the urine ACR. 
Routine chemistry included: 
Lipid profile: Cholesterol, Triglycerides (TG), High density lipoprotein cholesterol (HDL), 
Low density lipoprotein cholesterol (LDL) 
Liver function: Albumin 












Endocrine functions: Glucose, Insulin, Leptin, Adiponectin, 
Inflammatory and prothrombotic markers: Fibrinogen, C-reactive protein (CRP).  
 
For all these tests, conventional assays were used in the NHLS chemical pathology laboratory 
on auto-analysers with appropriate quality control.  
 
7.2.5.1 Glomerular Filtration Rate (GFR) 
This was calculated using the Modification of Diet in Renal Disease (MDRD) equation: 




 x (0.742 if female) x (1.210 if black) 
Although the MDRD Study equation has not been validated in subjects <18years, pregnant 
women, the elderly (age >70 years), racial or ethnic subgroups other than Caucasians and 
African Americans, in individuals with normal kidney function who are at increased risk for 
CKD, or in normal individuals it was still the preferred method for calculating the GFR. This 
is because GFR estimates using this equation are more accurate than serum creatinine alone; 
moreover, the MDRD Study equation has been rigorously developed and validated and it is 
more accurate than measured creatinine clearance from 24-hour urine collections (Levey et 
al. 2000). Table 7.1 shows estimates of GFR for stratification of age groups in decades. 
Table 7.1: Estimates of GFR for stratified age groups (Levey et al 2000). 



















7.2.5.2 Homeostasis Model Assessment (HOMA): 
Although the most appropriate method for assessing insulin resistance is the euglycaemic 
clamp method. HOMA has been shown to correlate with the degree of insulin resistance from 
different populations. 
It is calculated from the following equation:  
Fasting glucose * Fasting Insulin / 22.5 
The beta-cell function (%B) and the insulin sensitivity (%S) were estimated using the 
Diabetes Trial Unit (The Oxford centre for Diabetes, Endocrinology and Metabolism) online 
model assessment calculator (www.dtu.ox.ac.uk). 
 
 
7.2.5.3 Kidney Biopsy 
Although it had been intended that kidney biopsy would be performed in subjects with 
massive proteinuria, no such subject was identified during the course of this study. Kidney 
biopsy might illustrate if there are unique histological features peculiar to the MS and might 
have demonstrated if the features were similar or the same as features seen in obesity related 
glomerulopathy.  
 
7.2.5.4 Definition of the Metabolic Syndrome 
The MS was defined using cutoffs of the ATPIII as already discussed in chapter 3 of this 



















7.2.6 STATISTICAL ANALYSIS 
 
The data was first put into Microsoft Excel spreadsheets and exported into SPSS statistical 
software (SPSS version 11.0 Chicago USA). Continuous data were analysed using the 
students t-test. Analysis of variance (ANOVA) was used to compare the means of multiple 
variables.  Categorical data were analysed in contingency tables using χ
2
. Individual methods 
of analysis are indicated in the texts. The results were expressed as percentages or as mean ± 
SEM except if otherwise stated. In some cases where data was skew, logarithmic (log) 
transformation was done to adjust the data appropriately, however in such cases, the real 
values and not the log transformed values were used. Correlation coefficients (partial and 
regression) which in general statistical usage refers to the departure of two variables from 
independence were used to indicate the strength and direction of linear relationship between 
variables. Although a p value of <0.05 is arbitrarily accepted worldwide as significant 
(unlikely to have occurred by chance), it is the conventional value for statistical significance 




































The demographic features of the study participants are as shown in table 7.2. Male subjects 
made up 34.1% of the entire study population and the mean age of participants significantly 
and proportionally rose with increasing number of MS components. Due to differences in 
age, sex, and duration of hypertension, the p value was adjusted for these factors and also 
given in the tables. 
 
 





N – Number of subjects 
Values indicate mean (SEM).  
p values obtained from ANOVA of mean values. 













0 1 2 3 ≥4 
 N=334 (%) 36 (10.8) 56 (16.8) 130 (38.9) 73 (21.9) 39 (11.6)   
Age (yrs) 31.7 (2.3) 46.3 (2.0) 53.7 (1.0) 55.2 (1.2) 55.9 (1.7) <0.0001 _ 
Males (%) 18 (50.0) 34 (60.7) 32 (24.6) 24 (32.9) 6  (15.4) <0.0001 _ 
Yrs of Education 
(yrs) 
8.9 (0.5) 6.9 (0.5) 6.2 (0.2) 6.3 (0.3) 5.6 (0.5) <0.0001 0.009 
Physical Activity 
(Hours/week) 
4.5 (0.2) 4.5 (0.2) 4.4 (0.1) 4.2 (0.2) 4.2 (0.2 0.708 0.763 
Current Smokers 
(%) 
4.2 6.0 4.5 3.9 0.9 <0.0001 0.149 
Alcohol users (%) 5.1 8.4 9.3 6.3 2.1 0.002 0.700 
Duration of 
Hypertension (yrs) 












All the blood pressure measurements (SBP, DBP, MAP and Pulse pressure) significantly 
increased as components of the MS increased. However, after adjusting the p value for age, 
sex and differences in duration of hypertension, pulse pressure was no longer significantly 
different between the groups although it increased with increasing number of MS traits 
(Table 7.3) 
 
Table 7.3: Clinical features of the study participants. 
 
N – Number of subjects  
Values indicate mean (SEM).  
p values obtained from ANOVA of mean values. 
p§ - p value adjusted for differences in age, sex, duration of hypertension and use of anti-hypertensive 
medications. 
SBP – Systolic blood pressure, DBP – Diastolic blood pressure, MAP – Mean arterial pressure, BMI – Body 












0 1 2 3 ≥4 
 (N=334) (%) 36 (10.8) 56 (16.8) 130 (38.9) 73 (21.9) 39 (11.6)   
SBP (mmHg) 124.5 (2.4) 138.4(3.3) 148.2(1.8) 153.2(2.2) 161.1(1.7) <0.0001 0.001 
DBP(mmHg) 81.7 (1.5) 86.8(1.6) 93.4(1.0) 95.0(1.4) 100.5(6.8) <0.0001 <0.0001 
MAP (mmHg) 95.9 (1.7) 104.0 (2.1) 111.6 (1.2) 112.8(2.2) 117.4 (2.0) <0.0001 <0.0001 
Pulse Pressure 
(mmHg) 
42.9 (1.9) 51.6 (2.3) 54.9 (1.3) 57.5 (1.8) 57.1 (2.4) <0.0001 0.319 
BMI (kg/m
2
) 23.9 (0.9) 27.4 (0.8) 35.4 (0.8) 36.3 (0.8) 37.7 (1.1) <0.0001 <0.0001 
WC (cm) 80.9 (1.5) 92.8 (2.0) 109 (1.3) 114.2(1.5) 115.8(2.0) <0.0001 <0.0001 
Hip (cm) 97.8 (1.8) 105.3(2.0) 120.9(1.6) 122.2(1.8) 127.8(2.4) <0.0001 <0.0001 












Table 7.4.1 to 7.4.3 shows the biochemical features of all the study participants. Fasting 
glucose was significantly higher in subjects with the MS (3 or more traits). The 1 hour and 2 
hour post glucose load measurements were not different between the groups. Insulin, %S, and 
HOMA all increased with increasing MS traits and were significantly different at first, but 
again after adjusting the p value for age, sex and duration of hypertension were no longer 
different between the groups. 
All measured serum lipids including TG, HDL, LDL and Cholesterol remained significantly 























































0 1 2 3 ≥4 
 (N=334) (%) 36 (10.8) 56 (16.8) 130 (38.9) 73 (21.9) 39 (11.6)   
FBG (mmol/L) 4.7 (0.1) 4.7 (0.1) 5.0 (0.1) 5.5 (0.1) 5.8 (0.1) <0.0001 <0.0001 
60 Minutes*** 7.6 8.1 (1.2) 9.5 (0.5) 9.0 (0.5) 9.6 (0.5) 0.646 0.427 
120 Minutes*** 5.5 6.2 (0.5) 7.9 (0.4) 7.7 (0.4) 7.9 (0.3) 0.207 0.874 
Insulin (mU/L) 7.0 (0.7) 7.3 (1.0) 15.2 (1.8) 26.5 (4.6) 48.0 (11.1) <0.0001 0.857 
%B 113.8 (8.5) 112.3 (11.1) 121.2 (4.6) 134.2(8.9) 140.9(11.9) 0.153 0.752 
%S 123.7 (10.6) 134.2 (10.2) 97.3 (5.0) 76.5 (6.9) 58.3 (6.1) <0.0001 0.773 
HOMA 1.5 (0.1) 1.6 (0.2) 3.9 (0.7) 7.2 (1.4) 14.4 (3.5) <0.0001 0.746 
Albumin (g/L) 46.0 (0.4) 44.7 (0.4) 43.9 (0.3) 44.1 (0.3) 43.7 (0.5) 0.005 0.072 
 
 
N – Number of subjects  
*** The number of subjects who had OGTT and participated was 65. 
Values indicate mean (SEM).  
p values obtained from ANOVA of mean values. 
P§ - p value adjusted for differences in age, sex , duration of hypertension and use of anti-hypertensive 
medications. 
FBG – Fasting blood glucose, %B – Estimated beta cell function, %S – Estimated insulin sensitivity, HOMA – 
































0 1 2 3 ≥4 
 (N=334) (%) 36 (10.8) 56 (16.8) 130 (38.9) 73 (21.9) 39 (11.6)   
TG (mmol/L) 0.7 (0.1) 1.0 (0.1) 1.2 (0.1) 1.6 (0.1) 2.1 (0.1) <0.0001 <0.0001 
HDL (mmol/L) 1.7 (0.1) 1.7 (0.1) 1.5 (0.1) 1.3 (0.1) 1.2 (0.1) <0.0001 <0.0001 




4.0 (0.1) 4.5 (0.1) 4.9 (0.1) 4.9 (0.1) 5.3 (0.2) <0.0001 0.003 
 
 
N – Number of subjects  
Values indicate mean (SEM).  
p values obtained from ANOVA of mean values. 
P§ - p value adjusted for differences in age, sex , duration of hypertension and use of anti-hypertensive 
medications. 




Age and sex adjusted level of CRP was not significantly different between the different 
groups stratified according to number of MS traits. However, fibrinogen, a prothrombotic 
factor and marker for systemic inflammation was significantly higher in subjects with the 
MS. (Table 7.4.3) 
 
Both leptin and adiponectin [with the leptin –adiponectin ratio (LAR)] significantly increased 
with increasing number of MS traits. This remained true for adiponectin and LAR after age 
and sex adjustment for the p-value. However, this significance was lost for leptin after this 
adjustment which could indicate that one of these factors (age, sex, hypertension duration) 





















0 1 2 3 ≥4 
 (N=334) (%) 36 (10.8) 56 (16.8) 130 (38.9) 73 (21.9) 39 (11.6)   
CRP (mg/L) 4.3 (1.3) 8.0 (2.3) 9.7 (0.9) 10.7 (1.3) 9.1 (1.3) 0.109 0.684 
Fibrinogen 
(g/L) 
3.4 (0.1) 3.7 (0.1) 4.2 (0.1) 4.2 (0.1) 4.3 (0.1) <0.0001 0.033 
Adiponectin 
(μg/ml) 
8.7 (1.0) 9.1 (0.7) 8.0 (0.4) 5.4 (0.5) 5.8 (0.7) <0.0001 <0.0001 
Leptin (ng/ml) 14.3 (2.5) 18.7 (2.6) 35.8 (2.3) 34.9 (2.8) 36.9 (3.4) <0.0001 0.198 
LAR 2.1 (0.4) 3.5 (0.7) 6.1 (0.5) 9.7 (1.3) 10.0 (1.6) <0.0001 <0.0001 
 
N – Number of subjects  
Values indicate mean (SEM).  
p values obtained from ANOVA of mean values. 
P§ - p value adjusted for differences in age, sex , duration of hypertension and use of anti-hypertensive 
medications. 
CRP – C-reactive protein, LAR – Leptin to Adiponectin ratio. 
 
Serum creatinine tended to rise proportionally with MS traits but this was not significantly 
different between the different groups. Mean GFR difference was approximately 30% (133.9 
ml/min/1.73m
2
 to 94.4 ml/min/1.73m
2
) between subjects who had no MS trait to those with 4 
or more traits and this difference remained significant after adjusting for age, sex and 
duration of hypertension (p=0.028) (Table 7.5). 
 
Albumin-to-creatinine ratio increased four-fold from subjects with no MS traits to those with 
four or more traits and the incidence of microalbuminuria was higher in subjects with the MS. 
Four subjects had overt proteinuria. Two of these were in the group with 2 MS traits (1.5%) 

























0 1 2 3 ≥4 
 (N=334) (%) 36 (10.8) 56 (16.8) 130 (38.9) 73 (21.9) 39 (11.6)   
Creatinine 
(µmol/L) 





133.9 (6.1) 112.9 (3.5) 100.6 (2.6) 103.9(2.6) 94.4 (3.0) <0.0001 0.028 
ACR (mg/mmol) 1.4 (0.5) 1.2 (0.2) 2.8 (0.6) 3.3 (0.6) 4.7 (1.8) <0.0001 0.021 
Microalbuminuria 
(%) 
11.4 12.3 18.9 28.2 23.7 0.019 0.087 
Clinical 
proteinuria (%) 
_ _ 1.5 _ 5.1 _ _ 
 
N – Number of subjects , Values indicate mean (SEM).  
p values obtained from ANOVA of mean values. 
P§ - p value adjusted for differences in age, sex , duration of hypertension and use of anti-hypertensive 
medications. 
GFR- glomerular filtration rate, ACR- albumin-to-creatinine ratio. 
 
A student‘s t-test was used to compare the clinical and biochemical features of hypertensive 
and normotensive subjects according to the presence (ACR
+
) or absence (ACR
-
) of 
microalbuminuria. The total incidence of microalbuminuria was 19.5% and as would be 
expected, hypertensive subjects had a greater incidence of microalbuminuria compared with 
normortensive subjects. Blood pressure (SBP and DBP), fasting glucose and urine ACR were 
significantly higher in microalbuminuric hypertensives than in normoalbuminuric 
hypertensives (p<0.05 in all cases) (Table 7.6). Microalbuminuric normotensives had 
significantly elevated values of urine ACR compared with normoalbuminuric normotensive 





































N (%) 54 (21.5)*** 197 (78.5) 11 (13.3)*** 72 (86.7) 
Age (yrs) 55.4 (1.3) 56.2 (0.7) 37.4 (4.0) 34.2 (1.5) 
SBP (mmHg) 159.2 (2.7) 150.5 (1.4)** 127.3 (5.3) 126.9 (2.0) 
DBP (mmHg) 98.5 (1.6) 93.9 (0.8)** 83.6 (2.1) 82.9 (1.3) 
WC (cm) 110.0  (2.5) 108.7 (1.1) 97.0 (7.4) 93.2 (2.1) 
Fasting Glucose 
(mmol/L) 
5.4  (0.1) 5.2  (0.1)** 4.9 (0.2) 4.7 (0.1) 
TG (mmol/L) 1.5  (0.1) 1.4 (0.1) 1.3 (0.2) 0.9 (0.1) 
HDL (mmol/L) 1.5  (0.1) 1.4  (0.03) 1.5 (0.2) 1.7 (0.1) 
Leptin (ng/ml) 33.0  (3.5) 31.8 (1.7) 28.9 (7.7) 24.9 (2.5) 
Creatinine 
(µmol/L) 
92.4 (10.8) 79.6  (1.5) 72.1 (4.3) 71.1 (3.0) 
GFR (ml/min) 100.4  (4.2) 99.1 (1.6) 113.6 (8.2) 129.7 (4.1) 
ACR (mg/mmol) 10.9 (1.5) 0.8  (0.1)** 9.6 (2.3) 0.7 (0.1)* 
 
N – Number of subjects  
Values indicate mean (SEM).  
ACR
+ 
Indicates subjects with microalbuminuria 
ACR
-
 Indicates subjects without microalbuminuria. 
* Indicates significant difference between normoalbuminuric and microalbuminuric normotensive subjects 
** Indicates significant difference between normoalbuminuric and microalbuminuric hypertensive subjects. 
*** Indicates significant difference between microalbuminuric hypertensive and normotensive subjects 
SBP- systolic blood pressure, DBP- diastolic blood pressure, BMI- body mass index, WC- waist circumference, 
HOMA – Homeostasis model assessment, TG- triglycerides, HDL- high density lipoprotein, CRP- C-reactive 
protein, GFR- glomerular filtration rate, ACR- albumin-to-creatinine ratio, ACR
+
 is presence of 
microalbuminuria, ACR
-
















A partial correlation matrix was used to analyse the relationship between MS and both urine 
ACR (Table 7.7.1) and estimated GFR (Table 7.7.2). MS phenotypes were used as the 
variables, and differences in age, sex, and differences in duration of hypertension were 
controlled for.  
In subjects with the MS, SBP, DBP and Fasting glucose positively and significantly 
correlated with ACR whereas an inverse but significant correlation was observed between 
GFR with BMI and serum Leptin. In subjects without the MS, DBP and fasting TG modestly 
and positively correlated with urine ACR. 
 
 












SBP (mmHg) 0.255* 0.126 
DBP (mmHg) 0.206* 0.143* 
BMI (kg/m
2
) 0.078 - 0.088 
WC (cm) - 0.013 - 0.037 
TG (mmol/L) 0.062 0.156* 
HDL (mmol/L) 0.115 0.008 
Fasting glucose (mmol/L) 0.230* 0.084 




 Indicates subjects with the MS. 
MS
-
 Indcates subjects without the MS 
* Indicates significant correlation between variable and ACR 
SBP- systolic blood pressure, DBP- diastolic blood pressure, BMI- body mass index, WC- waist circumference, 



























SBP (mmHg) 0.059 - 0.031 
DBP (mmHg) - 0.023 - 0.057 
BMI (kg/m
2
) - 0.223** 0.098 
WC (cm) - 0.131 - 0.017 
TG (mmol/L) 0.007 - 0.111 
HDL (mmol/L) - 0.001 0.031 
Fasting glucose (mmol/L) - 0.073 - 0.111 





 Indicates subjects with the MS. 
MS
-
 Indcates subjects without the MS 
** Indicates significant correlation between variable and GFR 
SBP- systolic blood pressure, DBP- diastolic blood pressure, BMI- body mass index, WC- waist circumference, 






























Figure 7.1: Bar chart depicting the relationship between serum leptin (in quartiles) and Log 
transformed ACR after adjusting for confounding variables. 
 


















The relationship between serum leptin (quartiles) and microalbuminuria measured as urine 
ACR (log transformed) is represented in the bar chart in. ACR is seen to linearly increase 
across the four quartiles of serum leptin concentrations.  
 
Logistic regression analysis was used to determine the odds ratio (OR) for microalbuminuria 
with individual and several components of the MS. High SBP (≥130 mmHg), high DBP (≥ 85 
mmHg) and high fasting serum TG (≥1.7mmol/L) had significant OR of 2.59 (95%CI of 












for microalbuminuria increased with number of MS traits and was significant in subjects with 
the MS (Table 7.8). 
Table 7.8: Logistic regression analysis for predictors of microalbuminuria using individual 



































































































































In the Strong Heart Study of non-diabetic Native Americans, the MS did not predict an 
increase in incident CVD events (Resnick et al., 2003). However, results from other large 
population-based studies that included diabetics have shown that the presence of the MS is 
associated with a significantly increased risk of all-cause mortality and CVD morbidity and 
mortality (Lakka et al 2002). This study, the first of its kind in a non-diabetic and 
homogenous native black African population has some important renal observations that 
include: (1) A four-fold rise in ACR from subjects with no MS traits to those with 4 or more 
traits (table 7.5), (2) a significant decline in GFR with increasing number of MS traits (Table 
7.5), (3) an increasing odds ratio (likelihood) for the occurrence of the microalbuminuria with 
increasing MS phenotypes (Table 7.8), (4) ACR and GFR in MS subjects correlating 
significantly with SBP, DBP, fasting glucose; and with BMI and leptin respectively (Table 
7.7.1 and 7.7.2)  (5) High SBP, high DBP and hypertriglyceridaemia being the independent 
predictors of microalbuminuria (Table 7.8). 
 
Microalbuminuria implies endothelial dysfunction and may herald impending and serious 
renal damage. In hypertensives microalbuminuria is a marker of target organ damage whereas 
in diabetics it generally marks the beginning of nephropathy. In this population, the finding of 
an almost four fold rise in ACR from subjects with no MS traits to those with 4 or more traits 
clearly shows that additional metabolic risk factors, even in the absence of diabetes, increase 
the risk for kidney disease. This increase in ACR may mark the initiation of kidney damage, 
seen as significant decline in GFR with increasing MS traits. 
 
Also, the positive and significant correlation of ACR with SBP and DBP in subjects with the 












aetiology of kidney disease in black Africans. Although blood pressure alone is a significant 
cause of kidney disease, especially in black Africans, it might need the presence of other risk 
factors to accelerate the onset and progression of kidney disease. This concept was tested by 
Mule et al (2005) who studied the effects of additional risk factors on target organ damage 
caused by hypertension in a group of white hypertensives. They found that the occurrence of 
the MS may amplify hypertension related cardiac and renal damage over and above that 
which may result from individual contributions from each component.  
 
The studies of Salako et al (2007) in Nigeria and Rayner and Becker (2006) in South Africa 
have shown that microalbuminuria is common in treated and untreated hypertensive black 
Africans and both studies pointed out the implications of adequate BP control with regards to 
kidney disease. However, although kidney disease arising from hypertension tends to be 
common amongst people of African origin, hypertension alone may not account for the 
higher prevalence of kidney disease seen in blacks.  
 
Therefore, the significant inverse correlation observed for GFR with BMI and serum leptin 
(Table 7.7.2) and the linear increase of urine ACR across the four quartiles of serum leptin 
(Figure 7.1) may implicate obesity as a factor for renal disease in this population. Chen et al. 
(2004) have shown that the risk for being affected by CKD was more than twice as high in 
patients with an increased WC as in those without, suggesting that obesity may be an 
independent risk factor for CKD. Although the exact mechanisms that link obesity and renal 
damage have not yet been understood fully, it is suggested that some of the hormones 
secreted by fat cells (e.g. leptin, IL-6 and TNF-α) may be partly involved in promoting renal 












has been shown to predispose to glomerulosclerosis (Wolf et al 1999) and increased urine 
albumin excretion in women with type 1 diabetes (Rudberg and Persson 1998). 
 
This association suggests that obesity, both phenotypically and through the actions of its 
hormones, may play a significant role in initiating and leading to the progression of kidney 
disease in black Africans. The observation may also strongly support the Kincaid-Smith 
hypothesis (2004) that argued that renal disease in black Africans may be linked more closely 
to obesity and insulin resistance than to blood pressure alone as is generally supposed.  
 
Therefore, as hypertension alone may not explain or account for the majority of kidney 
disease cases seen worldwide, especially in black Africans who are more likely to be labelled 
as having hypertension-related ESRD, it has become necessary to explore other factors, 
(environmental or genetic) that may contribute to the increased incidence and progression of 
kidney disease amongst blacks. The MS as a ―single‖ entity provides an opportunity of 
finding such environmental factors and has been shown in this study to be associated with 
kidney disease. A potential genetic factor that may account for the higher prevalence of 
hypertension related kidney disease in black Africans could be the LEP gene (see chapter 5 
for effects of leptin on blood pressure and the kidney). This genetic influence is sought in the 


























ASSOCIATION STUDY OF THE LEP GENE AND VARIOUS PHENOTYPES THAT 




The increasing prevalence of obesity seen in many populations of the world and its major 
complications, especially CVD which is the principal source of morbidity and mortality in 
obese people, prompted a search for candidate genes that play a role in the pathophysiology 
of CKD and obesity.  
 
As discussed in chapter 6, several reports with conflicting results have been published on the 
association between the human LEP gene located in chromosome 7 and obesity phenotypes 
and serum leptin concentration. Despite the conflicting results, the leptin-signalling pathway 
is regarded as one of the most important routes in energy homeostasis in human metabolism 
(Tritos and Mantzoros 1997).  
 
There are very few studies that have sought for the existence of associations between 
polymorphisms of the LEP gene and CVD markers (other than obesity) given the identified 
role of obesity in CVDs generally. Also, there are no reports of studies in native black 
Africans on the relationship between the LEP gene and any marker of CVD.  
 
Three polymorphisms in the 5‘ untranslated region (5‘ UTR) of the LEP gene (G2548A, 
C188A, and A19G) have been studied and reported often from different populations. G2548A 
and C188A are in the promoter region of the gene and A19G in the non-coding exon 1. Also, 
a rare polymorphism in the non-coding sequence of exon 3, the C538T, has been reported 












a lower incidence of atherosclerosis in Caucasians. These four polymorphisms, having been 
previously studied in other populations were chosen, of the approximately 140 SNPs in the 
LEP gene, for the present study. Although these polymorphisms are in the non-coding 
regions of the LEP gene, studies on similar positioned polymorphisms from other genes have 
shown that they may influence the expression of the gene and its protein (Misquitta et al 
2001, Komar 2007). 
 
These polymorphisms were thus chosen for the current study, firstly because there have been 
reports about them from other populations providing a basis for comparison with results from 
our study. Secondly, leptin, the obesity gene product has been shown to play a role in obesity 
and hypertension and to cross-talk with insulin pathways and therefore could play a role in 
insulin resistance and the MS (see chapter 5). Thirdly, chronic leptin elevation has been 
shown to increase renal sympathetic nerve activity and to play a role in glomerulosclerosis 
and proteinuria (see chapter 5). Even though hyperleptinaemia has been shown to be related 
with renal disease, it is not known if the same association with renal disease exists with the 
LEP gene. 
 
Thus, in this part of the study we attempted an analysis of the LEP gene in order to establish 
the genotype–phenotype relationships between the selected SNPs and MS, obesity, 


















The recruitment process, sample size estimation, study population, and assessment of clinical 
and laboratory variables have been described in chapter 7. It is imperative to state here that 
the sample size for this part of the study was not separately estimated but was based on 
sample size obtained from the part described in chapter 7. Also, sample sizes for the different 
SNPs examined differed and were fewer than that of the entire study population and 
depended on availability of high quality DNA, successfully completed genotyping 
experiments or (in)ability to get the subject again for a repeat examination. Thus, there is 
variation in sample sizes of the different SNPs. Sample numbers analysed were: 250 – 
(G2548A [rs7799039]); 293 - (C188A [rs791620]); 293 - (A19G [rs2167270]) and 300 – 
(C538T [ENSSNP5824596]). For the purpose of simplicity, these genotypes will not be 
described in the text by their RefSeq ids. Consent was obtained from the subjects to have 
their blood genetically tested.  
 
8.2.1 GENETIC ANALYSIS: 
All the genetic analysis was carried out at the Human genetics Laboratory (Ramesar Lab) of 
the University of Cape Town. This involved DNA extraction, primer design, polymerase 
chain reaction (PCR) for DNA amplification and restriction enzyme (RE) digests of the 
amplified DNA. 
 
8.2.2 DNA EXTRACTION:  
Genomic DNA was isolated from peripheral blood lymphocytes using the Puregene DNA 
Isolation Kit (Gentra Systems, USA) according to the manufacturer‘s protocol.  
Specifically, the white cells from peripheral blood are separated from the red cells and lysed 












with the DNA from the white cells, and are removed with the enzyme proteinase K to prevent 
their interfering with downstream molecular experiments. The extraction process is 
completed by washing the DNA with ethanol and finally eluting with water. DNA purity and 
yield was confirmed using the Nanodrop ND-1000 spectrophotometer (Nanodrop 
Technologies Inc Welmington USA) 
 
8.2.3 POLYMERASE CHAIN REACTION AND RESTRICTION ENZYME DIGESTS 
Polymerase Chain Reaction (based on the enzymatic amplification of a DNA fragment that is 
flanked by two stretches of nucleotide primers, which hybridise to opposite strands of the 
sequence being investigated) was carried out individually for the 4 SNPs being tested. This 
was followed by RE digest on obtained PCR products. The REs are enzymes isolated from 
bacteria that recognize specific sequences of DNA and then cut the DNA to produce 
fragments called restriction fragments. The method employed for the PCR amplification 
across the 4 SNPs being analysed, along with the protocol for RE digests are as shown in the 
appendices A1.1 to A1.4. 
Briefly, amplicons of sizes 109 base pairs (bp) (G2548A), 261bp (C188A), 258bp (A19G) 
and 316bp (C538T) were generated by PCR. For G2548A, the RE HhaI which cuts the 
amplicon at position 62 was used to generate 2 fragments (62bp and 47bp - genotype GG) or 
3 bands (109bp, 62bp and 47bp - genotype GA) or one band if the amplicon is undigested 
(109bp - genotype AA). Similarly, the amplicon of the C188A polymorphism was digested 
with AscI which cuts at position 221 producing 2 fragments (221bp and 40bp - genotype CC) 
or 3 bands (261bp, 221bp and 40bp – genotype CA) while the undigested amplicon would be 
seen as one band (261bp – genotype AA). Also, the A19G polymorphism which had an 
amplicon size of 258bp was digested with Mspa1I cutting it at position 186 and generating 2 












or in the case of the undigested amplicon, one band (258bp – genotype AA). The RE TaiI cut 
the C538T amplicon at 2 positions (32 and 245) thus producing 3 bands (213bp, 76bp and 
32bp – genotype CC) for the completely digested PCR products. Partial digests gave rise to 4 
bands (289bp, 213bp, 76bp and 32bp – genotype CT) while undigested amplicon was seen as 




Analysis of variance (ANOVA) was used to compare the means of multiple variables.  
Categorical data were analysed in contingency tables using χ
2
. Three models were used in the 
contingency tables to determine the χ
2
 values and level of significance (p values) between 
subjects grouped according to the presence or absence of hypertension, obesity, the MS, 
microalbuminuria, difference in gender and high or normal serum leptin level. The first 
model assumes equal dominance of the genotypes of the SNP being studied (co-dominant 
model), the second (dominant model) assumes the homozygous genotype of the ancestral 
allele as dominant and compares this genotype with the sum of the heterozygous genotype 
and the homozygous recessive genotype. The third model (recessive model) compares the 
recessive genotype with the sum of the heterozygous and the homozygous dominant/ancestral 
genotypes. These models could not be applied to the G2548A and C538T polymorphisms in 
which only 2 genotypes were obtained. The results were expressed as percentages or as mean 
(SEM) except where otherwise stated. Logistic regression was used to determine the estimate 
of the odds ratio at 95% confidence interval of the means. 
R and R packages genetics (version 1.3.8.) and haplo.stats were used to perform haplotype 
analyses.  R is a free software environment for statistical computing and graphics. R is 
available from http://www.r-project.org. Linkage disequilibrium (LD) between each pair of 
the G2548A, C188A, A19G and C538T SNPs was assessed by calculating the disequilibrium 












D‘ is always positive, D and r have negative signs when the minor allele in one SNP is 
associated with the major allele in the other).  Haplo.stats is a set of functions for the analysis 
of indirectly measured haplotypes. Specifically, the method described by Sinnwell et al 
(2008) was used. The statistical methods assume that all subjects are unrelated and that 
haplotypes are ambiguous (due to unknown linkage phase of the genetic markers). The 
functions in haplo.stats are used for the estimation of haplotype frequencies, posterior 
probabilities of haplotype pairs for a subject, GLM regression models for the regression of a 
trait on haplotypes, model relationships between haplotypes and a wide variety of traits, 
including binary, ordinal, quantitative, and Poisson. The coefficient (β) in the model 
summary is the effect of that specific haplotype compared to the base (most common or 
assumed wild type) haplotype.  The effect is the estimated difference in the mean of the 
transformed phenotype between that haplotype and the reference haplotype.  A significant p-






































Genotype frequencies at all polymorphisms satisfied Hardy-Weinberg equilibrium (used to 
relate the frequencies of genotypes at a single mendelian locus to the phenotype frequencies 
in a population) and agreed closely with genotype frequencies described at these 
polymorphisms in black Africans in the Hapmap project (The International HapMap 
Consortium 2003) (Table 8.1(a)). Table 8.1(b) provides genotype and allele comparison with 
Hapmap data from black Africans of the Yoruba (YRI) ethnic group in West Africa. Minor 
but non-significant differences in allele and genotype frequencies can only be seen in the 
C188A polymorphism suggesting that black Africans may have similar occurrence of these 
polymorphisms. 
 
Table 8.1(a): Genotype and allele frequencies of the 4 SNPs in black South Africans. 
 
 



































































































N – Number of subjects 
Ancestral alleles – G2548A – G, C188A – C, A19G – G, C538T – C. 







































































* There are currently no Hapmap genotype frequencies available for this SNP and no RefSeq id. 
 
 
8.3.1 ANALYSIS OF THE LEP A19G GENOTYPES WITH A VARIETY OF STUDIED 
PHENOTYPES.  
Tables 8.2.1 to 8.2.3 show, respectively, the co-dominant, dominant and recessive models in 
comparing the frequencies of the 3 genotypes obtained for the polymorphism at exon 1 of the 
LEP gene (A19G). There was no difference in patterns of the genotype distribution between 
subjects categorised by differences in blood pressure (hypertensive / normotensive), obesity, 
MS (present or absent), kidney disease marker (microalbuminuric / normoalbuminuric), 
gender, and serum leptin concentration (high / low) in all three models.  
Although as shown in table 8.3, analysis of variance (ANOVA) of the mean values of the 
clinical and biochemical parameters of subjects in the 3 genotype groups did not reach 
statistical significance (at a p value of <0.05), we did observe a consistent pattern in which 












clinical and biochemical variables compared to the homozygous GG or the heterozygous 
group.  
Furthermore, studying the association between these genotypes and markers of kidney 
disease [serum creatinine concentration, estimated GFR, and urine albumin-to-creatinine 
(ACR) concentration], it was observed that GFR declined steadily from the homozygous 
dominant genotype (GG) to the homozygous recessive genotype (AA) and ACR increased in 
the same trend, with the recessive genotype having a modest but significantly higher mean 
ACR concentration (p=0.04) (Table 8.4.1a). 
In the probands, the homozygote genotype ―AA‖ had a higher GFR compared to subjects 
with the homozygote ―GG‖ or heterozygotes ―AG‖, however, this was not statistically 
significant (p = 0.658). Those with genotype ―AA‖ also had higher urine ACRcompared to 
the other two groups, but this only approached significance (p = 0.078) (Table 8.4.1b). 
This trend was sought for in the offspring (total of 50) of all the probands that had 
participated in the study and whose LEP A19G genotype had been ascertained (Table 8.4.2). 
Again, the estimated GFR was lowest in the homozygous recessive group (AA) and the urine 



























































































































































































N – Number of subjects  
























































































































































N – Number of subjects  

























































































































































N – Number of subjects  






























































































































































































N – Number of subjects  
Values are presented as mean (SEM). 
SBP- systolic blood pressure, DBP- diastolic blood pressure, BMI- body mass index, WC- waist circumference, 
HOMA – Homeostasis model assessment, TG- triglycerides, HDL- high density lipoprotein, CRP- C-reactive 
protein, GFR- glomerular filtration rate, ACR- albumin-to-creatinine ratio, ACR
+
 is presence of 
microalbuminuria, ACR
-


























































N – Number of subjects  
Values are given as mean (SEM) 
 
 


































N – Number of subjects  
Values are given as mean (SEM) 
 
 
Table 8.4.2: Analysis of the LEP A19G genotypes with markers of renal function in 










































N – Number of subjects  














Table 8.5: Univariate Logistic Odds Ratios of obesity, the metabolic syndrome and 

























1.11 (0.65 – 1.88) 
 
 
0.89 (0.51 – 1.56) 
 
 






0.74 (0.46 – 1.18) 
 
 
1.12 (0.68 – 1.83) 
 
 






1.47 (0.77 – 2.81) 
 
 
0.99 (0.51 – 1.90)  
 
 
1.61 (0.60 – 4.35) 
 
 




Univariate logistic regression odds ratio (OR) was calculated as an estimate of the relative 
risk for obesity, the MS and microalbuminuria associated with the LEP A19G genotypes. In 
keeping with the earlier observation in which subjects with the recessive genotype (AA) had 
significantly elevated urine ACR, they also had the highest risk for microalbuminuria 
OR=1.61 (95% CI - 0.60 to 4.35) compared with the dominant [OR=0.62 (95% CI – 0.29 -
1.30)] and heterozygous [OR=1.00 (95% CI – 0.55 – 1.82)] genotypes. The relative risk for 























8.3 .2 ANALYSIS OF THE LEP GENE PROMOTER REGION (G2548A AND C188A) 
GENOTYPES WITH A VARIETY OF STUDIED PHENOTYPES. 
 
For both polymorphisms in the LEP gene promoter region, there was no difference in the 
frequency of occurrence of the genotypes (GG/GA and CC/CA/AA) in the participants when 
they were categorised by blood pressure, obesity, MS, microalbuminuria, gender, and serum 
leptin concentration (Tables 8.6 and 8.7.1 to 8.7.3). Although this lack of difference was still 
present when the C188A genotypes were analysed as co-dominant, dominant and recessive 
models, the dominant model (CC vs. CA + AA) showed a trend towards significance with 
regards to obesity (p = 0.084) suggesting a possible relationship between the dominant 
genotype and obesity.  
 
Table 8.8 shows the univariate logistic regression odds ratio of obesity, the MS and 
microalbuminuria associated with the genotypes of the C188A polymorphism. This table 
shows that the OR for obesity is significantly higher in subjects of the dominant genotype i.e. 
CC: (OR=1.88, 95% CI – 1.03 to 3.46; p = 0.039) 
 
All the clinical and biochemical features, including obesity phenotypes, blood pressure, blood 
glucose, insulin and assayed cytokines (leptin and adiponectin) did not differ between the 



















































































































































N – Number of subjects  




















































































































































































N – Number of subjects  























































































































































N – Number of subjects  
























































































































































N – Number of subjects  

























Table 8.8: Univariate Logistic Odds Ratios of obesity, the metabolic syndrome and 


























1.88 (1.03 – 3.46) 
 
 
1.22 (0.63 – 2.36) 
 
 






0.56 (0.29 – 1.09) 
 
 
0.97 (0.48 – 1.98) 
 
 






1.00 (0.17 – 6.09) 
 
 
1.36 (0.22 – 8.28) 
 
 
0.81 (0.77 – 0.86) 
 







































































































































































































N – Number of subjects  
Values are presented as mean (SEM) 
SBP- systolic blood pressure, DBP- diastolic blood pressure, BMI- body mass index, WC- waist circumference, 
HOMA – Homeostasis model assessment, TG- triglycerides, HDL- high density lipoprotein, CRP- C-reactive 
protein, GFR- glomerular filtration rate, ACR- albumin-to-creatinine ratio, ACR
+
 is presence of 
microalbuminuria, ACR
-





















































































































































































































N – Number of subjects  
Values are presented as mean (SEM) 
SBP- systolic blood pressure, DBP- diastolic blood pressure, BMI- body mass index, WC- waist circumference, 
HOMA – Homeostasis model assessment, TG- triglycerides, HDL- high density lipoprotein, CRP- C-reactive 
protein, GFR- glomerular filtration rate, ACR- albumin-to-creatinine ratio, ACR
+
 is presence of 
microalbuminuria, ACR
-












8.3.3 ANALYSIS OF LEP C538T GENOTYPES WITH A VARIETY OF STUDIED 
PHENOTYPES. 
As only two genotypes (CC / CT) were obtained for the polymorphism in exon 3, only the co-
dominant model was used in the analysis of the genotype frequencies. No difference was 
observed in the frequency of the genotypes when the subjects were grouped according to 
blood pressure, obesity, MS, microalbuminuria, gender, and serum leptin concentration (high 
or low) (Table 8.11). 
 
Furthermore, comparison of the mean values of the clinical and biochemical features revealed 
no difference in age, obesity phenotypes (BMI, WC, WHR), blood pressures (SBP and DBP), 
lipids, inflammatory markers and assayed cytokines (Table 8.12). Subjects with the T allele 
i.e. subjects with genotype CT appeared to have ―better‖ mean values of serum creatinine, 
estimated GFR, and with a significantly lower mean urine ACR (p = 0.001).  
 
In table 8.13, the subjects were divided into two groups: proband and offspring and 
comparison of the markers of kidney function was carried out between the genotypes for 
these two groups. In the probands, GFR was significantly higher (better) in the CT group 
(108.7 ± 4.0 vs 97.1 ± 1.8; p = 0.010) and ACR was also significantly lower in the CT group 
(1.4 ± 0.3 vs 3.0 ± 0.5; p <0.004). This was also the observed trend in the offspring although 
the values did not reach significance.  
The odds ratio for microalbuminuria in subjects with the T allele (CT genotype) was 0.62 
(95% CI – 0.23 to 1.66), three-fold lower than in subjects with the dominant genotype CC 















































































































































N – Number of subjects  
























































































































































































N – Number of subjects  
Values presented as mean (SEM) 
SBP- systolic blood pressure, DBP- diastolic blood pressure, BMI- body mass index, WC- waist circumference, 
HOMA – Homeostasis model assessment, TG- triglycerides, HDL- high density lipoprotein, CRP- C-reactive 
protein, GFR- glomerular filtration rate, ACR- albumin-to-creatinine ratio, ACR
+
 is presence of 
microalbuminuria, ACR
-













Table 8.13: Analysis of LEP C538T Genotypes with markers of renal function in probands 




















































N – Number of subjects  
Values given as mean (SEM), GFR – Glomerular filtration rate, ACR – Albumin to creatinine ratio. 
* P = 0.010 







Table 8.14: Univariate Logistic Odds Ratios of obesity, the metabolic syndrome and 

























0.71 (0.35 – 1.45) 
 
 
0.60 (0.30 – 1.19) 
 
 






1.41 (0.69 – 2.84) 
 
 
1.67 (0.84 – 3.31) 
 
 
0.62 (0.23 – 1.66) 
 





















8.3.4: Haplotype Analysis 
 
 
There are 16 different possible haplotypes that can be constructed from 4 bi-allelic markers.  
Only 6 were observed in this sample, their inferred haplotype frequencies are shown in the 
bar chart in figure 8.1. A haplotype ―case-control‖ comparison was done (cases = probands, 
controls = relatives). The observed differences between the haplotype frequencies of cases 
and controls were not significant (Table 8.15.). The GCGC haplotype had the highest 
frequency of occurrence in the probands (42%) while the haplotype GCAC occurred more 
frequently in the relatives (46%).  
There was a significant difference between the GCAT and the base haplotype (GCGC) in 
markers of renal function in the probands.   Table 8.16a shows the summaries of linear 
regression of haplotypes on phenotypes of interest in probands. The GCAT haplotype 
decreases plasma creatinine (β = -0.41; p = 0.0279) and increases GFR (β = 0.46; p = 0.0173) 
compared to the GCGC haplotype. Although the GCAT decreases urine ACR, this effect was 
not significant in the probands (β = -0.12; p = 0.5960). Also, this haplotype (GCAT) had no 
significant effect on BMI (β = 0.35; p = 0.0514) or serum leptin concentration (β = 0.07; p = 
0.6886) in the probands. A second haplotype (GCAC) approached significant effect with 
BMI (β = 0.18; p = 0.0557) in the probands but did not significantly affect plasma creatinine 
(β = -0.04; p = 0.7230), GFR (β = 0.07; p = 0.5340), urine ACR (β = -0.08; p = 0.4970) and 
serum leptin (β = 0.07; p = 0.4040). 
In the relatives of the probands (Table 8.16b), the GAAC haplotype (compared to the base 
haplotype GCAC) was detected to significantly increase urine ACR (β = 0.71; p = 0.0437), 
but had no significant effect on other phenotypes of renal function: plasma creatinine (β = -
0.21; p = 0.4650), GFR (β = 0.22; p = 0.4930), or phenotypes of obesity: BMI (β = -0.36; p = 
0.2763) and serum leptin (β = -0.24; p = 0.3700). However, GCAT had a significant effect on 












however, this effect on urine ACR did not reach significance. Other haplotypes did not show 
any effect on these phenotypes (Tables 8.16a and 8.16b).      
 
Linkage disequilibrium was observed between G2548A and A19G (D‘ = 0.3767; χ
2
 = 4.21; p 
= 0.0401), C188A and A19G (D‘ = 0.9028; χ
2
 = 29.30; p < 0.0001) and A19G and C538T 
(D‘ = 0.9987; χ
2
 = 26.92; p < 0.0001) in probands (Figure 8.2a). In the relatives of probands 
(Figure 8.2b), LD was observed only between G2548A and A19G (D‘ = 0.9966; χ
2
 = 6.69; p 
= 0.0096) and between C188A and A19G (D‘ = 0.9986; χ
2





Table 8.15: Comparison of haplotype frequencies between probands and their first degree 















Total Probands Relatives 
 
G C A C 0.39 0.37 0.46 
G C A T 0.06 0.06 0.03 
G A A C 0.08 0.08 0.07 
G C G C 0.41 0.42 0.36 









































































































β p β p β p β p β p 
A C A C 0.03 0.29 0.3750 -0.41 0.1760 -0.03 0.9210 0.31 0.2519 0.25 0.3695 
A C G C 0.04 -0.12 0.7160 0.21 0.5210 -0.16 0.6490 0.29 0.2532 -0.10 0.6750 
G A A C 0.08 0.00 0.9870 -0.06 0.7420 -0.29 0.1480 0.12 0.4313 0.15 0.3297 
G C A C 0.37 -0.04 0.7230 0.07 0.5340 -0.08 0.4970 0.18 0.0557 0.07 0.4040 












Tests are adjusted for age and sex.   
β = estimated difference in transformed phenotype between individuals with a given haplotype and individuals with the base haplotype. 













































PCr GFR ACR BMI Leptin 
β p β p β p β p β p 
A C G C 0.05 -0.11 0.7650 0.29 0.4920 0.18 0.6835 0.46 0.3179 -0.34 0.3330 
G A A C 0.07 -0.21 0.4650 0.22 0.4930 0.71 0.0437 -0.36 0.2763 -0.24 0.3700 
G C A T 0.02 -0.28 0.4790 0.45 0.4820 1.35 0.0743 -0.99 0.0346 -0.50 0.2020 
G C G C 0.34 -0.01 0.9480 0.12 0.5380 0.19 0.3194 0.26 0.1872 0.05 0.7470 












Tests are adjusted for age and sex.   
β = estimated difference in transformed phenotype between individuals with a given haplotype and individuals with the base haplotype. 
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8.4.1: Genotype – phenotype Association: 
Leptin is the obesity gene product secreted by white adipose tissue. Serum leptin 
concentration increases proportionately with degree of fat mass or obesity and in obese 
humans, leptin exerts a deteriorative impact on the cardiovascular system and the kidneys by 
significant contribution to the pathogenesis of obesity-related hypertension.  
 
A number of studies (referenced in chapter 5 and below) have evaluated the effect of the LEP 
gene on CVD phenotypes like obesity often using BMI as the phenotype for obesity. Results 
from these studies have largely remained controversial with some studies reporting 
association and others reporting a lack of association. Few studies have studied the 
relationship between the LEP gene and CVD using markers other than BMI to represent 
CVD. 
 
In this study, the relationship between 4 non-coding SNPs (G2548A, C188A, A19G and 
C538T) spanning the different haplotypes of the LEP gene and CVD markers (obesity, the 
MS, hypertension and microalbuminuria) was explored in a non-diabetic native black (South) 
African population that included hypertensive parents and their normotensive first degree 
relatives. 
 
Although serum leptin had been shown to be positively and significantly correlated with all 
the obesity phenotypes (see chapter 7), there was no significant association between these 
polymorphisms and the obesity phenotypes or serum leptin concentration (BMI of ≥ 30kg/m
2
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of the polymorphisms in the promoter region of the gene (G2548A and C188A) showed a 
trend towards significance with regards to obesity. There were 14.6% obese subjects whose 
genotype was GA at the 2548 position compared with 7.2% non-obese subjects with the same 
genotype (p = 0.079) and the subjects with this genotype had a higher mean BMI compared 
with subjects in the GG genotype group (Table 8.6). Also, using the co-dominant model in the 
analysis of the C188A genotype, there was no difference between the distribution of obese 
and non-obese subjects within the 3 genotypes (CC/CA/AA); p = 0.194 (Table 8.7.1). 
However, analysis using the dominant model (CC vs. CA + AA) revealed a trend towards 
significance (p = 0.084) in relationship with obesity. 
 
Li et al (1999) reported significantly different frequencies in the distribution of the alleles of 
the A19G and G2548A polymorphisms between obese and average weight Caucasian women. 
Additionally, the A19G and C188A polymorphisms were found to predict the degree of 
obesity (Li et al 1999). Other studies that have reported association between obesity and LEP 
polymorphisms include those of Wang et al (2006), Jiang et al (2004), Hager et al (1998) and 
Mammes et al, (1998, 2000). These studies were carried out in Caucasian or Asian 
populations.  However, there are other studies like those of Yiannakouris et al (2003), 
Shintani et al (2002), Lucatoni et al (2000) and Gaukrodger et al (2005); also carried out in 
European or Asian populations that have reported lack of association between LEP 
polymorphisms and obesity. 
 
This study is the first in a homogenous black African population and as such provides 
reference data for this population. Beyond this however, it has shown that the common 
polymorphisms of the LEP gene are not significantly associated with obesity or increased 
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plays no role in the pathogenesis of common obesity occurring in many South African blacks. 
However, although these polymorphisms have shown no association with serum leptin 
concentration, it still does not rule out their possible role in the expression of the gene, 
conformation and structure of the gene product (not tested in this study) which might 
ultimately influence its function peripherally.  
 
It is thought that essential hypertension and obesity are both caused by multiple 
environmental and genetic determinants. Studies have shown that these two traits are linked 
and it is estimated that essential hypertension may be up to 3 times more prevalent among the 
obese (Van Itallie 1985). This correlation suggests that essential hypertension and obesity 
may share genetic determinants in some individuals. The cardiovascular effects of leptin have 
been discussed in chapter 5 and this study has already shown the increasing risk for kidney 
disease with increase in serum leptin concentration (figure 7.1).  
 
There are only a few studies that have studied the relationship between the LEP gene and 
CVD. For instance, Shintani et al (2002) reported association between a polymorphic 
tetranucleotide repeat (TTTC)n polymorphism in the 3‘ flanking region of the LEP gene and 
hypertension in a group of Japanese patients with essential hypertension. They found the 
frequency of the class I allele to be significantly higher in hypertensives compared with 
normotensive controls (Shintani et al 2002). In two other different studies in which the same 
polymorphism was examined in South Americans and Italians, there was no association 
between the class I / II genotypes or alleles with hypertension or CVD (Hinuy et al. 2006, 
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Gaukrodger et al (2005) reported an association between the rare C538T polymorphism in the 
non-coding region of exon 3 of the LEP gene with atherosclerosis. Their study has so far had 
the largest number of subjects in studies related to the obesity gene with a total of 1428 
United Kingdom participants. They found a strong association between the LEP C538T and 
both pulse pressure (p = 0.0001) and carotid intima-media thickness (CIMT), a surrogate 
marker of atherosclerosis (p = 0.008). They also observed that subjects with the C/T genotype 
had a 22% lower pulse pressure and a 17% lower CIMT than C/C homozygotes suggesting 
that the presence of the T allele is ―protective‖ for CVDs. 
 
In my study, although there has been no segregation of any of the genotypes or alleles with 
any particular phenotype assessed, it was observed that certain genotypes in 2 of the 
polymorphisms (A19G and C538T) showed significant relationship with microalbuminuria, a 
surrogate marker of endothelial dysfunction and CVD. 
 
Subjects with the AA genotype of the A19G polymorphism had a significantly higher mean 
urine ACR compared with genotypes AG and GG (3.7 ± 1.1; 2.4 ± 0.4; 1.4 ± 0.3; 
respectively, p = 0.049), a trend that appeared to show that ACR increased with an increasing 
presence of the A allele (Table 8.4.1). Also, subjects with the genotype AA, had the highest 
odds ratio for developing microalbuminuria, almost thrice that of subjects whose genotype 
was GG (Table 8.5) 
 
All the offspring (normotensive, non-diabetic, and non-obese) were analysed separately to 
study if the same genetic trend had been passed on to them (Table 8.4.2). Again, subjects with 
the AA genotype had a significantly higher mean ACR in comparison with those of the AG or 
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GFR was not significantly different between all the groups, GFR always was lowest in the 
AA genotype group compared with the other groups suggesting a poorer renal outcome in this 
group (Tables 8.4.1 and 8.4.2). 
Furthermore, although both genotypes of the C538T polymorphism showed no difference in 
frequency between groups divided along the lines of CVD (present or absent), subjects with 
the CT genotype had significantly lower ACR compared with those with genotype CC (1.3 ± 
0.2 vs. 2.7 ± 0.4; p = 0.001) (Table 8.12). The same trend was seen with the estimated GFR 
and when the subjects were analysed separately as probands and offspring (Table 8.13). 
Moreover, subjects with the CT genotype had a lower odds ratio for microalbuminuria 
compared with those with genotype CC. This pattern is similar to the earlier report of 
Gaukrodger et al. (2005) in which they found the T allele to be protective of CVD measured 
by atherosclerosis and defined by the thickness of the CIMT (Gaukrodger et al 2005). 
 
Although it cannot be said that there is significant difference in the distribution of these 
genotypes of the LEP gene by the presence or absence of markers of kidney disease in this 
population, the present trend with the genotypes of the A19G and C538T polymorphisms 
suggest that there may be some relationship between the LEP gene and kidney disease, 
especially since serum leptin has earlier been shown to correlate with decreasing GFR in this 
same population (chapter 7). There are no reports in the literature of relationships between 
this gene and kidney disease phenotypes despite the relationship between the gene product, 
obesity and kidney disease that has also been shown by the present study. This association is 
important as it shows that obesity plays a significant role in kidney disease both 
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The leptin signalling pathways cross-talks with the insulin signalling pathways and although 
the molecular mechanisms of these pathways were not analysed in this current study, it is 
possible that the pathway leading to inflammation might be involved in the associations found 
between these polymorphisms and microalbuminuria. Therefore their effect on the kidney 
may be through an autocrine or paracrine mechanism. Also, even though the C538T 
polymorphism is in the non-coding 3‘ UTR region of the gene, similar variants in other genes 
have been reported to affect their expression (Misquitta et al 2001). 
 
Although ESRD is quite common in people of African origin, there have often been questions 
as to why black Africans have a preponderance of hypertension-related ESRD. Differences in 
socio-economic status, higher prevalence of hypertension and an increased inherited 
susceptibility of black Africans to kidney disease have been suggested as explanations to 
account for these differences (Seedat 1999, Krop et al 1999). This thesis has shown that 
genetic factors such as the polymorphisms of the obesity gene contribute significantly to 
kidney disease patterns in black Africans.  
 
By whatever criteria the MS is defined, its presence can only be confirmed by the presence of 
multiple metabolic risk factors, as at least the combination of three or more risk factors out of 
a possible five are required to make the diagnosis. Studies that have reported association of 
candidate genes with the MS have often done so with specific genes related to one of the MS 
factors. For instance, Lee and Tsai (2002) reported association between the ACE I/D 
polymorphism and the 1998 WHO definition of the MS in Chinese NIDDM patients while 
Frederiksen et al (2002) also found an association between a polymorphism of the PPAR-
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In chapter 3 of this thesis, the mechanism of the MS was traced through the obesity pathway 
and was shown to be an inflammatory disease triggered by the presence of excess circulating 
fatty acids that ultimately result in the secretion of several pro-inflammatory cytokines. 
Although the relationship between obesity and the MS is very clear, Meirhaeghe et al (2005) 
found no association between a polymorphism of the obesity gene (LEP A19G) and the MS in 
Europeans. However, the National Heart, Lung, and Blood Institute (NHLBI) Family Heart 
Study on linkage analysis of a composite factor for the MS detected 2 regions on chromosome 
6 (for a factor loaded by BMI, leptin and fasting insulin) and chromosome 7 (for a lipid 
factor) with strong evidence for linkage to the MS (Tang et al 2003). In the NHLBI study, the 
region on chromosome 7 with suggestive evidence of linkage with the MS contained the 
leptin gene. 
 
Finally, although no association between the LEP gene and CVD marker has been seen in this 
study, the observed trend with the A19G and C538T polymorphisms with microalbuminuria 
suggests that an association indeed exists as the gene product has been shown to correlate 
with GFR in chapter 7.   
 
These findings do not rule out the importance of genetics or indeed the LEP gene in complex 
diseases such as obesity or the MS. However, in this specific population of native black 
Africans, the LEP gene has been shown to have no effect on complex disease phenotypes like 
hypertension, obesity and the MS, but may play a role in the pathogenesis of kidney diseases. 
 
The power of the entire study was appropriately high (80%) to demonstrate statistically 
significant associations that could be of clinical importance. The study was not powered for 
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microalbuminuria) are of statistical significance provides reassurance regarding the validity of 
the data presented herein. That these results may not have been due to poor sampling is also 
shown through comparable sample sizes with previous similar studies (already referred to) 
from other population. Only one study has used a very large number of subjects and the 
results obtained from this present study has been comparable (Gaukrodger et al. 2005).  
 
8.4.2: Haplotype Analysis: 
Only 2 of the 4 SNPs typed in this study are present in the HapMap YRI sample. As such, it is 
not possible to directly compare the haplotype frequencies in the present study with the YRI 
HapMap haplotype frequencies which represent the HapMap data from Africa. However, the 
polymorphisms we typed at LEP captured all common haplotype variations across the gene. 
The six haplotypes I reported in this population are similar to the top 5 haplotypes reported in 
a European population in which association between the leptin gene and atherosclerosis was 
found (Gaukrodger et al. 2005). The haplotype frequencies in this population are also 
comparable to the frequencies reported from the European population (Gaukrodger et al. 
2005). 
 
My analysis identified two haplotypes that affected phenotypes of renal disease (in 
comparison to the base haplotypes) in this Xhosa population (GCAT and GAAC). The GCAT 
(frequency of 6%) appeared to protect against renal disease (decreasing plasma creatinine, 
increasing GFR and reducing urine ACR), while the GAAC haplotype (frequency of 8%) in 
the relatives was observed to have an increasing effect on urine ACR. This might suggest that 
an allele in the GCAT haplotype could have a protective effect on kidney disease phenotypes 
in this population. As I have already shown in Table 8.13 (―Analysis of LEP C538T 
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of the C538T polymorphism had significantly lower urine ACR (p = 0.004) and higher GFR 
(p = 0.010) in the probands compared to the subjects with the CC genotype. This protective 
effect had also been reported in a different study among Europeans who carry the T allele of 
the C538T who were reported to have lower pulse pressure (p = 0.0001) and lower carotid 
intima-medial thickness (p = 0.0076) compared to those who did not carry this allele 
(Gaukrodger et al. 2005). The mechanism of this ―protection‖, although at present not clear, 
does not seem to be dependent on variation in serum leptin concentration which was not 
affected by the presence of this haplotype.  
 
The effect of the haplotype GAAC on urine ACR is in keeping with our finding from 
genotype analysis in which the ―A‖ allele of the A19G polymorphism was found to be 
associated with markers of kidney disease in this population (Tables 8.4.1, 8.4.2 and 8.5). 
This may suggest that the ―A‖ allele of A19G is a risk allele for kidney disease in this 
population. However, the presence of the T allele of C538T may probably mask the effect of 
this allele in the population. The mechanism of this relationship may, however, not be through 
the direct effects of serum leptin as there was no association between serum leptin and the 
haplotypes. This association may probably occur via an autocrine or paracrine effect of leptin 
due to the ubiquitous distribution of leptin receptors which underlies its pleiotrophic roles 
(Fruhbeck 2006). The paracrine loop will require the presence of a specific ligand-binding 
receptor on the target cell. Leptin receptors occur in multiple forms (see section 5.3); the long 
form (LRb) has an intracellular domain of sufficient length to provide for full signal-
transducing capabilities. LRb can activate STAT factors 1, 3, and 6, MAPK protein 
(Baumann et al. 1996). Although a number of studies (Kraus et al. 2002; Karmazyn et al. 
2007; Singhal et al. 2002) have suggested the autocrine and/or paracrine actions of leptin in 
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renal phenotypes have been affected in our study. Nevertheless, our finding is consistent with 
a previous report that the chromosome 7 harbours a locus for increased susceptibility to 
kidney disease in black Africans (Chen et al. 2007, Placha et al 2005). 
As my study design is confined to a single black African ethnic group (Xhosa) with a 
moderate sample size, the conclusion may not be pertinent to other races or ethnic groups and 
therefore replication of this study in other population may be required. However, the results 
obtained in this study from both genotype and haplotype analysis will suggest that the obesity 
gene plays some role in kidney disease in this population.  
 
Consequently, as already alluded to, there may well be other genes that are supplementary to  
the phenotypic expression of complex diseases like kidney disease, obesity and the MS. In the 
next chapter, we explore what further candidate genes may be identified through 
computational methods and that may play a role in the pathogenesis of the MS since we have 





































COMPUTATIONAL ANALYSIS FOR METABOLIC SYNDROME GENES 
 
As already stated in the acknowledgements section, the contents of this chapter represents 
collaborative work by Dr Nicki Tiffin (Bioinformaticist, Department of Human Molecular 
Genetics, UCT), Drs Miguel Andrade-Navarro and Carolina Perez-Iratxeta (Ontario 
Genomics Innovation Centre (OGIC), Ottawa Health Research Institute (OHRI) Ontario 
Canada and Department of Cellular and Molecular Medicine, Faculty of Medicine, 
University of Ottawa Canada) and myself. The work of this chapter was conceived by Dr 
Tiffin and me and she implemented the study and prepared the manuscript. Miguel and 
Carolina specifically ran the scripts for Genes2Disease (G2D) and GeneOntology (GO) and 
helped with the phenotype analysis associated with this chapter and also contributed to the 
manuscript. I provided clinical input and analysis and contributed to the manuscript. 
 
9.1 INTRODUCTION 
Many diseases may be caused by loss or gain of gene function, and several genes have been 
implicated in Mendelian diseases. The methods which have been used to find Mendelian 
disease genes have often failed to identify genes central to complex diseases that often present 
with a wide range of phenotypes and generally involve multiple aetiological mechanisms and 
contributing genes (Glazier et al. 2002). In complex diseases, the contribution of each of 
several genes related to the disease state is likely to be small, and only the sum of several 
susceptibility genes leads to disease, making functional validation of complex disease-causing 
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Also, the comprehensive analysis of so many genes generated through genome-wide 
techniques can be extensively time-consuming and expensive (Risch. 2000), for example, loci 
implicated in susceptibility to multi-factorial disease by linkage analysis can be up to 30 Mb, 
often containing several hundreds of genes (Perez-Iratxeta et al. 2002). Hence, computational 
methods embracing the so-called ―bioinformatics approach‖ have an important role in the 
analysis of candidate genes and in the selection of the most likely of these genes to be 
experimentally confirmed in complex diseases, such as the MS.  
 
A number of computational methods have been developed that search through many different 
data sources containing information on sequence, biology, function and expression of 
candidate genes (Kanehisa and Bork 2003). Here, we employ such methods to comprehend 
and select candidate genes that may play a role in the MS.  
 
9.2 EXISTING COMPUTATIONAL METHODS 
 
9.2.1 GENESEEKER (van Driel et al. 2005): 
(http://www.cmbi.ru.nl/geneseeker/)  
 
GeneSeeker is a web tool that filters positional candidate disease genes based on expression 
and phenotypic data from both human and mouse. Although it is particularly suited for 
syndromes in which the disease gene shows altered expression patterns in the affected tissues, 
it can also be applied to complex diseases.  
 
9.2.2 ANALYSIS OF CANDIDATE GENE EXPRESSION USING eVOC ANNOTATION 
(Kelso et al. 2003, Tiffin et al. 2005): 
(http://www.sanbi.ac.za/resources/tools-for-downloading/) 
 
This method performs candidate disease gene selection using a controlled and structured 
vocabulary for unifying gene expression data (the eVOC anatomy ontology) i.e. candidate 
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to integrate clinical and molecular data through a combination of text- and data-mining. It 
selects candidate genes according to their expression profiles within tissues associated with 
the disease of interest.  
 
9.2.3 DISEASE GENE PREDICTION (DGP) (Lopez-Bigas et al. 2004): 
(http://cgg.ebi.ac.uk/services/dgp/)  
 
Genes already known to be involved in monogenic hereditary disease follow specific 
sequence property patterns that make them more likely to mutate. Based on these patterns, 
DGP is able to assign probabilities to all the genes that indicate their likelihood to mutate 
based on their sequence properties. Properties of the gene analysed include protein length and 
the degree of conservation. Although designed for the prediction of Mendelian diseases, it can 
also be used for the identification of complex-disease genes as it will identify those genes 
with higher likelihood of suffering mutations. 
 




It can be shown that genes implicated in disease share certain patterns of sequence based 
features like larger gene lengths and broader conservation through evolution. PROSPECTR is 
an alternating decision tree programmed to use a scoring system to differentiate between the 
likelihood of a gene involvement in disease. It uses basic sequence information to classify 
genes and those that score over a certain threshold are classified as likely to be involved in 
some form of human hereditary disease while genes with scores under that threshold are 
classified as unlikely to be involved in disease. SUSPECTS then builds on this by 
incorporating annotation data from Gene Ontology (GO), InterPro and expression libraries 
and then ranks the genes according to the likelihood that they are involved in a particular 
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(www.geneontology.org) provides structured, controlled vocabularies and classifications that 
cover several domains of molecular and cellular biology and used in the annotation of genes, 
gene products and sequences. Many model organism databases and genome annotation groups 
use the GO and contribute their annotation sets to the GO resource (Harris et al 2004). 
 
9.2.5 GENES TO DISEASE (G2D) (Perez-Iratxeta et al. 2005): 
(http://www.ogic.ca/projects/g2d_2/)  
 
This system scores all terms in GO according to their relevance to each disease starting from 
MEDLINE queries featuring the name of the disease. To identify candidate genes in a given 
chromosomal region, G2D performs BLASTX searches of the region against all the (GO 
annotated) genes in RefSeq.  
 
 
9.2.6 POCUS (Turner et al. 2003): 
(http://www.hgu.mrc.ac.uk/Users/Colin.Semple/)  
 
POCUS exploits the tendency for genes predisposing to the same disease to have identifiable 
similarities, such as shared GO annotation, shared InterPro domains or a similar expression 
profile. Therefore where genes within different susceptibility regions for the same disease 
share GO or InterPro annotation and/or are co-expressed, these genes may be considered good 
candidates. Although genes may be selected as candidates on the basis of sharing only a 
single GO term or InterPro domain, genes lacking this annotation completely will not be 
selected.  
 
9.2.7 ENDEAVOUR (Altschul et al. 1997): 
(http://homes.esat.kuleuven.be/~bioiuser/endeavour/endeavour.php) 
 
This method ranks candidate genes according to their similarity to a training set of genes (a 
set of data for which the outcome of a method is known; and can therefore be used to define 
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MEDLINE abstracts, Locus Link data, GO data, InterPro and Bind protein-protein interaction 
data, KEGG (Kyoto encyclopaedia of genes and genomes) pathway data, microarray and 
Expressed Sequence Tag (EST) -based data, transcription factor binding site (TFBS) cis-
regulatory modules and sequence similarity by Basic Local Alignment Search Tool (BLAST), 
and returns a ranked list of candidates.  
 
9.3 METHODOLOGY  
An overview of the approach we used is shown in Figure 9.1. Multiple computational 
methods (described above) were used to analyse the starting set of candidate genes. The 
methods access an array of biological databases and analyse the candidates according to 
different criteria. Because of the large number of implicated loci, POCUS which is designed 
to analyse candidate genes lying in a few loci could not be used.  
 
Candidate genes were scored according to the number of methods that select them. All the 
methods were independently used to select most likely candidates for MS and for candidates 
for each MS phenotype. Genes common to all the methods for the MS and for each phenotype 
were then selected.  
 
Using a weighting system, genes selected for all the phenotypes were identified based on the 
frequency of occurrence of each phenotype in the presentation of MS. Data from Kraja et al 
(2005) and McCarthy et al. (2003) were used to repeat this analysis as they present 
frequencies of occurrence of these phenotypes in blacks and whites and in males and females 
respectively. Hence, the final candidate gene list consists of genes that are selected in the 
search for candidate genes for MS, and are also independently selected in the parallel 
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Figure 9.1. Overview of analysis, showing selection of genes common to all methods, 
weighted selection of genes common to all phenotypes, and selection of genes common to MS 
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9.3.1 GENERATING THE STARTING SET OF CANDIDATE GENES: 
Association studies for MS were used as a primary filter to select the starting set of candidate 
genes. Genes were compiled from cytogenetic loci using the Ensembl database 
Ensembl_mart_40 (www.ensembl.org) which provides a comprehensive and integrated source 
of annotation of chordate genome sequences (Hubbard et al 2007). The final candidate list 
comprised thirteen thousand, eight hundred and eighty-two (13 882) genes and covered all 
cytogenetic loci documented to be associated with the syndrome. Data for all genes was 
downloaded from the Ensembl database Ensembl_mart_41 into a local database for further 
analysis.  
9.3.2 COMPILATION OF SEARCH TERMS AND TRAINING SETS OF DISEASE 
GENES: 
Many of the methods described earlier require various user-defined inputs, and these are 
shown in table 9.1. These include disease search terms for querying abstracts in PubMed and 
anatomy terms used for GeneSeeker queries. Also shown are the top ranking eVOC terms 
selected by text-mining of PubMed abstracts containing the disease name. The MeSH terms 
used for each disease by G2D are as follows: for MS, all MeSH terms annotated in the 
literature references from the Online Mendelian Inheritance in Man (OMIM) entry 60552 
were used. For its phenotypes; ‗Obesity‘, ‗Hypertension‘, ‗Hypertriglyceridaemia‘, ‗Diabetes 
Mellitus‘, and ‗Cholesterol, HDL‘ were used.  
 
The SUSPECTS software (Adie et al. 2006) automatically retrieves genes implicated in a 
disorder from OMIM database (McKusick. 2007), the Human Gene Mutation Database 
(Stenson et al. 2003) and Genetic Association Database (Becker et al. 2004). These training 
sets were used for each of the phenotypes, using the search terms outlined in table 9.1. For 
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genes was used, as this is a very closely related condition. For ‗low HDL cholesterol‘ no 
associated genes were found and ‗HDL cholesterol‘-associated genes were used for the 
training set. Very few genes are associated with MS, so the training set was compiled from a 
set of MS-associated genes described by Matsunaga and Muramatsu (2005) which were 
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Table 9.1. Summary of search terms and training sets for MS and associated phenotypes. 
Query terms used to search biomedical literature for disease-relevant abstracts, and terms 
identified by text mining as most commonly associated with disease/phenotype (eVOC 
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'heart', 'oral|oral cavity'  

























‗HDL cholesterol‘  PPARG, 
GHR, LIPG, CETP, SCARB1, 
ABCA1  










―Hypertension‖ AGT, PNMT, 
AGTR1, GNB3, HSD11B2, 
NPR3, NOS3, SAH, CYP11B2, 
GNAS, TNF, LEPROT, 
ADRB2, NOS2A, RETN, 
TRHR, BDKRB2, ADM, 
EDNRA, CAT, DRD1, EDN2, 
APOE, HSD3B1, NPR1, 
NR3C2, ADD1, SCNN1B, 
SCNN1A, PPARG, PTGIS 















'heart', 'oral|oral cavity' 
―Diabetes‖ IRS1, TCF1, INSR, 
INS, AQP2, AVPR2, SLC2A4, 
AVP, HNF4A, SLC2A2, GCGR, 
GPD2, GYS1, HLA-DQB3, 
UCP3, PPARG, KCNJ11, IL6, 
IFNG, CYP1A1, CTLA4, 
BCHE, ADRB2, VDR, RETN, 
PAX4, CRP, ICAM1, PTPN22, 
IL18, TAP2, NOS2A, SUMO4, 
GH1, TCF2, IPF1, ADIPOQ, 
KCNJ9, IRS2, HK2, ISL1, 
FABP3, GCK, SORBS1, 
CAPN10, NOS3, FOXA2, 
MAPK8IP1, CP, GIPR, FOXP3, 
PTEN, CD38, AGER, STX1A, 
ABCC8, IAPP, TCF7, CPE, 
NEUROD1, AGRP, DCN, 
PPARA, UCP1, WFS1, 
ATP2A3, RXRG, PTGS2, LIPE 
Metabolic 
syndrome 







―metabolic syndrome‖ ACE, 
LMNA, genes identified by 
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9.3.3 COLLATION OF GENE LISTS AND CONSTRUCTION OF A SCORING MATRIX: 
Gene lists were analyzed using Microsoft Excel
TM
. Visual Basic software, written to compile 
the data, assign scores to the candidates, generate final scores for candidates, and graphically 
present and rank them. Because the databases accessed by the various methods may have 
slightly different content, not all methods will return a result for all genes. If a method returns 
the gene as a likely candidate (‗positive‘), that candidate is assigned a score of 1. If the 
method returns the gene as an unlikely candidate (‗negative‘), the gene is assigned a score of 
0. If the method does not analyze the gene (‗null‘), the score assigned is 0.5. Therefore, a gene 
that is not considered by a method has a marginally better ranking than a gene that is actively 
excluded by that method.  The frequency of occurrence of individual MS phenotype is used 
for each population group (black, white, male and female) and the following scoring system is 
used: genes selected for each phenotype are given a value of the frequency of occurrence of 
that phenotype within the population. The frequency values of the phenotypes are shown in 
table 9.2.  
 
For each gene, a final score is calculated as the sum of all scores assigned to it for that 
population. Final gene selections for each population are those genes selected for at least three 
of the five phenotypes (which are in general the highest scoring genes), and also any 
additional genes which score higher than the lowest score generated by the genes that are 
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Table 9.2. Phenotype frequency (%) described for four populations of MS patients. 
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9.3.4 AUTOMATED ANALYSIS OF FINAL GENE LIST: 
Enrichment for specific regulatory pathways and functional annotation was investigated using 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/) (Dennis et al. 2003); and the reaction pathway database 
REACTOME (www.reactome.org), (Vastrik et al. 2007). Additionally, GOstat was used 
(http://gostat.wehi.edu.au/), (Beissbarth and Speed. 2004) to measure overrepresentation of 
Gene Ontology annotations (http://www.geneontology.org), (Harris et al. 2004) in the final 
candidate gene list.  
 
In order to identify known relationships between the candidates described in the biomedical 
literature, the CHILIBOT data-mining software was used (www.chilibot.net) (Chen and 
Sharp. 2004), and the results obtained using CHILIBOT were manually curated for accuracy. 
Additionally the genes were investigated for known relationships to MS using CHILIBOT. 
Known or inferred protein-protein interactions between the candidate genes were investigated 
using STRING – the Search Tool for Retrieval of Interacting Proteins (http://string.embl.de); 
(von Mering et al. 2007). The interactions identified using STRING were manually curated 
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9.4 RESULTS: 
The numbers of genes selected by each method for MS and its five defining phenotypes are 
shown in table 9.3. The numbers of genes selected by all methods for each phenotype are 
shown in table 9.4, and those in common to both MS and all phenotypes, appropriately 
weighted according to frequency of occurrence of each phenotype, are also shown.  
For the MS, 54 genes were selected by all methods used while for each of the phenotypes, the 
following numbers of genes selected were common to all methods: abdominal obesity – 48; 
dysglycemia - 58; hypertension - 69; hypertriglyceridemia - 80; low HDL cholesterol - 14. 
Genes were then scored according to their selection for the individual phenotypes in a 
weighted system whereby genes for more common phenotypes received higher scores. Using 
the phenotype frequency weightings, the following numbers of top-scoring genes were 
selected for each population: white population – 34 (score >113), black population – 41 (score 
>103), males – 36 (score >128), females – 34 (score >144).  
There were 34 genes common to all these analyses, and of these 19 were also common to the 
set selected for MS (Appendix A5). These 19 were investigated further as a final candidate 
gene list. The genes selected using population-based weighting were compared to a selection 
made without weighting, i.e. all genes that appeared in at least three of the phenotype-specific 
sets were selected regardless of phenotype frequency. There were 34 genes that appeared in 
three or more phenotype sets, and these were the same 34 as for the white and female 
population-weighted data. However, six of these genes did not appear in the list selected using 
black population data. Seven additional unique genes appeared in the black population data 
set, and two additional unique genes were selected using the male population data. This 
illustrates the extent to which population-specific frequency data affects the final set of 
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DGP 3034 3034 3034 3034 3034 3034 
PROSPECTR 4287 4287 4287 4287 4287 4287 
eVOC 4342 3584 3584 3572 3571 4342 
GeneSeeker 959 1079 1263 1009 1032 1009 
SUSPECTS 1896 2422 1836 2409 1841 2301 
G2D 2369 2346 2473 145 2481 2446 
ENDEAVOUR 2607 2607 2607 2607 2607 2607 
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Table 9.4. Number of genes selected for MS, for each phenotype, and in common to the 
selected sets (starting set 13,882 genes). Number of genes selected with phenotype weighting 
is shown for white/black phenotype distribution (Kraja et al. 2005) and male/female 




















































































Common genes: 34 
 
Common Genes:                                                 19* 
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9.4.1 CLUSTERING OF GENES BY FUNCTIONAL ANNOTATION USING DAVID:  
The DAVID software analyses similarity of functional annotation of candidate genes, 
indicating the gene functions most commonly represented in the final candidate group of 19 
genes. When using high stringency, the most enriched functional cluster, with a score of 3.9, 
contained annotation terms relating to lipid metabolism and transportation. The terms, shown 
with number of genes and p-values in parentheses, were ―lipid transporter activity‖ (6; p = 1.3 
x 10
-8
), ―lipid metabolism‖ (5; p = 6.0 x 10
-3
), ―transporter activity‖ (6; p = 2.6 x 10
-2
). The 
second cluster, with a score of 2.91, contained the terms, ―signal‖ (10; p = 5.9 x 10
-5
), ―signal 
peptide‖ (10; p = 3.8 x 10
-3
) and ―disulphide bond‖ (9; p = 8.7 x 10
-3
). Using medium 
stringency generates a series of large, low-scoring term clusters that include terms involving 
lipid and chylomicron processing and transport, cell signalling, transmembrane/plasma 
membrane activity and tyrosine kinase activity.  
 
9.4.2 ANALYSIS OF PATHWAYS INVOLVING THE CANDIDATE GENES USING 
REACTOME: 
The SkyPainter utility available through the Reactome website highlights the pathways found 
most commonly associated within the final set of candidate genes. Of the starting set of 19 
candidate genes, 9 were found in the Reactome database. The pathway most commonly 
represented is ―Metabolism of lipids and lipoproteins‖ (p = 6.2 x 10
-4
). Processing of the 
chylomicron / apoE / LDLR complex is the most over-represented event, followed by 
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9.4.3 ANALYSIS OF OVER-REPRESENTED GENE ONTOLOGY ANNOTATION OF 
CANDIDATE GENES USING GOSTAT: 
The most representative GO terms for the final candidate gene list include terms relating to 
lipid transport and processing, signal transduction, plasma membrane location and 
development. The top-scoring fifteen terms, and the candidate genes that are annotated with 
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Table 9.5. Gene Ontology terms most overrepresented in the final candidate gene list, as 
determined using GOstat (http://gostat.wehi.edu.au/). Total number of candidate genes = 19, 
total number of annotated human genes used for statistical analysis = 33781.  GO ID and 
corresponding term are shown, ‗Count‘ is number of candidate genes with that annotation, 































GO:0005319 Lipid Transporter 
Activity 
APOE, LDLR, APOB, 






APOE, INSR, LDLR, ITGB1, 
APOB, GIPC1, IGF1, LPL, 











APOE, INSR, ITGB1, IGF1, 





GO:0007154 Cell Communication APOE, INSR, AXL, ITGB1, 
APOB, GIPC1, IGF1, PTPN11, 




































APOE, INSR, TIE1, UTRN, 





GO:0007165 Signal Transduction INSR, AXL, ITGB1, APOB, 
GIPC1, IGF1, PTPN11, TIE1, 





GO:0005887 Integral to Plasma 
Membrane 
INSR, TIE1, AXL, ADCY7, 




GO:0031226 Intrinsic to Plasma 
Membrane 
INSR, TIE1, AXL, ADCY7, 
LDLR, ITGB1, LRP1 




APOE, INSR, TIE1, UTRN, 
FYN, FOXO1A, IGF1, PTPN11 
8 1990 0.0003 
GO:0044459 Plasma Membrane 
Part 
INSR, TIE1, AXL, UTRN, 
ADCY7, LDLR, ITGB1, LRP1 
8 2149 0.000465 
GO:0008201 Heparin Binding APOE, APOB, LPL 3 78 0.000465 
GO:0032502 Developmental 
Process 
APOE, INSR, ITGB1, IGF1, 
PTPN11, TIE1, UTRN, FYN, 
FOXO1A, LRP1 
10 3887 0.000532 
GO:0007166 Cell Surface 
Receptor Linked 
Signal Transduction 
INSR, FYN, ADCY7, ITGB1, 
FOXO1A, GIPC1, LRP1, 
PTPN11 
8 2386 0.000812 
GO:0004713 Protein Tyrosine-
Kinase Activity 
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9.4.4 AUTOMATED LITERATURE ANALYSIS USING CHILIBOT: 
Automated analysis of PubMed abstracts using CHILIBOT (www.chilibot.net), can detect 
existing associations reported between the disease, its phenotypes, and selected candidate 
genes, thus giving an indication of the degree of relevance and/or novelty of the selected 
candidates. The disease name ―metabolic syndrome‖ was associated with 9/19 candidate gene 
names, and on inspection 8/19 were found to be real associations (APOB, APOE, FOXO1A, 
IGF1, INSR, LDLR, LPL and PTPN11 – the relationship indicated between ‗metabolic 
syndrome‘ and CAT was spurious).  
 
The nature of these associations is described in table 9.6. Potential indirect relationships with 
MS through one or more of the other short-listed candidates were indicated for all genes 
except ADCY7. Analysis of literature associating the candidate genes with each of the 
phenotypes indicates that only one of the candidates has been previously associated with all 
five phenotypes (APOB), five of the candidates have been associated with all phenotypes 
except dysglycaemia (IGF1, LDLR, APOE, INSR, LPL), and three of the candidates have not 
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Table 9.6. Genes previously associated with MS in the biomedical literature, as detected by 





Summary of association with metabolic syndrome 
APOB The serum level of ApoB showed a strong correlation with MS in an Asian population 
(Moon et al. 2007). 
APOE Genetically obese Ay ApoE(-/-) knockout mouse model fails to develop obesity and MS 
features (Gao et al. 2007). 
FOXO1  FoxO1 promotes insulin sensitivity and lipid synthesis in addition to glucose production. 
This dual role could explain the admixture of insulin resistance and sensitivity that is 
commonly observed in the MS (Matsumoto et al. 2006).  
IGF1 Individuals with MS had lower IGF-1 levels than subjects without MS with an almost 
linear decline of IGF-1 levels as the number of fulfilled criteria of the MS (none to 5) 
increased (Efstratiadis et al. 2006).  
INSR A Muscle-Specific Insulin Receptor Knockout Exhibits Features of the MS of NIDDM 
(Hegele. 2003).  
LDLR Polymorphisms in LDLR were associatied with MS in coronary heart disease patients 
(LDLR_1 P =0.008; LDLR_2 P=0.018) (McCarthy et al. 2003).  
An LDLR knockout mouse is used as a model for MS (Seidelmann et al. 2005). 
LPL Decreased expression of LPL possibly causes the insulin resistance, in addition to 
hypertriglyceridemia, in MS (Shibasaki et al. 2006).  
PTPN11 
(SHP2) 
Upregulation of cytosolic PTPN11 expression may contribute to the hemodynamic 
action as well as metabolic action in hypertensive MS (Wakino et al. 2004). 
 
9.4.5 PROTEIN BINDING AND PROTEIN NETWORK ANALYSIS USING STRING: 
STRING analysis indicates two main groups of interacting proteins within the final candidate 
list (figure 9.2.1). The first centres around PTPN11 (also called SHP2), and interactions 
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have been experimentally documented. These interactions are also described in the 
biomedical literature (PubMed abstracts) and in additional protein interaction databases 
(KEGG), which further extend the group by indicating interaction between ITGB1 and UTRN 
via FYN.  
 
The second centres around LRP1, which interacts with GIPC1, LPL and APOE (which in turn 
interacts with LDLR and APOB). These interactions are also described in the biomedical 
literature and pathway databases. FOXO1A (also called FOXO1 and FKHR) lies between 
these two clusters, and a possible connection between the two clusters facilitated by this 
transcription factor is presented below.  Proteins PFKM and ADCY7 are not included in the 
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Figure 9.2.1 Curated results from STRING analysis showing protein-protein interactions 
between the candidate genes (gene symbol shown at each node). Bold lines: experimental 
evidence; broken lines: evidence in pathway databases; grey dotted lines: evidence in the 
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The potential interactions between the candidate genes‘ protein products are represented in 
figure 9.2.2, illustrating the predominance of genes in the final candidate set that are involved 
in chylomicron processing, transmembrane receptor activity and signal transduction. 
 
Chylomicron processing is mediated by binding of an extracellular complex containing 
APOB, APOE and LPL to the transmembrane receptors LDLR and LRP1. The APOE and 
APOB components interact with LDLR; and the APOE and LPL components bind to LRP1 to 
facilitate chylomicron remnant uptake (Heeren et al. 2006). Three distinct complexes of 
transmembrane proteins can be identified in the candidate set. LDLR and LRP1 form one 
complex which binds GIPC1. UTRN, ITGB1 and FYN form a second (Wary et al. 1998).  
 
Finally, INSR binds extracellular IGF1 as well as intracellular PTPN11 (also commonly 
called SHP2) (Asante-Appiah and Kennedy. 2003) to form the third complex.  CAT and its 
binding partner HSD17B4, TIE1, FYN and AXL are also implicated in this third complex 
through their interactions with PTPN11 (Yano et al. 2004, van Grunsyen et al. 1998, Marron 
et al. 2000, Tang et al. 1999, Gallicchio et al. 2005). Additionally, the ability of FYN to 
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Figure 9.2.2 Potential binding interactions amongst candidate gene products, showing 
downstream signalling pathways activated. Candidate gene names are shown in red, 
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Three distinct signalling pathways are activated by genes in the final candidate set: The 
LDLR/LRP1 receptor complex activates G-protein signalling (Gotthardt et al. 2000); 
UTRN/ITGB1 in complex with FYN activates the MAP/ERK pathway and IGF1 binding to 
INSR activates the PI3K pathway (Kadowaki et al. 1996). LPL has also been implicated in 
INSR signalling, although the mechanism of this interaction is unclear (Shibasaki et al. 2006). 
 
FOXO1A is the only nuclear transcription factor in the final candidate list, and is regulated 
via PTPN11 and IGF1/INSR binding and activation of the PI3K pathway (Schinner et al. 
2005, Xu et al. 2004). FOXO1A can in turn upregulate expression of LPL (Kamei et al. 
2003), an integral protein for chylomicron processing and a proposed regulator of insulin 
signalling (Shibasaki et al. 2006), thus providing a possible regulatory connection between 
transmembrane receptor activation/signal transduction, and the processes of chylomicron 



















- 214 - 
 
9.5 DISCUSSION: 
We used computational methods to select the most likely candidate genes for MS, starting 
with a set of genes selected from all loci previously associated with the disease. The five 
phenotypes that define MS as well as phenotype and population-specific filters were used to 
refine the starting set of genes. The top-scoring 19 genes from the final candidate list were 
selected as most likely disease gene candidates. These candidates are found to most 
commonly represent pathways involving metabolism of lipids and lipoproteins, as well as 
transmembrane signalling and subsequent activation of signal transduction pathways.  
 
Given the diversity of the five phenotypes associated with MS, and the variety of the 
phenotype combinations that present clinically, it would seem unlikely that genes belonging 
to specific and restricted pathways are causative of this syndrome. Instead, disease candidates 
are more likely to belong to non-specific pathways with multiple downstream effects, and 
thus be capable of generating a diverse array of phenotypic effects if disrupted. The 
predominance of receptor and signalling molecules in the candidate set fits this model: signal 
transduction pathways can have a large variety of initiating events and multiple downstream 
targets, regulated through a common signal transduction pathway. Additionally, because of 
the cascade effect in signal transduction events, even small changes in top-level signalling 
events can have large and diverse downstream effects – such as the variety of phenotypes seen 
in MS.  
 
Of interest, the only transcription factor candidate, FOXO1A, appears to connect chylomicron 
remnant uptake with insulin signalling, and possibly functions in a feedback loop: FOXO1A 
is regulated by insulin signalling and upregulates LPL expression; and LPL in turn activates 










- 215 - 
 
selected are also annotated with terms relating to development (Table 9.5). This most likely 
reflects a role for lipids and insulin in regulating genes involved in development (for example, 
neural development as described in (Gotthardt et al. 2000) rather than a role for 
developmental genes in MS - although this cannot be completely excluded, and these genes 
may have dual roles in metabolism as well as development. 
 
Individually, eight of the candidates have been previously implicated in MS, and notably, 
polymorphisms in LDLR have been associated with MS previously (McCarthy et al. 2003). 
Only one of the candidates (APOB) has been previously associated with all five phenotypes. 
Three of the candidates show no association to these phenotypes, and one of these also has no 
direct or indirect association with MS (ADCY7) and is therefore a totally novel candidate. 
This selection of the top ranking 19 most likely candidates therefore presents an array of 
genes including a gene containing known disease-associated SNPs, some genes previously 
associated with MS and/or its phenotypes, and some entirely new candidates for further 
investigation. This demonstrates that novel predictions can be made from existing data using 
computational approaches, and that this approach is truly synthetic, and not simply 
sophisticated data-mining of existing knowledge. 
 
Certain issues intrinsic to computational analysis however do arise. Firstly, differences 
between gene sets in different databases or versions of the same database was accommodated 
in part in this study by the scoring system, avoiding biased negative scoring against genes not 
measured by all methods. Secondly, genes with better annotation are generally more likely to 
be selected, resulting in a bias towards selection of well-investigated genes (including 
disease-related genes) rather than novel predicted or uncharacterised genes. Scoring by DGP, 
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sequence similarity to analyse uncharacterised genes and are based on mapping of EST 
sequences from cDNA libraries regardless of the characterisation and annotation of the gene. 
 
Thirdly, the use of training sets in selection limits the search to fit existing paradigms 
regarding the type of gene causing the disease, and limits the possibility of finding novel 
disease mechanisms. It would, however, be possible to investigate candidates selected without 
the use of training sets by excluding the methods that require a training set of known disease 
genes.  
 
Finally, thresholds and cut-offs for selection of most likely candidates can be arbitrary or an 
‗informed guess‘ for methods that rank genes (in comparison to straightforward 
inclusion/exclusion). Where possible, thresholds in this study have been based on results from 
test datasets, as described in the seminal reference for each method.  
 
Association studies have failed to date to identify causative genes underlying the syndrome, 
despite clear evidence for heritability (Pollex and Hegele. 2006), and this is most likely due to 
complex disease genetics whereby many aetiological genes of low penetrance, rather than a 
single causative gene, result in the syndrome. With multiple contributing phenotypes as well 
as many permutations of those phenotypes, the syndrome lends itself to being deconstructed 
for systematic computational analysis.  
 
Here, the identification of ―most likely‖ disease genes for MS has been addressed using 
computational rather than empirical methods. Results of published association studies have 
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used multiple computational methods to select most likely candidate genes in a combinatorial 
approach informed by the clinical presentation of the syndrome.  
 
Given the increasing urgency of understanding and managing MS effectively, it is shown here 
that computational analysis can offer new insights into genetic determinants and regulatory 
pathways that may be involved and presents a selection of genes that includes both novel and 
identified candidates for further empirical analysis. Exploring new avenues can also lead to a 














































10.1 GENERAL DISCUSSIONS 
 
Cardiovascular diseases constitute a major threat to the economies of many developing 
nations of the world. A number of these countries are confronted with a ―double edged 
sword‖ situation in which they have to tackle epidemics of infectious diseases as well as those 
of NCDs. Kidney diseases requiring RRT for instance, require trained and dedicated health 
care workers, expensive machines and procedures, together with costly drugs, which most 
developing nations cannot afford, especially in the face of the need for measures to combat 
infectious diseases, poverty and hunger. Thus although the focus of several health care 
systems in Africa is often encouraged to revolve around communicable diseases like malaria, 
TB and HIV/AIDS, it is becoming increasingly clear that NCDs like obesity contribute 
significantly to morbidity and mortality in Africa. 
 
As the obesity pandemic continues to gain momentum it will probably continue to profoundly 
affect mortality, morbidity, and quality of life worldwide unless measures are sought to 
address our ever increasing obesogenic environment. The MS, which is common and has been 
demonstrated to be prevalent in obese individuals, presents a prospect for seeking other 
factors (aside from hypertension alone) that potentially drive the increased prevalence of 
kidney disease in people of the black race.  
 
This study has used the MS to investigate CVDs (using microalbuminuria as an entity that 
represents organ damage) in a homogenous population of native black Africans. The findings 
from this study have focussed on the phenotypic features and the genetic influence of the 
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Although other studies have previously reported on the association of the MS and kidney 
disease, this study is the first of its kind in native black Africans, in whom it has been found 
that kidney disease, defined by the presence of microalbuminuria is found to be prevalent, 
with added metabolic risk factors such as the four-fold rise of ACR from subjects without MS 
phenotypes to those with 4 or more of the phenotypes and an increasing odds ratio for 
microalbuminuria with an increasing number of MS phenotypes (see chapter 7). Additionally, 
correlations between obesity phenotypes and markers of renal function have also been 
reported as has been in other studies (Chen et al. 2004; Bonneta et al. 2006). This study has 
also found serum leptin to be inversely and significantly correlated with markers of renal 
function, further implicating obesity specifically in the pathogenesis of kidney disease and 
more generally in CVDs.  
 
Even though the exact mechanisms that link obesity and renal disease are still unknown, it has 
been suggested that some hormones secreted by fat cells (e.g. leptin, IL-6 and TNF-α) could 
be implicated in promoting renal damage (Wisse 2004). Leptin has previously been shown to 
be correlated with increased urine albumin excretion in women with type 1 diabetes melliuts 
(Rudberg and Persson 1998), suggesting a role in renal injury in this independent cohort. 
 
An important question arising from this study pertains to the mechanism of kidney disease 
from a mutation occurring in the non-coding 5‘ UTR of the LEP gene. Our study showed that 
mean values of ACR was higher in subjects homozygous for the A allele of the A19G 
polymorphism (Chapter 8). This question is relevant because the effects on protein function of 
SNPs found in the 5‘ UTR region of the LEP gene have not been determined. Also, the 
5‘UTR region of any gene may influence translation of its down stream cistron (segment of 
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on internal ribosome entry and the efficacy of translation of the downstream cistron 
(Pickering and Willis 2005).  
 
The A19G polymorphism, together with 2 other SNPs (G2548A and C188A) analysed in this 
study are in the 5‘UTR region of the LEP gene and therefore could affect the translation of 
the downstream cistron. The serum leptin concentration was not significantly different 
between the three genotype categories of the A19G polymorphism, however, protein function 
could conceivably be altered either by an abnormal folding pattern or conformation. This was 
not tested in the current study. Kimchi-Sarfaty et al (2007) have recently provided evidence 
that SNPs which have been assumed to be ―silent‖ since they provide no change to the amino 
acid composition of the protein may indeed have significant effects on the protein function as 
such SNPs may alter the translation kinetics of the gene resulting in an abnormally folded and 
functioning protein (Kimchi-Sarfaty et al 2007).  
 
In this thesis, bioinformatics methods have also been used to select the ―most likely‖ 
candidate genes for the MS because the obesity gene didn‘t seem to be ―it‖. The use of simple 
association methods underlying Mendelian diseases often fail to find genes responsible for 
complex diseases which usually occur from small contributions from several genes whose 
effects influence pathways related to the complex disease phenotype.  
 
Here, the identification of ―most likely‖ disease genes for metabolic syndrome has been 
addressed using computational rather than empirical methods. Results of published 
association studies have been used as a primary filter to select the starting set of candidate 
disease genes, and then used multiple computational methods to select most likely candidate 
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The top-scoring 19 candidate genes (See appendix A5) we reported are found to most 
commonly represent pathways involving metabolism of lipids and lipoproteins, as well as 
transmembrane signalling and subsequent activation of signal transduction pathways. That 
these genes represent pathways involving the metabolism of lipids and lipoproteins suggest 
that obesity is important in the pathogenesis of the MS. It also demonstrates that novel 
predictions can be made from existing data using computational approaches. With multiple 
contributing phenotypes as well as many permutations of those phenotypes, the syndrome 
lends itself to being deconstructed for systematic computational analysis.  
 
Given the increasing urgency of understanding and managing MS effectively, it is shown here 
that computational analysis can offer new insights into genetic determinants and regulatory 
pathways that may be involved and presents a selection of genes that includes both novel and 
identified candidates for further empirical analysis. Exploring such new avenues can also lead 
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10.2 CONCLUSIONS AND RECOMMENDATIONS 
 
The central theme of this study has been around obesity either manifesting as the MS or 
resulting in renal disease through the syndrome of insulin resistance. Certain conclusions can 
be drawn from the observations in this study:  
 
1. The first is related to the principally observed phenotype results i.e. relationship between 
the MS and kidney disease. Although some have argued about the true relevance of the MS as 
a risk factor for CVD (Kahn et al. 2005), others have shown it is relevant in predicting CVD 
(Chen et al. 2004). This study has shown that such a relationship exists (with kidney disease) 
in non-diabetic subjects and underscores the importance of NCDs in populations of 
developing nations who are too selectively focused on the scourge of common communicable 
diseases.  
 
2. This study has also shown that the LEP gene, in native black Africans, is associated with 
kidney disease measured by the presence of microalbuminuria. This therefore generates a 
novel hypothesis: that the LEP gene may be associated with kidney disease in non-diabetic 
black Africans and may need to be considered a candidate gene for kidney disease in black 
Africans. However, in view of small sample sizes in some of the analyses, this conclusion is 
to be taken cautiously and creates the need to replicate this finding in a similar population. 
The National Cancer Institute–National Human Genome Research Institute (NCI-NHGRI) 
working group have indeed suggested that replication studies need to be done on initial 
studies reporting an association (Chanock et al. 2007). 
 
3. This study has found 8 out of 19 genes common to blacks and whites and males and 
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tested, it is proposed that empirical studies be carried out both in black and white populations 
to find a true association between the genes selected by computational methods and the MS 
and its phenotypes. This will strengthen the use of computational methods to select the ―best‖ 
candidate genes underlying complex diseases.  
 
Although, there have previously been reports from other population on the renal effects of the 
MS, this study is unique being the first to look for such an association in an indigenous black 
African population and having found such a relationship, corroborates previous reports from 
other populations. The novelty of this study also touches upon it being the first to report an 
association between the LEP gene and markers of kidney disease and in using computational 
methods to select candidate genes for the MS common to blacks and whites.  
 
 
10.3 STRENGTHS AND LIMITATIONS OF THE STUDY. 
 
 
There are a number of strengths and weaknesses identified in this study, summarized below. 
 
STRENGTHS: 
1. Focussing on the relationship between the leptin gene and renal disease phenotypes is a 
novel idea. This is important because there has been little empirical testing of this association, 
despite suggestive evidence in the literature. Investigating this issue within the context of the 
thesis therefore provides useful data as well as stimulating further studies. 
 
2. The study of a population with no prior similar studies: black South Africans, is useful. In 
general, African populations are under-represented in such studies despite the useful insights 
that can be gained from them. Much of Africa is undergoing an epidemiologic and nutritional 
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hypertension, T2DM and the metabolic syndrome. The frequency of individual, behavioural 
and environmental risk factors for many complex diseases is lower and much more varied 
than in many Western countries, providing an opportunity to understand rural-urban 
differences and regional variation in Africa. African populations have the greatest genetic 
diversity of any continental populations and studies of African populations have the potential 
to exploit this diversity to identify disease associations and gain insights into biology. 
 
3. A further strength of the study is that it represents an in-depth study of a large set of 
clearly-defined clinical and biochemical characteristics (i.e. a comprehensive study of a large 
number of variables in a modest number of study participants) rather than studying a few 
variables in thousands of subjects. This is clearly an advantage in exploratory studies such as 
this and the findings can then be used to design studies of more targeted variables in much 
larger samples. 
 
4. The investigative use of bioinformatics techniques to provide additional insight into the 
potential genetic influences on the metabolic syndrome. As the volume and quality of data in 
the genetics and genomics-related databases have swollen in recent years, the use of 
computational biology techniques to guide, interpret or contextualize ―wet-lab‖ experiments 
has become more and more important.   
 
WEAKNESSES: 
5. A modest sample size of three hundred and thirty-six subjects (336). While this was 
adequate for assessing the relationship between the metabolic syndrome an kidney disease in 
this population (upon which sample size estimation was based), it was insufficient for some of 
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in normotensive offspring of probands in which the total number was fifty (50) and those who 
were homozygous for the ―A‖ allele were only six (6) subjects. 
  
6. The cross-sectional nature of the study. Within cross-sectional studies, the ‗exposure‘ and 
the ‗outcomes‘ are usually assessed at the same time this hampers the interpretation of 
associations, as the data will usually not tell the investigator which came first: the ‗exposure‘ 
or the ‗outcomes‘ (Jager et al 2007). Therefore, this study design can draw limited inference 
with regard to relationships between exposure and outcome. It would have enhanced the study 
if the subjects were followed up for some period of time to determine phenotype end-points, 
for example the development of overt proteinuria – this was beyond the scope of this study 
due to time and patient availability constraints. This would clearly show, for instance, that 
subjects that started out with the MS and no microalbuminuria went on to develop full blown 
kidney disease much earlier than those without this condition or that normotensive, non-
diabetic offspring of the probands who were homozygous AA for the LEP A19G 
polymorphism developed CKD much before hypertensive subjects without this genotype. A 
follow up would also help to determine if the GCAT haplotype protected those with 
hypertension or diabetes from developing kidney disease relative to blood pressure and 
glycaemic control. However, such a study would be very expensive and requires significant 
further time.   
 
10.4 RECOMMENDATIONS 
As in other genetic studies reporting association, a replication study is needed to confirm the 
results obtained from the present study. Future genetic studies should be adequately powered, 
especially for genetic analysis and should not be limited by the number of SNPs studied. Such 
studies may also examine the downstream effects of leptin on its signalling pathways and how 
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A1. PCR AND RESTRICTION ENZYME DIGESTS 
 
A1.1 PCR ASSAY OF LEP A19G IN EXON 1 OF THE GENE 
 
There are a number of studies that have reported about the A19G mutation (in text). These 
studies have done so with respect to obesity phenotypes and or serum leptin concentrations. 
Reports from the different populations have been non-uniform. I am presently unaware of 
reports of this mutation from studies conducted in any black African population. 
The assay involves producing a fragment of 258 bp with 1 cutting site at position 186 of the 
fragment for the restriction enzyme MspA1I (cuts at 5‘---C(A/C)G↓C(G/T)G---3‘ or 3‘---
G(T/G)C↑G(C/A)C---5‘). A cut at this position (homozygote GG) will result in 2 bands (186 







CTTCCTCCTTCTCTGCTGGTCTTTCTTGGCAG GCCACAGGGC CC-3‘ 
 
A1.1.1 PRIMERS: 
FP:     5’- GCCCCGCGAGGTGCACACTG -3’   (20mer) 




 Stock concentration Volume (μL) Final concentration 
Distilled water  16.9  
Buffer  5x 5.0  
dNTP 5 μm 1.0 1 μm 
Forward primer 100 nm/μL 0.5 50 nm/assay 
Reverse primer 100 nm/μL 0.5 50 nm/ assay 
Pm Taq  0.1  






















A1.1.3 PCR CONDITIONS: 
 
Stage 1: Denaturation: 
94 
o
C for 5 minutes (x 1 cycle) 
Stage 2: Annealing: 
94 
o
C for 30 seconds (x 35 cycles) 
62 
o
C for 30 seconds (x 35 cycles) 
72 
o
C for 40 seconds (x 35 cycles) 
Stage 3: Extension: 
72 
o
C for 7 minutes (x 1 cycle) 
 
Restriction conditions: MspA1I is incubated at 37 
o
C for 4 hours using 0.5 μL of the 
restriction enzyme per 1.5 μL of PCR product  
A1.1.4 GEL: 
A 3% Agarose gel (with Ethidium Bromide) is prepared. The PCR products are loaded into 
the wells and run at a voltage of 160 mV for 45 minutes. View under UV illumination and 
document the image with the UVITEC transilluminator (Cambridge UK) 
 
 
Figure 1 shows PCR products of exon 1 
(A19G). Lane 1 is the 1000bp marker 












Figure 2: shows RE digest of PCR products of 
exon 1. 
M – Marker (1000bp) 
U – Uncut PCR product 
Sample 122 – (1 band) 258bp 
Samples 123-125 – (2 bands) 186bp and 62bp 















A1.2 PCR ASSAY OF LEP C538T IN EXON 3 OF THE LEP GENE 
This polyporphism was first reported by Karvonen et al (1998) who found no association 
between the genotype and obesity phenotypes. It was again reported by Gaukrodger et al 
(2005) who found an association of the T allele with CIMT. 
The assay involves producing a fragment of 316 bp with 2 cutting sites at positions 32 and 
245 of the fragment for the restriction enzyme TaiII (cuts at 5----A C G T↓----3 or 3----↑T G 
C A----5). The homozygote genotype (CC) thus has 3 bands: 213bp, 71bp and 32bp 
fragments, while the heterozygote (CT) has 4 bands: 284bp, 213bp, 71bp and 32bp fragments. 
 







TCCAGGATTGAAGAGCATT GCATGGACAC CCCTTATCCA GGAC-3‘ 
 
A1.2.1 PRIMERS: 
FP:   5’- CGACCTGGAGAACCTCCG- 3 ‗(18mer) 




 Stock concentration Volume (x1) Final concentration 
Distilled water  16.9  
Buffer  5x 5.0  
dNTP 5 μm 1.0 1 μm 
Forward primer 100 nm/μL 0.5 50 nm/assay 
Reverse primer 100 nm/μL 0.5 50 nm/ assay 
Pm Taq  0.1  
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A1.2.3 PCR CONDITIONS: 
 
Stage 1: Denaturation: 
94 
o
C for 5 minutes (x 1 cycle) 
Stage 2: Annealing: 
94 
o
C for 30 seconds (x 35 cycles) 
53 
o
C for 30 seconds (x 35 cycles) 
72 
o
C for 40 seconds (x 35 cycles) 
Stage 3: Extension: 
72 
o
C for 7 minutes (x 1 cycle) 
 
Restriction conditions: TaiI (MaeII) is incubated at 65 
o
C for 4 hours using 0.5 μL of the 
restriction enzyme per 10.0 μL of PCR product. 
 
A1.2.4 GEL: 
A 3% Agarose gel was prepared to run the restriction enzyme digested PCR products. Th 
products were loaded into the wells and run at 160mv for 45 minutes. This was then viewed 
under UV illumination and the image documented as shown below. 
 






Figure 1: Shows PCR products of exon 3 
(C538T). Lane 1 is the marker with 
1000bp ladder. 3
rd
 rung from bottom 
corresponds to 300bp fragments. 
Figure 2: Restriction enzyme digests of PCR 
products of exon 3.  
M – Marker (1000bp) 
U – Uncut PCR product 321bp 
Samples 122 – 125 (3 bands) 213bp, 71bp, and 
32bp 
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A1.3 PCR ASSAY OF LEP C188A IN THE PROMOTER REGION OF THE LEP 
GENE 
 
A number of studies have reported about this polymorphism and its association with obesity 
and serum leptin concentrations. Assaying for this SNP involves producing a fragment of 
261bp with 1 cutting site for the restriction enzyme AscI. This cut at position 221 produces 2 
fragments (221bp and 40bp) and represents the homozygote genotype (CC). The heterozygote 
(CA) has 3 bands representing 261bp, 221bp and 40 bp. The enzyme cuts at 5‘---G G ↓C G C 
G C C---3‘ or 
3‘---C C G C G C ↑G G ---5‘. 
 








FP:   5’ CAACGAGGGCGCAGCCGTAT 3’ (20mer)  





 Stock concentration Volume (x1) Final concentration 
Distilled water  16.9  
Buffer  5x 5.0  
dNTP 5 μm 1.0 1 μm 
Forward primer 100 nm/μL 0.5 50 nm/assay 
Reverse primer 100 nm/μL 0.5 50 nm/ assay 
Pm Taq  0.1  
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A1.3.3 PCR CONDITIONS: 
 
Stage 1: Denaturation: 
95 
o
C for 5 minutes (x 1 cycle) 
Stage 2: Annealing: 
95 
o
C for 30 seconds (x 35 cycles) 
62 
o
C for 30 seconds (x 35 cycles) 
72 
o
C for 40 seconds (x 35 cycles) 
Stage 3: Extension: 
72 
o
C for 7 minutes (x 1 cycle) 
 
Restriction conditions: AscI is incubated at 37 
o
C for 4 hours using 0.5 μL of the restriction 
enzyme per 10.0 μL of PCR product. 
A1.3.4 GEL: 
A 3% Agarose gel was prepared to run the restriction enzyme digested PCR products. Th 
products were loaded into the wells and run at 160mv for 45 minutes. This was then viewed 












Figure 1: PCR products on a 1% Agarose gel 
(with Ethidium Bromide). Lane 1 is a 1000bp 
marker. 
Figure 2: AscI digest of PCR products of C188A. 
M – Marker (1000bp) 
U – Uncut PCR product (261bp) 
204 – 3 bands (261bp, 221bp and 40bp) 
205 – 1 band (261bp) 
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A1.4 PCR ASSAY OF LEP G2548A IN THE PROMOTER REGION OF THE LEP 
GENE 
 
This SNP appears to be the most studied of the obesity gene, many contradictory reports on 
its association with obesity and serum leptin levels can be found in the literature. The assay 
involves producing a small fragment of 109bp with a cut at position 62 with the enzyme HhaI. 
This cut produces 2 fragments of 62bp and 47bp representing the homozygote genotype (GG). 
Due to the sizes of these products, only the 62bp fragment is often only seen on the 3% 
Agarose/Ethidium Bromide gel. Hence, only 1 band is seen in the homozygotes (GG) whereas 
2 bands instead of 3 are seen in th heteroygotes (GA). HhaI cuts at 5‘---G C G↓ C ----3‘ or 3‘-









FP:   5’ TTTCCTGTAATTTTCCCGTGAG 3’  (22mer) 






 Stock concentration Volume (x1) Final concentration 
Distilled water  16.9  
Buffer  5x 5.0  
dNTP 5 μm 1.0 1 μm 
Forward primer 100 nm/μL 0.5 50 nm/assay 
Reverse primer 100 nm/μL 0.5 50 nm/ assay 
Pm Taq  0.1  





















- 264 - 
 
 
A1.4.3 PCR CONDITION: 
 
Stage 1: Denaturation: 
94 
o
C for 5 minutes (x 1 cycle) 
Stage 2: Annealing: 
94 
o
C for 30 seconds (x 35 cycles) 
48 
o
C for 30 seconds (x 35 cycles) 
72 
o
C for 40 seconds (x 35 cycles) 
Stage 3: Extension: 
72 
o
C for 7 minutes (x 1 cycle) 
 
Restriction conditions: HhaI is incubated at 37 
o
C for 4 hours using 0.5 μL of the restriction 
enzyme per 10.0 μL of PCR product. 
 
A1.4.4 GEL: 
A 3% Agarose gel was prepared to run the restriction enzyme digested PCR products. Th 
products were loaded into the wells and run at 160mv for 45 minutes. This was then viewed 









Figure 1: PCR products on a 1% Agarose 
gel (with Ethidium Bromide). Lane 1 is 
the marker and the lowest rung is 100bp. 
PCR product sizes are 109bp 
 
Figure 2: shows HhaI digested bands of 
PCR products for G2548A. 
M – 1000bp marker 
U – Uncut PCR product. 
137-142: (1 band) 62bp product 




















ADCY Adenylate cyclase 
APOB Apolipoprotein B 
ApoE Apolipoprotein E 
AXL AXL Receptor tyrosine kinase 
CAT Catalase 
FOXO1 Forkhead box 01 
FYN FYN oncogene related to SRC, FGR, YES 
GIPC1 GIPC PDZ domain containing family, member 1 
HSD17B4 Hydroxysteroid (17-beta) dehydrogenase 4 
IGF-1 Insulin-like growth factor-1 
INSR Insulin receptor 
ITGB1 Integrin beta 1 
LDLR Low-density Lipoprotein Receptor 
LPL Lipoprotein Lipase 
LRP1 Low density lipoprotein receptor-related protein 1 
PFKM Phosphofructokinase, muscle 
PTPN11 Protein Tyrosine Phosphatase, non-receptor type 11 


























You are invited to participate in this study. This information leaflet will help you decide if 
you would like to participate. Before you agree, you should fully understand what is involved. 
If you have any questions, which you do not understand, please do not hesitate to discuss this 
with the study doctor. You should not agree unless you are completely happy about this study, 
and you are strongly recommended to discuss it with your personal doctor, wherever possible. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
You have high blood pressure which can cause damage to the kidneys especially in the 
presence of some other factors like increased body weight, high levels of lipids (fat) in the 
blood, etc. We want to see how these factors, together, can cause damage to the kidneys. 
 
WHAT IS THE DURATION OF THE STUDY AND WHAT PROCEDURES WILL BE 
PERFORMED? 
You will be seen once and will undergo full medical examination. Blood and urine tests will 
be performed. In some cases you may require an oral glucose tolerance test. The test will 
require you to drink a glucose solution after an overnight fast of about twelve hours during 
which you are not allowed to take any food but can drink some water. Blood will be taken 
from you on the morning of the test; at the commencement of the test and at one and two 
hours from the time of commencement. You may also be asked to come for a kidney biopsy if 
the results of your urine test indicate you have a moderate-to-severe kidney disease. 
 
HAS THE STUDY RECEIVED ETHICAL APPROVAL? 
The Research Ethics Committee of the University of Cape Town has approved the study 
protocol. 
 
WHAT ARE MY RIGHTS AS A PARTCIPANT IN THE STUDY? 
Your participation is entirely voluntary and you can refuse to participate or stop at any time 
without stating a reason. Your withdrawal will not affect your access to future medical care. 














ARE THERE ANY BENEFITS TO ME? 
Early detection of factors that can lead to kidney damage will have definite health benefits to 
you. If you undergo a kidney biopsy, the exact nature of kidney disease will be identified. 
There may be no other benefits to you. 
 
MAY THE STUDY PROCEDURES RESULT IN DISCOMFORT OR 
INCONVINIENCE? 
Blood tests may result in a bruise at the puncture site, swelling of the vein, infection, or 
bleeding. In experienced hands this is highly unlikely and only minor discomfort may occur. 
(Renal biopsy – refer to separate consent form). 
INSURANCE AND FINANCIAL ARRANGEMENTS 
All the study doctors are covered by insurance for medical liability and if any study related 
injury occurs, you have the right to legal action against the study doctor concerned. 
You will not be paid to participate but will receive compensation for transport costs for each 
visit. 
SOURCE OF ADDITIONAL INFORMATION 
If at any time you have symptoms causing you problems or questions please do not hesitate to 
contact the investigator at this telephone number. 
CONFIDENTIALITY 
All information during the course of the study is strictly confidential. Data will be reported in 
scientific journals, but will not include information that identifies you. 
It is important that the Research Ethics Committee of the University of Cape Town be able to 
























A4. INFORMED CONSENT 
 
I hereby confirm that the study doctor (Dr. ------------------------------------------------------------) 
has informed me about the nature, conduct, benefits and risks of this study. I have also 
received, read, and understand the written Patient Information. 
I am aware that the results of the study will be anonymously processed into a study report. 
I may, at any stage, withdraw my consent and participation without prejudice. 
I have had sufficient opportunity to ask questions and declare myself prepared to participate 
in the study. 
 
 
Patient‘s Name: -------------------------------------------------------------------------- (Print) 
 
Patient‘s Signature: ------------------------------------------ Date: -------------------------- 
 
Study Doctor‘s Name: ------------------------------------------------------------------- (print) 
 
Study Doctor‘s Signature: ----------------------------------- Date: --------------------------- 
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A5. STUDY PROTOCOL 
 
1. SERIAL NUMBER     ---------------------------------- 
2. HOSPITAL NUMBER   -------------------------------- 
3.  DATE OF INTERVIEW----------------------------------- 
4. DEMOGRAPHIC DATA: 
 
4.1 NAME  
4.2 DOB YYYY MMM DD 
4.3 AGE  






4.6 TELEPHONE HOME  





XHOSA ZULU SOTHO 
TSWANA OTHER 
4.8 OCCUPATION UNEMPLOYED STUDENT INFORMAL 
  FORMAL PENSIONER 







4.10 EDUCATIONAL STATUS (SPECIFY)  
4.11 DURATION OF HYPERTENSION (SPECIFY)  








4.13 HISTORY OF CVD? Y N  
 
4.14 
SMOKING (DURATION) (SPECIFY)  




ALCOHOL PER DAY* 
NON-USER OCCASIONAL 1-2 DRINKS 




EXERCISE (HRS/WEEK) (SPECIFY) 
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TIME 0 min TIME 60 min TIME 120 min 
   
6.2 Triglyceride (mmol/L)   
6.3 HDL-cholesterol (mmol/L)   
6.4 LDL-cholesterol (mmol/L)   
6.5 Fibrinogen (mg/dl)   
6.6 CRP   
6.7 Insulin   
6.8 Leptin   
6.9 Adiponectin   
6.10 Creatinine   
6.11 Albumin   




GENOTYPE    
G2548A GG AG AA 
C188A CC CA AA 
A19G GG AG AA 
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A6: PUBLICATIONS AND CONFERENCE PRESENTATIONS FROM THIS STUDY: 
 
―Association of Microalbuminuria and the Metabolic Syndrome‖ 
Abstract book: South Africa Renal Congress, Cape Town. 
March 2006. 
 
―CRP is elevated in Obese Subjects with the Metabolic Syndrome‖ 
Abstract book: South Africa Renal Congress, Cape Town. 
March 2006. 
 
―Plasma Leptin and Metabolic Risk Profiles in Hypertensive Black South Africans.‖ 
Joint Conference of the Royal college of Physicians and the College of Medicine South 
Africa, Cape Town. 
February 2007. 
 
―The Metabolic syndrome and Early Kidney disease in non-diabetic black Africans‖ 
Abstract book: 2
nd




―LEP C538T Polymorphism and Obesity related phenotypes: An Association Study in Black 
Hypertensives.‖ 
Abstract book: South African Hypertension Congress, Johannesburg, South Africa.  
May 2007. 
 
―A Polymorphism in the 5‘ UTR Region of the Obesity Gene is associated with Kidney 
Disease in Black Africans‖. 
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PUBLICATIONS  
―LEP C538T Polymorphism and Obesity related phenotypes: An Association Study in Black 
Hypertensives.‖ Cardiovasc J Afr 2007; 18: (3 suppl) S23-24 (Abstract). 
 
―Microalbuminuria and the metabolic syndrome in non-diabetic black Africans‖ Diabetes 
Vasc Dis Res 2007;4: 365-367. 
 
―Prioritization of candidate disease genes for metabolic syndrome by computational analysis 
of its defining phenotypes‖. Physiol Genomics. 2008; 35: 55-64 
 
ARTICLES YET TO BE PUBLISHED 
 
1. Plasma Leptin and Metabolic Risk Profiles in Hypertensive Black South Africans. 
 
2. The LEP A19G polymorphism is associated with markers of early kidney disease in black 
Africans with Hypertension. 
 
